
<html lang="en"     class="pb-page"  data-request-id="f47a0970-a0d8-4a85-ba51-baa3908b3bb0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm300035p;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2012.55.issue-10;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies" /></meta><meta name="dc.Creator" content="Yan  Lou" /></meta><meta name="dc.Creator" content="Timothy D.  Owens" /></meta><meta name="dc.Creator" content="Andreas  Kuglstatter" /></meta><meta name="dc.Creator" content="Rama K.  Kondru" /></meta><meta name="dc.Creator" content="David M.  Goldstein" /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 21, 2012" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300035p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300035p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300035p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300035p" /></link>
        
    
    

<title>Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300035p" /></meta><meta property="og:title" content="Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="" /></meta><meta name="twitter:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta name="twitter:title" content="Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300035p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300035p">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300035p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300035p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300035p&amp;href=/doi/10.1021/jm300035p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4539-4550</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201649s" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm201107g" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Lou">Yan Lou</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+D.++Owens">Timothy D. Owens</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Kuglstatter">Andreas Kuglstatter</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rama+K.++Kondru">Rama K. Kondru</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+M.++Goldstein">David M. Goldstein</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Discovery Chemistry, Small Molecule Research, pRED, Pharma Research and Early Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States</span></div><div class="corresp-info"><strong>*</strong>For Y.L.: phone, 973-235-7648; fax, 973-235-6263; e-mail, <a href="/cdn-cgi/l/email-protection#86ffe7e8a8eae9f3a8ffeab7c6f4e9e5eee3a8e5e9eb"><span class="__cf_email__" data-cfemail="7009111e5e1c1f055e091c4130021f1318155e131f1d">[email protected]</span></a>, <a href="/cdn-cgi/l/email-protection#a9d0c8c787c5c6dce9cec4c8c0c587cac6c4"><span class="__cf_email__" data-cfemail="8bf2eae5a5e7e4fecbece6eae2e7a5e8e4e6">[email protected]</span></a>. For T.D.O.: phone, 650-416-7725; e-mail, <a href="/cdn-cgi/l/email-protection#56223f3b7839213338251626243f38353f263f37343f397835393b"><span class="__cf_email__" data-cfemail="88fce1e5a6e7ffede6fbc8f8fae1e6ebe1f8e1e9eae1e7a6ebe7e5">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300035p&amp;href=/doi/10.1021%2Fjm300035p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4539–4550</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 6, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 January 2012</li><li><span class="item_label"><b>Published</b> online</span>21 March 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 May 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300035p" title="DOI URL">https://doi.org/10.1021/jm300035p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4539%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYan%2BLou%252C%2BTimothy%2BD.%2BOwens%252C%2BAndreas%2BKuglstatter%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D10%26contentID%3Djm300035p%26title%3DBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitors%253A%2BApproaches%2Bto%2BPotent%2Band%2BSelective%2BInhibition%252C%2BPreclinical%2Band%2BClinical%2BEvaluation%2Bfor%2BInflammatory%2BDiseases%2Band%2BB%2BCell%2BMalignancies%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4550%26publicationDate%3DMay%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300035p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4486</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">61</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300035p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Lou&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;D. Owens&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Kuglstatter&quot;},{&quot;first_name&quot;:&quot;Rama&quot;,&quot;last_name&quot;:&quot;K. Kondru&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;M. Goldstein&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;4539-4550&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300035p&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300035p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300035p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300035p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300035p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300035p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300035p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300035p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300035p&amp;href=/doi/10.1021/jm300035p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300035p" /></input><a href="/doi/pdf/10.1021/jm300035p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26pmid%3D22394077%26genre%3Darticle%26aulast%3DLou%26date%3D2012%26atitle%3DBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitors%253A%2BApproaches%2Bto%2BPotent%2Band%2BSelective%2BInhibition%252C%2BPreclinical%2Band%2BClinical%2BEvaluation%2Bfor%2BInflammatory%2BDiseases%2Band%2BB%2BCell%2BMalignancies%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D10%26spage%3D4539%26epage%3D4550%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/10" title="Go to Volume 55, Issue 10"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jmcmar.2012.55.issue-10/production/jmcmar.2012.55.issue-10.largecover.jpg" alt="Go to Volume 55, Issue 10"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span>†</span> Author Present Address</h4><p class="last">Principia Biopharma, 400 E. Jamie Court, Suite 302, South San Francisco, CA 94080.</p></div><div class="extra-info-sec articleNote"><h4><span>‡</span> Author Present Address</h4><p class="last">F. Hoffmann-La Roche, 4070 Basel, Switzerland.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02388" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02388" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bruton’s tyrosine kinase (BTK) is a member of the Tec tyrosine kinase family.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> BTK is expressed in most hematopoietic cells such as B cells, mast cells, and macrophages but not in T cells, natural killer cells, and plasma cells.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> BTK plays key roles in multiple cell signaling pathways including BCR and FcR signaling cascades. Mutations in the human BTK gene cause the inherited disease X-linked agammaglobulinemia (XLA), with lack of peripheral B cells and low levels of serum Ig.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In XLA, the primary immune deficit is B cell specific. In fact Rituxan, a CD20 antibody, has impacted B cells on the pathogenesis of many autoimmune diseases, such as RA, SLE, and MS.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> This has fueled interest by multiple pharmaceutical companies in pursuing small molecule BTK inhibitors in the treatment of autoimmune diseases. Likewise, there is also interest in the development of BTK inhibitors for the treatment of hematological malignancies, as aberrant activating BTK has been implicated in the pathogenesis of B cell lymphoma.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Detailed reviews and articles on BTK biology and its therapeutic potentials have been reported.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9">(5-9)</a></div><div class="NLM_p last">Kinase selectivity is a central issue in discovering efficacious and safe small molecule inhibitors for kinase targets, especially for non-life-threatening diseases such as RA.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> To prevent adverse toxicological events caused by immunological responses, the pharmaceutical industry has largely focused its small molecule drug discovery efforts on agents that interact noncovalently with their target proteins. This strategy has been followed despite numerous examples of marketed drugs with target-specific covalent mode-of-action.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> In the case of protein kinase targets for which selectivity and efficacy pose major challenges for noncovalent inhibitors, targeted covalent inhibition has provided an attractive alternative.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Both approaches, noncovalent and covalent inhibition of protein kinases, benefit tremendously from high resolution structural information from protein crystal structures. This article will review BTK structural biology with a focus on design features for selective BTK inhibitors. We first summarize the publically available structural information on the BTK kinase domain. Then we will provide a brief summary and analysis with key SAR information for the most potent inhibitors reported for the chemical classes that have been disclosed in patents and publications. When available, preclinical and clinical data for advanced compounds will be summarized.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Structural Biology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86442" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86442" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Protein crystal structures of inhibitor complexes are routinely accessible and successfully used in kinase drug discovery efforts. Structural information on inhibitors binding to BTK, however, has been only recently published. The first X-ray crystal structure of the BTK kinase domain has been determined in its apo form.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> More recently, crystal structures of complexes with nine distinct inhibitors have been reported (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> All crystal structures have been determined with unphosphorylated BTK protein. A Y551E phosphomimetic BTK variant was used for the complex with compound <b>1</b> (dasatinib).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The spectrum of BTK protein conformations observed in these crystal structures is remarkable, exhibiting a broad range of shapes and properties for the ATP binding region to be targeted by small molecules using structure-based drug design.</div><div class="NLM_p">Compounds <b>1</b>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a><b>5</b>, and <b>6</b><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> bind to the active state conformation of BTK where helix C (amino acids 439–452) and the DFG sequence (amino acids 539–541) are in their “in” positions and the conserved salt bridge between K430 and the helix C residue E445 is formed. Compounds <b>2</b> (B43),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a><b>3</b>, <b>4</b> (R406), <b>7</b>, <b>8</b>,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and <b>9</b> (CGI1746)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> stabilize six different conformations that represent inactive states of BTK (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The pharmacologically highly relevant DFG-out conformation, often associated with slow binding kinetics, is stabilized by compound <b>8</b>. An atypical DFG conformation is observed in the presence of <b>4</b>.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Unique and distinct activation loop (amino acids 542–559) conformations that reshape the ATP binding pocket are induced by <b>2</b>, <b>3</b>, <b>4</b>, and <b>9</b>. Helix C is stabilized in varying “out” positions by compounds <b>2</b>, <b>3</b>, <b>4</b>, <b>7</b>, and <b>9</b>, preventing the formation of the K430-E445 salt bridge.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Crystal Structures of BTK Kinase Domain in the PDB</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0001.gif" alt="" id="fx1" /></img><div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">APPROACHES To Design Kinome Selective Btk Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23288" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23288" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Two general approaches to design selective BTK inhibitors have been used and will be summarized here. One is to target amino acid residues found in BTK but uncommon in the kinome, and the other is to target binding pockets of inactive BTK conformations not commonly observed in other kinases. Inactive conformations of kinases are considered promising starting points for the design of highly kinome-selective inhibitors because they are often specific to particular kinases or kinase families.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Analysis of 491 kinase sequences for positional similarity within the ATP binding pocket revealed that C481 of BTK is the amino acid most unique to BTK. The most common amino acid at this position is D (161 occurrences), followed by S (116), E (91), N (44), T (28), and A (15). The residue distribution is given in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>. The presence of the threonine gatekeeper and resulting smaller back pocket is critical to the good selectivity profile of 4-[(4-methylpiperazin-1-yl)methyl]-<i>N</i>-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide (imatinib, Glivec, STI571), a rationally developed, targeted anticancer drug.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> About 20% of all human protein kinases share threonine as gatekeeper residue, but when combined with C481, the total number of kinases decreases to just eight.</div><figure id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Analysis of corresponding amino acid residues in kinome at the positions aligned with T474 (gatekeeper) and C481 of BTK. <i>X</i>-axis refers to the identity of the amino acid, and <i>Y</i>-axis is the corresponding total count in the human kinome. For BTK, C481 ranks as the most uncommon residue whereas T474 ranks as the 17th.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Gatekeeper Residue T474</h3><div class="NLM_p">The back pocket of protein kinases is a lipophilic region separated from the ATP binding site by the so-called “gatekeeper” residue. The relatively small gatekeeper residue T474 in BTK allows ATP-competitive inhibitors to occupy the back pocket. Rotation of the gatekeeper threonine side chain induced in the mitogen activated protein kinase p38α by the phenoxy side chain of compounds like <b>7</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> has not been observed for BTK.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> About 20% of all human protein kinases share threonine as the gatekeeper residue, providing a starting point for the rational design of kinome selective BTK inhibitors. To our knowledge, the first attempt to design BTK-specific inhibitors by interacting with T474 dates back to 1999 when researchers at the Parker Hughes Cancer Center used homology modeling and docking to rationally design the leflunomide metabolite <b>10</b> (LFM-A13) (IC<sub>50</sub> = 2.5 μM) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> On the basis of the proposed BTK binding mode of <b>10</b> and promising yet limited kinase profiling data, it was suggested that interactions with T474 could yield to selectivity against other kinases.</div><figure id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. BTK inhibitors <b>10</b>, <b>11</b>, and <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The hypothesis of gaining BTK specificity for small molecule inhibitors by interacting with the gatekeeper residue T474 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) was further strengthened by selectivity data obtained for the irreversible inhibitor <b>11</b> (PCI-32765)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and its noncovalent precursor <b>12</b> (PCI-29732).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Screening of <b>12</b> against more than 100 kinases by ligand replacement showed that the tightest binding was observed for 13 kinases that all contain threonine as gatekeeper residue.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Kinome profiling shows that <b>11</b> has the greatest affinity for 10 kinases, which all share the threonine gatekeeper residue.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> These data strongly indicate that interaction with the gatekeeper residue T474 can significantly contribute to the kinome selectivity of BTK inhibitors.</div><figure id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Amino acids in the ATP binding pocket of BTK targeted for the design of selective inhibitors. Shown in yellow is a ribbon representation of the protein component of the BTK crystal structure bound with <b>9</b>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Side chains of amino acids targeted for selectivity design are shown in ball-and-stick representation: the gatekeeper residue T474 (cyan), C481 (green), and the specificity pocket (pink). For orientation, an ATP molecule (carbon atoms in gray) has been modeled into the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> C481</h3><div class="NLM_p">The second approach reported to yield inhibitors specific for BTK is to interact with the side chain of C481. Sequence alignment of 491 human kinases shows that cysteine occurs at this position in only nine other kinases: BLK, BMX, EGFR, ERBB2, ERBB4, ITK, JAK3, TEC, and TXK.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> All 10 kinases have as gatekeeper a threonine residue at position 474 except JAK3 and ITK, which have methionine and phenylalanine as the gatekeeper residues, respectively. Compound <b>12</b>, a close analogue of <b>2</b> with presumably the same BTK binding mode (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A), shows that this approach can indeed lead to kinome selectivity.</div><figure id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structures of BTK-inhibitor complexes: (A) compound <b>2</b> at 1.94 Å resolution; (B) compound <b>9</b> at 1.8 Å resolution. Inhibitors are displayed in green and selected amino acids in yellow. Black dashes indicate hydrogen bonds. A structurally important water molecule is drawn in cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Screening of <b>12</b> against more than 100 kinases showed that the tightest binding was observed for nine kinases that contain either cysteine or serine at the position equivalent to the BTK residue C481.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The crystal structure of BTK in complex with the close analogue <b>2</b> shows that the cyclopentyl ring of the ligand is within 4 Å of the C481 side chain.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Presumably, amino acids larger than cysteine or serine at this position, and present in about 70% of all human kinases, are likely to clash with the ligand, which results in significant loss of inhibitory potency.</div><div class="NLM_p last">To further improve the kinome selectivity, BTK inhibitors that bind covalently to C481 have been synthesized.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The irreversible inhibitor <b>11</b> blocks three protein kinases with subnanomolar potency: BTK (IC<sub>50</sub> = 0.5 nM), BLK (IC<sub>50</sub> = 0.5 nM), and BMX (IC<sub>50</sub> = 0.8 nM), all sharing the rare cysteine.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Compound <b>11</b> blocks another 12 human protein kinases with IC<sub>50</sub> < 50 nM.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Four of these kinases possess a cysteine residue as the amino acid at the positions equivalent to the BTK residue C481, and eight kinases have serine residues. These kinases also contain a threonine gatekeeper with the exception of RET, which contains a valine gatekeeper. This may explain its relatively modest activity against RET, with an IC<sub>50</sub> of 37 nM. Consequently, <b>11</b> achieves a >100-fold selectivity window in vitro over kinases with amino acids other than cysteine or serine at this position, and it achieves maximum potency against BTK and two other kinases that have the C481 residue. These findings demonstrate that interaction with C481 is a valid approach for the design of kinome selective BTK inhibitors.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Specificity Pocket</h3><div class="NLM_p">A third and very successful approach reported to design BTK-specific inhibitors is to fill a “specificity pocket”, also referred to as the “H3 pocket”, about 15 Å away from the hinge region (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Compound <b>9</b> is a potent (IC<sub>50</sub> = 1.9 nM), ATP-competitive inhibitor of BTK with ∼1000-fold selectivity over Tec and Src family kinases. The high kinome selectivity of the BTK inhibitor <b>9</b> and related analogues (vide infra) stems from its <i>tert</i>-butylphenyl moiety that occupies the specificity pocket with great complementarity (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). This pocket is formed to a large extent by residues L542, S543, V546, and Y551 of the fully ordered activation loop. The side chains of the Gly-rich loop residues Q412 and F413, the catalytic loop residues D521 and N526, and the DFG residue D539 also contribute to the specificity pocket.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Interestingly, the specificity pocket is also present in the crystal structure of BTK complexed with <b>2</b>, even though this inhibitor does not occupy the pocket. Equivalent pockets created by the same activation loop conformation have been observed in crystal structures of SRC<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and HCK.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> A crystal structure of ITK in complex with an inhibitor bound also shows this activation loop conformation, yet the side chain of the phosphorylatable Y512 does not point into the protein, contributing to the specificity pocket, but occupies a solvent-exposed position.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> It remains to be seen whether more selective kinase inhibitors will emerge from exploiting this specificity pocket.</div><div class="NLM_p">The side chains of residues S543, V546, and Y551 are presumably responsible for the high selectivity to be gained from filling the BTK specificity pocket. Sequence analysis of 491 human kinases shows that the V546/Y551 pair occurs in only three other kinases, BMX, ITK, and TXK. The triple S543/V546/Y551 is completely unique to BTK. Notably, BMX, ITK, and TXK all have a threonine residue at the BTK position S543. For ITK, it has been proposed that this threonine prevents the activation loop tyrosine rotamer required for formation of the BTK selectivity pocket.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p last">The side chains of two amino acids contributing to the formation of the BTK specificity pocket, unphosphorylated Y551 and D521, form an intramolecular hydrogen bond (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). After phosphorylation of Y551, electrostatic repulsion between these two side chains prevents formation of the BTK specificity pocket. Consequently, by binding to and stabilizing the BTK specificity pocket, <b>9</b> blocks the activation loop phosphorylation of BTK and to a much lesser extent inhibits the activity of phosphorylated BTK.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Surface plasmon resonance data show that <b>9</b> binds with 32-fold greater affinity to the nonphosphorylated form than to the phosphorylated form (<i>K</i><sub>d</sub> of 2.9 nM vs 94.1 nM, respectively) of the enzyme. Competition binding of <b>9</b> in the Ambit panel of 385 kinases at 1 μM reveals only five kinases with more than 50% displacement of control ligand (BTK 100%, CASK 69%, MINK 77%, NEK11 59%, PDGFRB 59%). Compound <b>9</b> binds MINK1, the second most tightly bound kinase, with a <i>K</i><sub>d</sub> of 40 μM vs 1.5 nM for BTK. A biochemical screen of 47 purified kinases at <i>K</i><sub>m</sub> for ATP showed that BMX, with IC<sub>50</sub> = 1.87 μM, was the next most potently inhibited kinase after BTK, with a nearly 1000-fold reduction in potency relative to BTK.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Irreversible Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21204" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21204" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Pharmacyclics</h3><div class="NLM_p">Pharmacyclics screened a variety of scaffolds for inhibitory activity of BTK and found that compound <b>12</b> was a potent (IC<sub>50</sub> = 8.2 nM) inhibitor. Compound <b>12</b> and others from this compound class (i.e., <b>2</b>) had previously been found to be potent inhibitors of Itk as well as other kinases from the Tec and Src family. On the basis of the proposed binding mode of <b>12</b> in a homology model, a series of inhibitors targeting the C481 with electrophilic Michael acceptors were designed. Of these early published examples, <b>11</b> was the most potent in enzymatic assays (IC<sub>50</sub> < 0.5 nM) and showed cellular selectivity, with >10 times greater inhibition of Ca<sup>2+</sup> flux in B cell related (Ramos) cells vs T cells (Jurkat).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Examples of other BTK inhibitors that have been claimed in Pharmacyclics patents are shown (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31 ref32">(27-32)</a></div><figure id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative BTK inhibitors from Pharmacyclics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharmacyclics has reported on the development of the selective irreversible Btk inhibitor, <b>11</b>, that is currently in phase II clinical trials in patients with relapsed or refractory mantle cell lymphoma<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and phase Ib/II trials for multiple B-cell related malignancies.<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34-36)</a></div><div class="NLM_p">As described above, <b>11</b> is a selective BTK inhibitor with potent enzyme activity (IC<sub>50</sub> = 0.5 nM). In cells, <b>11</b> blocks BCR-stimulated activation of NF-kB and ERK, inhibiting growth and inducing apoptosis in B cell lymphoma cell lines. It was shown to be efficacious in multiple preclinical oncology models, including a transgenic murine model of BCR-driven lymphoma. In dogs, <b>11</b> induced objective clinical responses with spontaneous B-cell non-Hodgkin’s lymphoma (NHL). Additionally, orally administered <b>11</b> showed activity in a mouse collagen-induced arthritis model, reducing the level of circulating autoantibodies and completely suppressing disease. Finally, <b>11</b> also was effective in the MRL-Fas(lpr) lupus model of kidney disease.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">A phase I dose-escalating, multicenter, open-label study of <b>11</b> in patients with relapsed aggressive NHL was conducted to evaluate its safety and pharmacokinetic profile. Compound <b>11</b> was well tolerated with minimal toxicities at doses up to 12.5 mg kg<sup>–1</sup> day<sup>–1</sup>, and MTD was not reached. A second primary end point of the study was to obtain a PK/PD assessment, and as determined by ex vivo competition experiments with an irreversible fluorescent probe, full occupancy of BTK was achieved at doses of ≥2.5 mg/kg per day.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">Phase I results with multiple ascending doses of <b>11</b> have been reported for a variety of B cell malignancies. Generally the compound was well tolerated, with diarrhea and fatigue being the most common side effects and with no hepatic or renal toxicity reported even after more than 6 months of dosing. An objective response rate of 45% was achieved across all patient cohorts with the highest efficacy seen for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) with rates of 56% and 78% respectively achieving a complete or partial response. Additionally, data in CLL or SLL patients showed an initial treatment-related lymphocytosis that could be due to a BTK mechanism-driven inhibition of integrin-mediated B cell homing. This shift into the peripheral circulation may contribute to overall CLL regression by loss of malignant B cell survival signals provided by the lymph node and bone marrow microenvironment.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">Subsequent phase II clinical trials for <b>11</b> are either planned or currently ongoing. A safety and efficacy study using a single agent (560 mg daily) for treatment of relapsed/refractory MCL<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> with or without prior treatment with bortezomib has been initiated as well for diffuse large B cell lymphoma (DLBCL).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Phase II trials are also ongoing at a slightly lower dose (420 mg daily) for CLL/SCL<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> in combination with existing therapies. Efficacy data for these larger trials are expected in the first half of 2012. It is interesting to note here that the doses (560 and 420 mg daily) chosen for efficacy studies are significantly higher than the minimal dose determined to give full target occupancy coverage in blood (2.5 mg/kg, ∼150 mg daily).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Though no rationales have been given by the investigators, it is possible that higher doses are needed to account for PK variability in a larger patient population. It is also possible that higher doses can provide full target coverage for malignant B cells in bone marrow or in lymph nodes than in blood to maximize the clinical efficacy.</div><div class="NLM_p last">Recently, <b>16</b> (PCI-45292, structure not disclosed), another irreversible inhibitor of BTK, was highlighted as a potential treatment for autoimmune disorders. While its structure has not yet been disclosed, a comprehensive patent analysis suggests that the compounds highlighted in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> may represent this lead series of inhibitors.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> This compound was described as having a reduced potential for off-target protein binding and improved metabolic stability compared to <b>11</b>. Compound <b>16</b> dose-dependently inhibited inflammatory synovitis, pannus formation, synovial fluid cytokines, cartilage damage, and bone erosion in both preventive and established murine collagen-induced arthritis (CIA) models.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Recently, further studies were halted because of an undesirable organ effect in all dose groups in rats. However, it was noted that the effect was not seen in a second tox species or with <b>11</b> and that it did not appear to be related to BTK inhibition. A backup compound for autoimmune applications is expected to be disclosed soon.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Avila Therapeutics</h3><div class="NLM_p">Avila is developing orally available, covalent BTK inhibitors as a potential treatment of B-cell-related hematological cancers such as non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as autoimmune diseases such as rheumatoid arthritis. Avila’s lead compound <b>17</b> (AVL-292, structure not disclosed) is likely based on the diaminopyrimidine scaffold decorated with acrylamide warheads which have been described in patents.<a onclick="showRef(event, 'ref44 ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46 ref47">(44-47)</a> From analysis<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> of the BTK patents from Avila Therapeutics, the structures that may represent their lead series of inhibitors are as represented in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>.</div><figure id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative BTK inhibitors from Avila.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>22</b> (AVL-101, structure not disclosed) was the first lead compound disclosed by Avila. It was designed to form a covalent bond with C481 of BTK.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Studies from mass spectrometry and prolonged inhibition (over 8 h) of cell-based assays after washout confirmed the irreversible inhibition. Compound <b>22</b> was shown to inhibit BTK substrate phosphorylation (P-PLCγ2) and B cell proliferation with EC<sub>50</sub> between 1 and 10 nM. When <b>22</b> was tested at 1 μM against 62 kinases, it was found to inhibit eight other kinases at >60% (AURORA-A, BMX, FGFR1, FLT4, ITK, JAK2, RET, and TRKA). No further development of <b>22</b> was described.</div><div class="NLM_p last">Avila’s most advanced BTK inhibitor <b>17</b> has potent activity with enzyme IC<sub>50</sub> < 0.5 nM and EC<sub>50</sub> < 10 nM in preventing BTK autophosphorylation and BTK substrate PLCγ2.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> It was reported to have good selectivity when measured in a panel of 62 kinases. However, without complete profiling of kinome selectivity, it is so far not possible to compare Avila’s covalent BTK inhibitors with Pharmacyclics’ covalent BTK inhibitors. Because <b>17</b> and <b>22</b> do not seem to bind into the back pocket, thus not taking advantage of the T474 gatekeeper residue, one would expect to see some differences in off-target kinase activities for these two classes of covalent inhibitors. Compound <b>17</b> was demonstrated to be efficacious in a collagen induced arthritis model, with significant efficacy at a dose of 3 mg/kg, and at doses of 10 mg/kg and higher, it completely suppressed signs and symptoms of collagen-induced arthritis in both prophylactic and therapeutic settings. A phase Ia single dose trial in healthy volunteers demonstrated that <b>17</b> was well tolerated up to a 7 mg/kg dose and a BTK occupancy with patient samples was assessed to determine optimum dosing for phase Ib studies. Preliminary data in patients with relapsed and/or refractory B cell NHL, CLL, and Waldenstrom’s macroglobulinemia have recently been reported.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Five of six patients receiving once daily dosing of <b>17</b> at either the 125 or 250 mg dose level had stable disease and remained on the study for more than 28 days with all three patients at the 125 mg level remaining on treatment for more than 100 days. Consistent with the proposed mechanism and clinical results for <b>11</b>,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> within these cohorts, for all four CLL patients, absolute lymphocyte counts increased after 4 weeks of treatment.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Locus Pharmaceuticals</h3><div class="NLM_p">Scientists at Locus Pharmaceuticals have identified novel pyrrolotriazines acting as inhibitors of BTK that are reported to be useful for the treatment of allergic conditions, autoimmune disorders, thromboembolism, B cell lymphoma, and inflammatory diseases such as rheumatoid arthritis.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> A representative compound, <b>23</b> (Figure<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) inhibited the activity of BTK (IC<sub>50</sub> = 2 nM) with selectivity of 1750-, 10000-, and >10000-fold over LCK, LYN, and FYN, respectively. The agent significantly inhibited the activation of murine B-cell splenocytes (IC<sub>50</sub> = 130 nM). In pharmacokinetic studies in Sprague–Dawley rats, a close analogue (at 2 mg/kg po) displayed the following values: oral bioavailability of 24%, <i>C</i><sub>max</sub> = 0.227 μg/mL, AUC = 652 ng·h/mL, and clearance of 0.74 mL h<sup>–1</sup> kg<sup>–1</sup>.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> These inhibitors are structurally related to <b>11</b>, with the main difference in the kinase hinge-binding core motif.</div><figure id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representative BTK inhibitors reported by Locus Pharmaceuticals and Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Pfizer</h3><div class="NLM_p last">Recently scientists at Pfizer described a series of imidazo[1,5-1]quinoxalines as potent and selective irreversible BTK inhibitors.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> An optimized compound <b>24</b> has BTK IC<sub>50</sub> of 1.93 nM as compared to LYN IC<sub>50</sub> of 624 nM. It is also active in cells with IC<sub>50</sub> of 3.41 nM for the inhibition of B cell proliferation. Compound <b>24</b> was also evaluated in semitherapeutic mouse CIA model, where it significantly inhibited the progression of the disease compared to vehicle control at 3 and 10 mg/kg after oral dosing.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Reversible Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> CGI Pharmaceuticals/Genentech</h3><div class="NLM_p">CGI/Genentech pioneered the discovery and development of selective reversible inhibitors of BTK. In 2006, CGI first described a series of imidazo[1,2-<i>a</i>]pyrazinylamines with activity IC<sub>50</sub> < 10 nM in an in vitro biochemical assay and IC<sub>50</sub> < 500 nM for inhibition of B-cell proliferation.<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53-55)</a> Subsequent patent filings focused on replacing imidazo[1,2-<i>a</i>]pyrazinylamino with other kinase hinge binding motifs.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The discovery of <b>25</b> (CGI560, Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>),<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> with IC<sub>50</sub> = 400 nM for BTK, from site-directed libraries and the optimization efforts that led to <b>9</b> have been described. Solution of the crystal structure of this inhibitor bound to the human BTK kinase domain (vide supra) explained the unique selectivity of this class of compounds and allowed evaluation of this class of inhibitors in a variety of in vivo studies.</div><figure id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. CGI/Genentech’s BTK inhibitors <b>25</b> and <b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further optimization of <b>9</b> focused on improving potency and achieving oral bioavailability.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Scaffold hopping and replacement of the key lipophilic <i>tert</i>-butyl group with a tetrahydrobenzothiophene moiety reduced the in vivo clearance in rats, giving much improved oral exposure. Solubility was addressed by the addition of an amine group in the solvent-exposed region, ultimately leading to the development candidate <b>26</b> (GDC-0834).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">The effect of targeting the inactive, nonphosphorylated form of BTK with <b>9</b> on cellular signaling and in animal efficacy models was studied. Compound <b>9</b> was shown to inhibit the anti-IgM-induced phosphorylation of BTK Y551 and Y223 as well as PLCγ2 Y1217 in both human and murine B cells. Functionally, <b>9</b> inhibits anti-IgM-induced human B cell proliferation with an IC<sub>50</sub> of 42 nM while having no effect on anti-CD3 and anti-CD28-induced T cell proliferation. A variety of animal models of arthritis were also investigated with this new tool compound and showed striking efficacy. Prophylactic, subcutaneous administration of <b>9</b> (100 mg/kg b.i.d.) provided IC<sub>90</sub> coverage for 50% of the dosing period and significantly (>97%) inhibited clinical arthritis scores in a mouse CIA model, superior to dexamethasone. Compound <b>9</b> also inhibits FcR signaling, inhibiting TNFα production by stimulation of macrophages with immobilized immune complexes in a dose-dependent manner with an IC<sub>50</sub> of 25 nM. Identical dosing of <b>9</b> (100 mg/kg b.i.d.) was also effective in the passive anti-collagen II antibody-induced arthritis model (CAIA), effectively preventing arthritis development when compared to untreated animals. Analysis of cytokine production in joints showed reduced levels of TNFα, IL-1β, IL-6, MCP1, and MIP1α. Btk inhibition was also found to affect established arthritis, where treatment was initiated 3 days subsequent to secondary collagen immunization. Compound <b>9</b> showed efficacy comparable to that of TNFα blockade and significantly reduced bone loss, proliferative synovitis, subsynovial pannus formation, and cartilage destruction.</div><div class="NLM_p">In summary, across multiple cellular pathways and using various animal models, selective inhibition of Btk through reversible binding to the unactivated protein shows great promise as an effective treatment for rheumatoid arthritis and perhaps other autoimmune and inflammatory diseases. While <b>9</b> served as an excellent tool compound, the need for subcutaneous dosing becomes clear when noting that it has rapid clearance (86 mL min<sup>–1</sup> kg<sup>–1</sup>) and very low bioavailabilility (<1%) when dosed orally in rats. Additionally, potency in whole blood assay was poor (CD63 inhibition EC<sub>50</sub> = 1.2 μM).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p last">Compound <b>26</b><a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> represents CGI/Genentech’s first reported clinical candidate and possesses potent enzyme activity (IC<sub>50</sub> = 2.3 nM) as well as excellent activity in a human whole blood CD63 assay (IC<sub>50</sub> = 397 nM). Cellular mode of action studies indicate that efficacy is driven through BCR and FcR signaling as described above for <b>9</b>. Additionally, this molecule was reported to have a good PK profile in rat and dog and a good safety profile both in vitro and in vivo. Compound <b>26</b> was shown to suppress arthritis in the rat CIA model with dosing at 100 mg/kg b.i.d., giving results comparable to those from methotrexate treatment. Additionally, a PK/PD model was established that linked the level of pBTK inhibition and antiarthritis effect, with >60% inhibition of pBTK required for reduction of ankle diameter and 73% inhibition for half-maximal activity.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> While this holds promise for future trial design, clinical development of <b>26</b> has been suspended because of poor pharmacokinetic properties in humans. Specifically, in a single dose human clinical trial the rapid hydrolysis of the amide bond resulted in below quantitative levels of <b>26</b> and the presence of the primary aniline and derivatives as the major metabolites.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Roche</h3><div class="NLM_p">Roche has disclosed various novel classes of specific BTK inhibitors. A class of potent urea compounds was claimed,<a onclick="showRef(event, 'cit60a cit60b'); return false;" href="javascript:void(0);" class="ref cit60a cit60b">(60a, 60b)</a> as exemplified in structure <b>27</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), which has an enzyme IC<sub>50</sub> of 13 nM. Multiple types of bicyclic compounds with isoquinolone, quinolone, and quinazolinone ring systems were exemplified,<a onclick="showRef(event, 'cit60b cit60c cit60d cit60e cit60g'); return false;" href="javascript:void(0);" class="ref cit60b cit60c cit60d cit60e cit60g">(60b-60e, 60g)</a> which have replaced the secondary amide moiety typically conserved in other patent publications. More recent analogues with unusual [7, 6] bicyclic ring systems were claimed to have very good HWB potency, with compound <b>28</b> having an HWB IC<sub>50</sub> of 4 nM for CD69 inhibition.<a onclick="showRef(event, 'cit60f'); return false;" href="javascript:void(0);" class="ref cit60f">(60f)</a></div><figure id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Representative BTK inhibitors reported by Roche.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Roche reported preclinical studies with a reversible, potent, and highly selective BTK inhibitor, <b>29</b> (RN486).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> It binds the enzyme in a competitive manner in a TR-FRET-based competitive assay with an IC<sub>50</sub> of 0.3 nM. Compound <b>29</b> exhibited a high degree of selectivity over a large panel of 396 kinases, including SYK and JAK, two validated RA targets. The enzyme that was inhibited the most by <b>29</b> next to BTK was SLK, an enzyme not implicated in autoimmune responses, with 139-fold selectivity.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Together, these data indicate that <b>29</b> is a selective and potent inhibitor for Btk. It blocks both BCR and FcR signaling, inhibiting IgM-stimulated CD69 expression in B cells in human whole blood, IgG-FcγR mediated TNFα release in monocytes, and IgE-Fce cross-linking induced histamine release in mast cells with IC<sub>50</sub> values of 17, 4, and 29.2 nM, respectively. In contrast, as expected, <b>29</b> is inactive in the Jurkat T cell calcium flux assay. Compound <b>29</b> dose-dependently inhibits disease progression in both mCIA and mCAIA models, as well as demonstrates an additive effect of inhibiting inflammation and bone erosion in adjuvant-induced arthritis. When <b>29</b> was administered orally in a preventive mode at doses of 3, 30, and 100 mg/kg in a mouse CIA model, it completely inhibited ex vivo anti-IgD stimulated CD69 expression at 3 and 6 h postdose at all doses and by approximately 50–80% 24 h postdose. Compound <b>29</b> showed complete inhibition of arthritis as measured by clinical scores at 100 mg/kg, similar to dexamethasone. When <b>29</b> was studied in a therapeutic mode in mCIA and mCAIA models, animals treated with <b>29</b> did not show progression of disease at 30 mg/kg. In addition, <b>29</b> demonstrated a greater effect (91%, 30 mg/kg) than cyproheptadine, a nonselective antihistamine agent (69% maximum inhibition) in blocking the hypersensitive immune responses in a rat passive cutaneous anaphylaxis (rPCA) model. Both BCR and FcR pathways are known to play an essential role in the development of RA and other autoimmune diseases. Therefore, the blockade of both signaling pathways may have contributed to the anti-inflammatory effects observed with <b>29</b> in the various preclinical disease models. BTK inhibition is suggested to protect bone erosion not only indirectly by inhibiting ongoing inflammation but also directly by affecting osteoclast differentiation. In addition, observed additive effects between <b>29</b> and low dose methotrexate in a rat AIA model demonstrated the potential of combination therapies for BTK inhibitors.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> BMS</h3><div class="NLM_p">The small molecule kinase inhibitor <b>1</b> is approved for the treatment of imatinib-resistant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. The primary targets of <b>1</b> are the tyrosine kinases Bcr-Abl and Src family members, and numerous other kinases have been reported to be inhibited at nanomolar concentrations.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Chemical proteomics experiments using CML cells have demonstrated that <b>1</b> also binds to BTK. <b>1</b> inhibits the kinase activity of BTK in vitro with IC<sub>50</sub> = 5 nM, and it abolishes autophosphorylation on Y223 in cells at 100 nM.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Compound <b>1</b> has also been shown to bind to BTK in B cells, basophils, and mast cells.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Inhibition of BTK with <b>1</b> has been indicated to block the secretion of proinflammatory cytokines. At 1 μM, the multitargeted kinase inhibitor almost completely blocks basal and LPS-induced TNFα secretion of vitamin D3-differentiated U937 cells, and it completely inhibits antigen-induced secretion of IL6 in murine mast cells.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Inhibition of BTK with <b>1</b> has also been indicated to block histamine release. At 1 μM, <b>1</b> completely abolishes anti-IgE antibody-induced histamine release from primary human basophils.<a onclick="showRef(event, 'ref63 ref65'); return false;" href="javascript:void(0);" class="ref ref63 ref65">(63, 65)</a> It also significantly reduces antigen-induced histamine release from bone marrow-derived murine mast cells. The level of reduction is similar to that in cells derived from BTK deficient animals.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Consequently, <b>1</b> has been suggested to be of potential benefit for the treatment of inflammatory and immunological diseases involving BTK-dependent signaling pathways.<a onclick="showRef(event, 'ref63 ref65'); return false;" href="javascript:void(0);" class="ref ref63 ref65">(63, 65)</a> However, its off-target activity against other tyrosine kinases may limit its potential applications for chronic inflammatory diseases.</div><div class="NLM_p">BMS has also disclosed diverse chemical classes of kinase inhibitors specific for BTK. Substituted carbazoles were claimed to be effective inhibitors of BTK and other Tec family kinases such as ITK with a representative example compound <b>30</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) with BTK IC<sub>50</sub> of 0.7 nM and Ramos FLIPR IC<sub>50</sub> of 11 nM.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Substituted imidazotriazines<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67, 68)</a> have some pharmacophore features that are similar to known selective BTK inhibitors (CGI bicyclic core patents). Compound <b>31</b>, with a piperidine group instead of a phenyl group, retains potent BTK activity, having IC<sub>50</sub> values of 13 and 56 nM in human enzyme assays and mouse splenic B cell proliferation assays, respectively.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> This modification avoids the potential of generating primary aniline metabolites and may provide improved physical properties compared to aromatic amides. An amino group on the imidazole ring was shown to increase potency. For example, compound <b>33</b> is about 5-fold more active than compound <b>32</b>.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> In the human enzyme assay and the human Ramos cell FLIPR assay, <b>33</b> has IC<sub>50</sub> values of 30 and 32 nM, versus 144 and 142 nM for <b>32</b>. The amino group is presumably in proximity to the gatekeeper Thr residue, possibly making favorable H-bond interaction with the Thr group. A more recent patent<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> described a series of 3-aminoazaindazole compounds as BTK inhibitors. A representative compound, <b>34</b>, is reported to have a BTK IC<sub>50</sub> of 1 nM.</div><figure id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Representative BTK inhibitors reported by BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Biogen Idec</h3><div class="NLM_p">Multiple compounds with pyrrolopyrimidine cores were recently claimed by Biogen Idec as selective BTK inhibitors.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Compounds <b>35</b>–<b>38</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>) are some representative examples with BTK enzyme IC<sub>50</sub> less than 100 nM. The vector off the piperidine ring seems to project into the selectivity pocket, albeit with very different functionalities from the <i>tert</i>-butyl benzyl group. None of the claimed inhibitors have obvious solvent-exposed groups, unlike the other types of reversible BTK inhibitors. However, lack of more detailed information such as binding affinity and cellular activity precludes meaningful comparison.</div><figure id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Representative BTK inhibitors reported by Biogen Idec.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08374" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08374" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">BTK inhibition has emerged as a target of growing interest in both oncology and inflammation settings in the past 10 years. Careful analysis of the unique amino acid sequences and structural characterization by X-ray crystallography of ligands bound to BTK have enabled the strategic development of potent and exquisitely selective BTK inhibitors. Targeting the relatively unique C481 of BTK has led to selective <i>covalent</i> inhibitors that have provided validation of the target in animal models of inflammation and cancer. Most recently, a compound from this class has advanced to phase II clinical trials in an oncology setting, showing acceptable toxicities at doses that provide complete BTK occupancy and significant clinical efficacy. Concerted screening, crystallography, modeling, and medicinal chemistry efforts have led to highly selective, <i>noncovalent</i> BTK inhibitors that bind to a specificity pocket present in the nonphosphorylated form of BTK. Recent disclosures have shown that these molecules exhibit similar in vivo effects in animal models of arthritis, mediated through inhibition of BCR and FcR signaling. Recent patent activity demonstrates that there is continued interest in further exploring both covalent and noncovalent inhibitors of BTK with improved potency and druglike physicochemical properties and safety profiles. Ultimately, more data from ongoing and planned clinical trials in both oncology and inflammation settings will determine whether BTK inhibition with small molecules will play a role in improving human health.</div></div><div class="NLM_back"><div class="NLM_notes" id="NOTES-d926e1263-autogenerated"><p class="first last">The authors declare no competing financial interest.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm300035p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14038" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14038" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Lou</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Small Molecule Research, pRED, Pharma Research and Early
Development, Hoffmann-La Roche Inc., 340
Kingsland Street, Nutley, New Jersey 07110, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#067f6768286a6973287f6a37467469656e632865696b267f6768286a697346616b676f6a2865696b26726f6b2869716368754676746f68656f766f67646f692865696b"><span class="__cf_email__" data-cfemail="5c253d32723033297225306d1c2e333f3439723f3331">[email protected]</span> <span class="__cf_email__" data-cfemail="4e372f206022213b0e29232f2722602d2123">[email protected]</span> <span class="__cf_email__" data-cfemail="e89c8185c6879f8d869ba8989a81868b819881898a8187c68b8785">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy D. Owens</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Small Molecule Research, pRED, Pharma Research and Early
Development, Hoffmann-La Roche Inc., 340
Kingsland Street, Nutley, New Jersey 07110, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3b425a551557544e1542570a7b495458535e155854561b425a551557544e7b5c565a5257155854561b4f525615544c5e55487b4b49525558524b525a59525415585456"><span class="__cf_email__" data-cfemail="c0b9a1aeeeacafb5eeb9acf180b2afa3a8a5eea3afad">[email protected]</span> <span class="__cf_email__" data-cfemail="86ffe7e8a8eae9f3c6e1ebe7efeaa8e5e9eb">[email protected]</span> <span class="__cf_email__" data-cfemail="3c48555112534b59524f7c4c4e55525f554c555d5e5553125f5351">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Kuglstatter</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Small Molecule Research, pRED, Pharma Research and Early
Development, Hoffmann-La Roche Inc., 340
Kingsland Street, Nutley, New Jersey 07110, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rama K. Kondru</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Small Molecule Research, pRED, Pharma Research and Early
Development, Hoffmann-La Roche Inc., 340
Kingsland Street, Nutley, New Jersey 07110, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David M. Goldstein</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Small Molecule Research, pRED, Pharma Research and Early
Development, Hoffmann-La Roche Inc., 340
Kingsland Street, Nutley, New Jersey 07110, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48560" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48560" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Yan Lou</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yan Lou</b> graduated from the University of Science and Technology of China in 1998. After receiving his Ph.D. in 2002 from Dartmouth College, NH, under the supervision of Prof. David M. Lemal, he joined Prof. E. J. Corey’s group at Harvard University, MA. After beginning his medicinal chemistry career at Roche in 2005, he has led the chemistry teams for multiple projects in the inflammation and oncology therapeutic areas. His main interest and expertise are in using structure based drug design to guide drug discovery for kinases, proteases, and epigenetic and protein–protein interaction targets.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Timothy D. Owens</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Timothy D. Owens</b> received his B.S. degree from University of California—San Diego and his Ph.D. from University of California—Berkeley under the guidance of Prof. Jonathan Ellman, designing chiral sulfinamide-based catalysts for asymmetric synthesis. He pursued postdoctoral studies in natural product synthesis at Memorial Sloan-Kettering in New York with Prof. Samuel Danishefsky before joining Roche Palo Alto in 2004. Working at Roche Nutley since 2009, his research included CNS, inflammation, and oncology programs as well as chemical biology approaches to finding novel therapeutic targets. In December 2011, Tim joined Principia Biopharma in South San Francisco, CA, as an Associate Director of Medicinal Chemistry.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Andreas Kuglstatter</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=bio3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andreas Kuglstatter</b> received an M.S. degree from the University of Frankfurt, Germany, in 1999 for the characterization of photosynthetic reaction centers, and a Ph.D. from the University of Cambridge, U.K., in 2003 for structural analysis of RNA–protein complexes. After 2 years as a Postdoctoral Fellow at F. Hoffmann-La Roche in Basel, Switzerland, he joined Roche Palo Alto, CA, where he was Head of Protein Crystallography. In 2009, Andreas joined the Discovery Technology Department at Hoffmann-La Roche in Nutley, NJ, and in 2011 he returned to F. Hoffmann-La Roche in Basel, Switzerland. His main areas of expertise are kinase inhibitors, fragment-based drug discovery, protein engineering, and external collaborations.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Rama K. Kondru</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=bio4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Rama K. Kondru</b> received his B.S. and M.S. from Indian Institute of Technology in Mumbai, India. He received his Ph.D. from the University of Pittsburgh, PA, in 1999. His research interests are in structure-based drug design and computational chemistry. He is currently the Head of the Computational Chemistry and Data Mining Group at Hoffmann-La Roche, Nutley, NJ.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">David M. Goldstein</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=bio5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>David M. Goldstein</b> received his Ph.D. in Organic Chemistry from the Department of Chemistry at the University of Virginia in 1992. He went on to complete postdoctoral studies at the University of Pittsburgh, PA, in 1994 and subsequently joined Syntex in Palo Alto, CA. David continued on with Roche in 1995 where his research focused on the discovery of small molecule inhibitors in the areas of inflammatory, respiratory, autoimmune, and virology diseases. In 2009, David became a Senior Director and the Head of Inflammation Chemistry at Hoffmann-La Roche in Nutley, NJ. In 2011, David joined Principia Biopharma in South San Francisco, CA, as the Vice President of Drug Discovery.</p></figure></div><div class="ack" id="ACK-d926e1260-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Drs. Ronald Hill, Julie DeMartino, Jutta Wanner, Yimin Qian, and Francisco Lopez-Tapia for helpful discussions and proofreading of the manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i27" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i27"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i28" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i28"> Abbreviations Used</h2><tr><td class="NLM_term">AURORA-A</td><td class="NLM_def"><p class="first last">Aurora kinase A</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B cell receptor</p></td></tr><tr><td class="NLM_term">BLK</td><td class="NLM_def"><p class="first last">B lymphosite kinase</p></td></tr><tr><td class="NLM_term">BMX</td><td class="NLM_def"><p class="first last">kinase encoded by <i>BMX</i> gene</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CASK</td><td class="NLM_def"><p class="first last">calcium/calmodulin-dependent serine protein kinase</p></td></tr><tr><td class="NLM_term">CD63</td><td class="NLM_def"><p class="first last">antigen encoded by the <i>CD63</i> gene</p></td></tr><tr><td class="NLM_term">CD69</td><td class="NLM_def"><p class="first last">lectin protein encoded by the <i>CD69</i> gene</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen induced arthritis</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B cell lymphoma</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ERBB2</td><td class="NLM_def"><p class="first last">kinase of epidermal growth factor receptor family (also known as HER2, Neu, and CD340)</p></td></tr><tr><td class="NLM_term">ERBB4</td><td class="NLM_def"><p class="first last">kinase of epidermal growth factor receptor family encoded by <i>ERBB4</i> gene</p></td></tr><tr><td class="NLM_term">FcR</td><td class="NLM_def"><p class="first last">Fc receptor</p></td></tr><tr><td class="NLM_term">FGFR1</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 1</p></td></tr><tr><td class="NLM_term">FLIPR</td><td class="NLM_def"><p class="first last">fluorescence imaging plate reader</p></td></tr><tr><td class="NLM_term">FLT4</td><td class="NLM_def"><p class="first last">FMS-related tyrosine kinase 4</p></td></tr><tr><td class="NLM_term">FYN</td><td class="NLM_def"><p class="first last">tyrosine kinase encoded by the <i>FYN</i> gene</p></td></tr><tr><td class="NLM_term">HCK</td><td class="NLM_def"><p class="first last">hemopoietic cell kinase</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">ITK</td><td class="NLM_def"><p class="first last">IL2-inducible T-cell kinase</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">LCK</td><td class="NLM_def"><p class="first last">lymphocyte specific protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">LYN</td><td class="NLM_def"><p class="first last">V-yes-1 Yamaguchi sarcoma viral relate oncogene homologue</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">MINK</td><td class="NLM_def"><p class="first last">misshapen-like kinase 1</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">multiple sclerosis</p></td></tr><tr><td class="NLM_term">NEK11</td><td class="NLM_def"><p class="first last">NIMA (never in mitosis gene a)-related kinase 11</p></td></tr><tr><td class="NLM_term">NHL</td><td class="NLM_def"><p class="first last">non-Hodgkin’s lymphoma</p></td></tr><tr><td class="NLM_term">PDGFRB</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor, β polypeptide</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">tyrosine kinase encoded by the <i>RET</i> proto-oncogene</p></td></tr><tr><td class="NLM_term">rPCA</td><td class="NLM_def"><p class="first last">rat passive cutaneous anaphylaxis</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">SLL</td><td class="NLM_def"><p class="first last">small lymphocytic lymphoma</p></td></tr><tr><td class="NLM_term">SLK</td><td class="NLM_def"><p class="first last">Ste20-like kinase</p></td></tr><tr><td class="NLM_term">SRC</td><td class="NLM_def"><p class="first last">sarcoma kinase</p></td></tr><tr><td class="NLM_term">SYK</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr><tr><td class="NLM_term">TEC</td><td class="NLM_def"><p class="first last">tyrosine kinase encoded by the <i>TEC</i> gene</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">TRKA</td><td class="NLM_def"><p class="first last">neurotrophic tyrosine kinase receptor type 1</p></td></tr><tr><td class="NLM_term">TXK</td><td class="NLM_def"><p class="first last">tyrosine kinase encoded by the <i>TXK</i> gene</p></td></tr><tr><td class="NLM_term">XLA</td><td class="NLM_def"><p class="first last">X-linked agammaglobulinemia</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50726" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50726" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 70 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Vetrie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorechovsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinter, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarstrom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinnon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobrow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentley, D. R.</span><span> </span><span class="NLM_article-title">The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">226</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=1993&pages=226-233&author=D.+Vetrieauthor=I.+Vorechovskyauthor=P.+Siderasauthor=J.+Hollandauthor=A.+Daviesauthor=F.+Flinterauthor=L.+Hammarstromauthor=C.+Kinnonauthor=R.+Levinskyauthor=M.+Bobrowauthor=C.+I.+E.+Smithauthor=D.+R.+Bentley&title=The+gene+involved+in+X-linked+agammaglobulinaemia+is+a+member+of+the+src+family+of+protein-tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVetrie%26aufirst%3DD.%26aulast%3DVorechovsky%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DFlinter%26aufirst%3DF.%26aulast%3DHammarstrom%26aufirst%3DL.%26aulast%3DKinnon%26aufirst%3DC.%26aulast%3DLevinsky%26aufirst%3DR.%26aulast%3DBobrow%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DBentley%26aufirst%3DD.%2BR.%26atitle%3DThe%2520gene%2520involved%2520in%2520X-linked%2520agammaglobulinaemia%2520is%2520a%2520member%2520of%2520the%2520src%2520family%2520of%2520protein-tyrosine%2520kinases%26jtitle%3DNature%26date%3D1993%26volume%3D361%26spage%3D226%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Smith, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humire-Greiff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniar, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjellen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarstrom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetrie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorechovsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideras, P.</span><span> </span><span class="NLM_article-title">Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=8283037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1994&pages=557-565&author=C.+I.+Smithauthor=B.+Baskinauthor=P.+Humire-Greiffauthor=J.+N.+Zhouauthor=P.+G.+Olssonauthor=H.+S.+Maniarauthor=P.+Kjellenauthor=J.+D.+Lambrisauthor=B.+Christenssonauthor=L.+Hammarstromauthor=D.+Bentleyauthor=D.+Vetrieauthor=K.+B.+Islamauthor=I.+Vorechovskyauthor=P.+Sideras&title=Expression+of+Bruton%E2%80%99s+agammaglobulinemia+tyrosine+kinase+gene%2C+BTK%2C+is+selectively+down-regulated+in+T+lymphocytes+and+plasma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span></div><div class="casAuthors">Smith, C. I. Edvard; Baskin, Berivan; Humire-Greiff, Patricia; Zhou, Jian Nian; Olsson, Per G.; Maniar, Hina S.; Kjellen, Peter; Lambris, John D.; Christensson, Birger; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">557-65</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">The gene mutated in the human disease, X-linked agammaglobulinemia (XLA), is related to the Src gene family of cytoplasmic protein-tyrosine kinases and is designated Btk (Bruton's agammaglobulinemia tyrosine kinase; formerly Atk/Bpk; the human gene is denoted BTK, using capital letters according to the kinase nomenclature).  The authors have recently reported that this gene is expressed in B lymphocytes and that the specific mRNA was undetectable in T cells using Northern blotting.  Further analyses of different sources of B and T lymphocytes confirmed this pattern.  However, BTK transcripts were undetectable in four plasmacytoma lines.  Moreover, as virtually normal amts. of BTK transcripts were found in PBMC from two patients carrying a point mutation in BTK, despite low B cell nos., the authors anticipated that the gene would also be expressed in cells of other lineages.  The erythroleukemia cell line K-562, the promyelocytic line HL-60 and the histiocytic lymphoma line U-937 were found to have BTK mRNA levels comparable to B cells.  BTK mRNA was also detected in monocytes from healthy donors as well as in the human immature basophilic cell line KU812, in the human mast cell leukemia cell line HMC-1 and in the CD34 expressing myeloblast KG-1.  A similar expression pattern was obtained when BTK protein was analyzed by immunopptn. and Western blotting.  Using a polymerase chain reaction-based anal., a small amt. (less than 1% of the level in B cells) of BTK mRNA was identified in T lymphocytes.  The authors' findings are compatible with a general expression of the BTK gene in hematopoietic cells, except in T lymphocytes and plasma cells, in which the transcript level is selectively down-regulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKw_P8osJHjLVg90H21EOLACvtfcHk0liMd4OV8_kAxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D&md5=c18d78dc39ed08bd0c1fb784cbf549a1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHumire-Greiff%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%2BN.%26aulast%3DOlsson%26aufirst%3DP.%2BG.%26aulast%3DManiar%26aufirst%3DH.%2BS.%26aulast%3DKjellen%26aufirst%3DP.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DHammarstrom%26aufirst%3DL.%26aulast%3DBentley%26aufirst%3DD.%26aulast%3DVetrie%26aufirst%3DD.%26aulast%3DIslam%26aufirst%3DK.%2BB.%26aulast%3DVorechovsky%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26atitle%3DExpression%2520of%2520Bruton%25E2%2580%2599s%2520agammaglobulinemia%2520tyrosine%2520kinase%2520gene%252C%2520BTK%252C%2520is%2520selectively%2520down-regulated%2520in%2520T%2520lymphocytes%2520and%2520plasma%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D1994%26volume%3D152%26spage%3D557%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Conley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbs, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigoriadou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coustan-Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campana, D.</span><span> </span><span class="NLM_article-title">Primary B cell immunodeficiencies: comparisons and contrasts</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1146%2Fannurev.immunol.021908.132649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19302039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=199-227&author=M.+E.+Conleyauthor=A.+K.+Dobbsauthor=D.+M.+Farmerauthor=S.+Kilicauthor=K.+Parisauthor=S.+Grigoriadouauthor=E.+Coustan-Smithauthor=V.+Howardauthor=D.+Campana&title=Primary+B+cell+immunodeficiencies%3A+comparisons+and+contrasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Primary B cell immunodeficiencies: comparisons and contrasts</span></div><div class="casAuthors">Conley, Mary Ellen; Dobbs, A. Kerry; Farmer, Dana M.; Kilic, Sebnem; Paris, Kenneth; Grigoriadou, Sofia; Coustan-Smith, Elaine; Howard, Vanessa; Campana, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">199-227</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Sophisticated genetic tools have made possible the identification of the genes responsible for most well-described immunodeficiencies in the past 15 years.  Mutations in Btk, components of the pre-B cell and B cell receptor (λ5, Igα, Igβ), or the scaffold protein BLNK account for approx. 90% of patients with defects in early B cell development.  Hyper-IgM syndromes result from mutations in CD40 ligand, CD40, AID, or UNG in 70-80% of affected patients.  Rare defects in ICOS or CD19 can result in a clin. picture that is consistent with common variable immunodeficiency, and as many as 10% of patients with this disorder have heterozygous amino acid substitutions in TACI.  For all these disorders, there is considerable clin. heterogeneity in patients with the same mutation.  Identifying the genetic and environmental factors that influence the clin. phenotype may enhance patient care and the understanding of normal B cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_hgfd2bSrJ7Vg90H21EOLACvtfcHk0liMd4OV8_kAxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D&md5=83216a7a297af38c2efdf9d3e79a1213</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132649%26sid%3Dliteratum%253Aachs%26aulast%3DConley%26aufirst%3DM.%2BE.%26aulast%3DDobbs%26aufirst%3DA.%2BK.%26aulast%3DFarmer%26aufirst%3DD.%2BM.%26aulast%3DKilic%26aufirst%3DS.%26aulast%3DParis%26aufirst%3DK.%26aulast%3DGrigoriadou%26aufirst%3DS.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DHoward%26aufirst%3DV.%26aulast%3DCampana%26aufirst%3DD.%26atitle%3DPrimary%2520B%2520cell%2520immunodeficiencies%253A%2520comparisons%2520and%2520contrasts%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D199%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Gürcan, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keskin, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J. N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitzberg, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shekhani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. R.</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2Fj.intimp.2008.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19000786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FmtF2ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=G%C3%BCrcan%2C+H.+M.%3B+Keskin%2C+D.+B.%3B+Stern%2C+J.+N.+H.%3B+Nitzberg%2C+M.+A.%3B+Shekhani%2C+H.%3B+Ahmed%2C+A.+R.Int.+Immunopharmacol.+2009%2C+9%2C+10%E2%80%9325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the current use of rituximab in autoimmune diseases</span></div><div class="casAuthors">Gurcan Hakan M; Keskin Derin B; Stern Joel N H; Nitzberg Matthew A; Shekhani Haris; Ahmed A Razzaque</div><div class="citationInfo"><span class="NLM_cas:title">International immunopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-25</span>
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    </div><div class="casAbstract">Rituximab is a human/murine chimeric monoclonal antibody primarily used for treating non-Hodgkin's B-cell lymphoma.  Recently it has also been used in the treatment of several autoimmune diseases.  A literature review was conducted to determine the efficacy of rituximab in the treatment of some of these autoimmune diseases.  Multiple mechanisms proposed for the rituximab mediated B cell depletion are also discussed.  The efficacy of rituximab is well-established and it is FDA approved for treatment of Rheumatoid arthritis.  In this review, data on the use of rituximab is presented from 92 studies involving 1197 patients with the following diseases: systemic lupus erythematosus, idiopathic thrombocytopenic purpura, anti-neutrophil cytoplasmic antibody associated vasculitis, Grave's disease, autoimmune hemolytic anemia, pemphigus vulgaris, hemophilia A, cold agglutinin disease, Sjogren's syndrome, graft vs. host disease, thrombotic thrombocytopenic purpura, cryoglobulinemia, IgM mediated neuropathy, multiple sclerosis, neuromyelitis optica, idiopathic membranous nephropathy, dermatomyositis, and opsoclonus myoclonus.  The efficacy varies among different autoimmune diseases.  The cumulative data would suggest that in the vast majority of studies in this review, RTX has a beneficial role in their treatment.  While rituximab is very effective in the depletion of B cells, current research suggests it may also influence other cells of the immune system by re-establishing immune homeostasis and tolerance.  The safety profile of RTX reveals that most reactions are infusion related.  In patients with autoimmune diseases the incidence of serious and severe side effects is low.  Systemic infection still remains a major concern and may result in death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSN4idF-uziT9XdcedVHT5tfW6udTcc2eY_76ffl6uYPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FmtF2ksg%253D%253D&md5=5dd07b14f6c46a71b64cad7afe9dfc04</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2008.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2008.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCrcan%26aufirst%3DH.%2BM.%26aulast%3DKeskin%26aufirst%3DD.%2BB.%26aulast%3DStern%26aufirst%3DJ.%2BN.%2BH.%26aulast%3DNitzberg%26aufirst%3DM.%2BA.%26aulast%3DShekhani%26aufirst%3DH.%26aulast%3DAhmed%26aufirst%3DA.%2BR.%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2009%26volume%3D9%26spage%3D10%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesser, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeland, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braziel, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubbs, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">463</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+Yangauthor=W.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+active+B-cell-receptor+signalling+in+diffuse+large+B-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520active%2520B-cell-receptor%2520signalling%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backesjo, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faryal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aints, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglof, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.+M.+Backesjoauthor=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Berglofauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0lguW-vVsSRxFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBackesjo%26aufirst%3DC.%2BM.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBerglof%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Pan, Z.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase as a drug discovery target</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1358%2Fdnp.2008.21.7.1255308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19259548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOgurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=357-362&author=Z.+Pan&title=Bruton%E2%80%99s+tyrosine+kinase+as+a+drug+discovery+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase as a drug discovery target</span></div><div class="casAuthors">Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (Btk) is an important mediator in multiple signal transduction pathways.  Fifteen years of research have revealed a complex role for Btk in hematopoietic cells.  These studies suggest that Btk may be a promising target for therapeutic intervention for several complicated diseases.  Inhibitors targeting the Btk kinase domain have been developed and show clear beneficial effects in animal models of rheumatoid arthritis, lymphoma and other diseases.  Here, an overview of these studies is presented with an emphasis on results stemming from medicinal chem. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Pn8DtrLdQ7Vg90H21EOLACvtfcHk0ljEgjfCodnNaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOgurnP&md5=dbb3e077ce56474a93b83c3be3783334</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2008.21.7.1255308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2008.21.7.1255308%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520as%2520a%2520drug%2520discovery%2520target%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2008%26volume%3D21%26spage%3D357%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beasley, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appell, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span> </span><span class="NLM_article-title">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">903</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1517%2F14728222.12.7.883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=18554156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=883-903&author=L.+L.+Rokoszauthor=J.+R.+Beasleyauthor=C.+D.+Carrollauthor=T.+Linauthor=J.+Zhaoauthor=K.+C.+Appellauthor=M.+L.+Webb&title=Kinase+inhibitors+as+drugs+for+chronic+inflammatory+and+immunological+diseases%3A+progress+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span></div><div class="casAuthors">Rokosz, Laura L.; Beasley, James R.; Carroll, Carolyn DiIanni; Lin, Tsung; Zhao, Jiuqiao; Appell, Kenneth C.; Webb, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  At the time of writing, there are seven marketed kinase inhibitor drugs.  The first kinase inhibitor, imatinib mesilate (Gleevec, Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases.  The most recent kinase inhibitor to come to market, disatinib (Sprycel, Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase.  To date, kinase inhibitor drugs are approved for oncol. and demonstrate that it is possible to develop compds. with relative selectivity for the target kinase against the broader kinome.  However, the use of kinase inhibitors in chronic inflammatory and immunol. diseases may require greater selectivity for the target kinase.  This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq458NGQKTbcbVg90H21EOLACvtfcHk0ljEgjfCodnNaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D&md5=6db3fdcc34b3ec97394c9dc6cdca8b99</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.7.883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.7.883%26sid%3Dliteratum%253Aachs%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DBeasley%26aufirst%3DJ.%2BR.%26aulast%3DCarroll%26aufirst%3DC.%2BD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DKinase%2520inhibitors%2520as%2520drugs%2520for%2520chronic%2520inflammatory%2520and%2520immunological%2520diseases%253A%2520progress%2520and%2520challenges%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26spage%3D883%26epage%3D903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Uckun, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbles, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassilev, A. O.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase as a new therapeutic target</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">632</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=624-632&author=F.+M.+Uckunauthor=H.+E.+Tibblesauthor=A.+O.+Vassilev&title=Bruton%E2%80%99s+tyrosine+kinase+as+a+new+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUckun%26aufirst%3DF.%2BM.%26aulast%3DTibbles%26aufirst%3DH.%2BE.%26aulast%3DVassilev%26aufirst%3DA.%2BO.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520as%2520a%2520new%2520therapeutic%2520target%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D624%26epage%3D632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0ljEgjfCodnNaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Thaimattam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miglani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, J.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors: structural insights into selectivity</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2751</span><span class="NLM_x">–</span> <span class="NLM_lpage">2765</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.2174%2F138161207781757042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=17897021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGmt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2751-2765&author=R.+Thaimattamauthor=R.+Banerjeeauthor=R.+Miglaniauthor=J.+Iqbal&title=Protein+kinase+inhibitors%3A+structural+insights+into+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors: structural insights into selectivity</span></div><div class="casAuthors">Thaimattam, Ram; Banerjee, Rahul; Miglani, Rajni; Iqbal, Javed</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2751-2765</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in many diseases like cancer, inflammation, cardiovascular disease, and diabetes.  They have become attractive target classes for drug development, making kinase inhibitors as important class of therapeutics.  The success of small-mol. ATP-competitive kinase inhibitors such as Gleevec, Iressa, and Tarceva has attracted much attention in the recent past.  Kinases make use of ATP for phosphorylation of a specific residue(s) on their protein substrates.  More than 400 x-ray structures of about 70 different kinases are publicly available.  These structures provide insights into selectivity and mechanisms of inhibition.  However, prediction of binding specificity of kinase inhibitors based on structural information alone appears to be insufficient.  Here, we will review these observations to gain insights into the rules that govern protein kinase inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBCSBUk5vhbVg90H21EOLACvtfcHk0ljcYiS98XD8kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGmt7jN&md5=b4bffab06eddc7d04f7b0f5a4ad3fad4</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.2174%2F138161207781757042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207781757042%26sid%3Dliteratum%253Aachs%26aulast%3DThaimattam%26aufirst%3DR.%26aulast%3DBanerjee%26aufirst%3DR.%26aulast%3DMiglani%26aufirst%3DR.%26aulast%3DIqbal%26aufirst%3DJ.%26atitle%3DProtein%2520kinase%2520inhibitors%253A%2520structural%2520insights%2520into%2520selectivity%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D2751%26epage%3D2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0ljcYiS98XD8kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0ljcYiS98XD8kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluge, A. F.</span><span> </span><span class="NLM_article-title">Targeted covalent drugs of the kinase family</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2Fj.cbpa.2010.06.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20609616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=475-480&author=J.+Singhauthor=R.+C.+Petterauthor=A.+F.+Kluge&title=Targeted+covalent+drugs+of+the+kinase+family"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent drugs of the kinase family</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Kluge, Arthur F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-480</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the past decade tremendous progress has been made toward a new class of therapeutics termed 'targeted covalent drugs', in which structure-based approaches are employed to create small mols. that inactivate their protein target through targeted covalent attachment to a specific cysteine.  In the kinase field, this approach is demonstrating promise in overcoming the potency, selectivity, and efficacy challenges currently faced by reversible kinase inhibitors, with several advancing into late stage clin. testing.  This design paradigm has been successfully applied to making drug candidates for epidermal growth factor receptor (EGFR), Her2, and Bruton's tyrosine kinase (Btk).  Here we review recent pre-clin. and clin. advances with targeted covalent kinase inhibitors, and the potential for broader application of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQb40Eok-vbVg90H21EOLACvtfcHk0lidKOK7GqRSRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D&md5=ee3b8b9e0c6ec317f975a426cf08428f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.168%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DTargeted%2520covalent%2520drugs%2520of%2520the%2520kinase%2520family%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D475%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Mao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uckun, F. M.</span><span> </span><span class="NLM_article-title">Crystal structure of Bruton’s tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">41435</span><span class="NLM_x">–</span> <span class="NLM_lpage">41443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=41435-41443&author=C.+Maoauthor=M.+Zhouauthor=F.+M.+Uckun&title=Crystal+structure+of+Bruton%E2%80%99s+tyrosine+kinase+domain+suggests+a+novel+pathway+for+activation+and+provides+insights+into+the+molecular+basis+of+X-linked+agammaglobulinemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DUckun%26aufirst%3DF.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520domain%2520suggests%2520a%2520novel%2520pathway%2520for%2520activation%2520and%2520provides%2520insights%2520into%2520the%2520molecular%2520basis%2520of%2520X-linked%2520agammaglobulinemia%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D41435%26epage%3D41443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Marcotte, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arduini, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hession, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miatkowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildes, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertsching, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanowski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvian, L. F.</span><span> </span><span class="NLM_article-title">Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&author=D.+J.+Marcotteauthor=Y.+T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+human+Bruton%E2%80%99s+tyrosine+kinase+in+active+and+inactive+conformations+suggest+a+mechanism+of+activation+for+TEC+family+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0lidKOK7GqRSRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520human%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520active%2520and%2520inactive%2520conformations%2520suggest%2520a%2520mechanism%2520of%2520activation%2520for%2520TEC%2520family%2520kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span> </span><span class="NLM_article-title">Insights into the conformational flexibility of Bruton’s tyrosine kinase from multiple ligand complex structures</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1002%2Fpro.575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=21280133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=428-436&author=A.+Kuglstatterauthor=A.+Wongauthor=S.+Tsingauthor=S.+W.+Leeauthor=Y.+Louauthor=A.+G.+Villasenorauthor=J.+M.+Bradshawauthor=D.+Shawauthor=J.+W.+Barnettauthor=M.+F.+Browner&title=Insights+into+the+conformational+flexibility+of+Bruton%E2%80%99s+tyrosine+kinase+from+multiple+ligand+complex+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures</span></div><div class="casAuthors">Kuglstatter, Andreas; Wong, April; Tsing, Stan; Lee, Simon W.; Lou, Yan; Villasenor, Armando G.; Bradshaw, J. Michael; Shaw, David; Barnett, Jim W.; Browner, Michelle F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases.  We have detd. the X-ray crystal structures of BTK kinase domain in complex with six inhibitors from distinct chem. classes.  Five different BTK protein conformations are stabilized by the bound inhibitors, providing insights into the structural flexibility of the Gly-rich loop, helix C, the DFG sequence, and activation loop.  The conformational changes occur independent of activation loop phosphorylation and do not correlate with the structurally unchanged WEI motif in the Src homol. 2-kinase domain linker.  Two novel activation loop conformations and an atypical DFG conformation are obsd. representing unique inactive states of BTK.  Two regions within the activation loop are shown to structurally transform between 310- and α-helixes, one of which collapses into the adenosine-5'-triphosphate binding pocket.  The first crystal structure of a Tec kinase family member in the pharmacol. important DFG-out conformation and bound to a type II kinase inhibitor is described.  The different protein conformations obsd. provide insights into the structural flexibility of BTK, the mol. basis of its regulation, and the structure-based design of specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbjgkMYHniALVg90H21EOLACvtfcHk0lidKOK7GqRSRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFWnuro%253D&md5=4e46f4d05ac3d7b90f1a3e89c0275516</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fpro.575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.575%26sid%3Dliteratum%253Aachs%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DTsing%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26atitle%3DInsights%2520into%2520the%2520conformational%2520flexibility%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520from%2520multiple%2520ligand%2520complex%2520structures%26jtitle%3DProtein%2520Sci.%26date%3D2011%26volume%3D20%26spage%3D428%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Di Paolo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barck, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carano, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForge, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrando, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staker, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lhW-_ycZXIuig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span> </span><span class="NLM_article-title">Structural biology contributions to tyrosine kinase drug discovery</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2Fj.ceb.2009.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19208462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVCksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=280-287&author=S.+W.+Cowan-Jacobauthor=H.+Mobitzauthor=D.+Fabbro&title=Structural+biology+contributions+to+tyrosine+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structural biology contributions to tyrosine kinase drug discovery</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Moebitz, Henrik; Fabbro, Doriano</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-287</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Successful kinase inhibitor drug discovery relies heavily on the structural knowledge of the interaction of inhibitors with the target.  Structural biol. of kinases and in particular of tyrosine kinases has given detailed insights into the intrinsic flexibility of the catalytic domain and has provided a rational basis for obtaining selective inhibitors.  Important progress was made recently, both in academia and in the pharmaceutical industry, with respect to solving structures of inactive, multidomain or protein-protein complexes of kinases, which helps our understanding of the dynamics of regulation of kinase activity.  This leads to a better understanding of how mutations lead to activation of kinases and resistance, in addn. to providing opportunities for novel modes of targeting kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo09-Hgo00-bLVg90H21EOLACvtfcHk0lhW-_ycZXIuig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVCksr8%253D&md5=125e7217308850813cde9dce356bf1a4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMobitz%26aufirst%3DH.%26aulast%3DFabbro%26aufirst%3DD.%26atitle%3DStructural%2520biology%2520contributions%2520to%2520tyrosine%2520kinase%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D280%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lhW-_ycZXIuig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M. J.</span><span> </span><span class="NLM_article-title">Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2345</span><span class="NLM_x">–</span> <span class="NLM_lpage">2353</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9012906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2345-2353&author=D.+M.+Goldsteinauthor=A.+Kuglstatterauthor=Y.+Louauthor=M.+J.+Soth&title=Selective+p38alpha+inhibitors+clinically+evaluated+for+the+treatment+of+chronic+inflammatory+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm9012906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9012906%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DSoth%26aufirst%3DM.%2BJ.%26atitle%3DSelective%2520p38alpha%2520inhibitors%2520clinically%2520evaluated%2520for%2520the%2520treatment%2520of%2520chronic%2520inflammatory%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2345%26epage%3D2353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudbeck, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hupke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uckun, F. M.</span><span> </span><span class="NLM_article-title">Rational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-<i>N</i>-(2,5-dibromophenyl)propenamide]</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">9587</span><span class="NLM_x">–</span> <span class="NLM_lpage">9599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=9587-9599&author=S.+Mahajanauthor=S.+Ghoshauthor=E.+A.+Sudbeckauthor=Y.+Zhengauthor=S.+Downsauthor=M.+Hupkeauthor=F.+M.+Uckun&title=Rational+design+and+synthesis+of+a+novel+anti-leukemic+agent+targeting+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%2C+LFM-A13+%5Balpha-cyano-beta-hydroxy-beta-methyl-N-%282%2C5-dibromophenyl%29propenamide%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DSudbeck%26aufirst%3DE.%2BA.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DDowns%26aufirst%3DS.%26aulast%3DHupke%26aufirst%3DM.%26aulast%3DUckun%26aufirst%3DF.%2BM.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%2520a%2520novel%2520anti-leukemic%2520agent%2520targeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%252C%2520LFM-A13%2520%255Balpha-cyano-beta-hydroxy-beta-methyl-N-%25282%252C5-dibromophenyl%2529propenamide%255D%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D9587%26epage%3D9599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0liW60ZZGdpqeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S. C.</span><span> </span><span class="NLM_article-title">Crystal structures of c-Src reveal features of its autoinhibitory mechanism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2FS1097-2765%2800%2980356-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=10360179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADyaK1MXjslCqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=629-638&author=W.+Xuauthor=A.+Doshiauthor=M.+Leiauthor=M.+J.+Eckauthor=S.+C.+Harrison&title=Crystal+structures+of+c-Src+reveal+features+of+its+autoinhibitory+mechanism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of c-Src reveal features of its autoinhibitory mechanism</span></div><div class="casAuthors">Xu, Wenqing; Doshi, Amish; Lei, Ming; Eck, Michael J.; Harrison, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-638</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Src family kinases are maintained in an assembled, inactive conformation by intramol. interactions of their SH2 and SH3 domains.  Full catalytic activity requires release of these restraints as well as phosphorylation of Tyr-416 in the activation loop.  In previous structures of inactive Src kinases, Tyr-416 and flanking residues are disordered.  We report here four addnl. c-Src structures in which this segment adopts an ordered but inhibitory conformation.  The ordered activation loop forms an α helix that stabilizes the inactive conformation of the kinase domain, blocks the peptide substrate-binding site, and prevents Tyr-416 phosphorylation.  Disassembly of the regulatory domains, induced by SH2 or SH3 ligands, or by dephosphorylation of Tyr-527, could lead to exposure and phosphorylation of Tyr-416.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCsIh6d9RHa7Vg90H21EOLACvtfcHk0lhs1jIoPaexww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslCqu7o%253D&md5=926f6a6a4097ce667168b5b81d9a1092</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980356-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980356-1%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%26aulast%3DDoshi%26aufirst%3DA.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DHarrison%26aufirst%3DS.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520c-Src%2520reveal%2520features%2520of%2520its%2520autoinhibitory%2520mechanism%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D629%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicheri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pico, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=639-648&author=T.+Schindlerauthor=F.+Sicheriauthor=A.+Picoauthor=A.+Gazitauthor=A.+Levitzkiauthor=J.+Kuriyan&title=Crystal+structure+of+Hck+in+complex+with+a+Src+family-selective+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DPico%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520Hck%2520in%2520complex%2520with%2520a%2520Src%2520family-selective%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D639%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kutach, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belunis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deval, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novak, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span> </span><span class="NLM_article-title">Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1111%2Fj.1747-0285.2010.00993.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20545945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2010&pages=154-163&author=A.+K.+Kutachauthor=A.+G.+Villasenorauthor=D.+Lamauthor=C.+Belunisauthor=C.+Jansonauthor=S.+Lokauthor=L.+N.+Hongauthor=C.+M.+Liuauthor=J.+Devalauthor=T.+J.+Novakauthor=J.+W.+Barnettauthor=W.+Chuauthor=D.+Shawauthor=A.+Kuglstatter&title=Crystal+structures+of+IL-2-inducible+T+cell+kinase+complexed+with+inhibitors%3A+insights+into+rational+drug+design+and+activity+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation</span></div><div class="casAuthors">Kutach, Alan K.; Villasenor, Armando G.; Lam, Diana; Belunis, Charles; Janson, Cheryl; Lok, Stephen; Hong, Li-Na; Liu, Chao-Min; Deval, Jerome; Novak, Thomas J.; Barnett, Jim W.; Chu, Wei; Shaw, David; Kuglstatter, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">IL-2-inducible T cell kinase plays an essential role in T cell receptor signaling and is considered a drug target for the treatment of Th2-mediated inflammatory diseases.  By applying high-throughput protein engineering and crystn., we have detd. the x-ray crystal structures of IL-2-inducible T cell kinase in complex with its selective inhibitor BMS-509744 and the broad-spectrum kinase inhibitors sunitinib and RO5191614.  Sunitinib uniquely stabilizes IL-2-inducible T cell kinase in the helix C-in conformation by inducing side chain conformational changes in the ATP-binding site.  This preference of sunitinib to bind to an active kinase conformation is reflective of its broad-spectrum kinase activity.  BMS-509744 uniquely stabilizes the activation loop in a substrate-blocking inactive conformation, indicating that structural changes described for Src family kinases are also involved in the regulation of IL-2-inducible T cell kinase activity.  The obsd. BMS-509744 binding mode allows rationalization of structure-activity relationships reported for this inhibitor class and facilitates further structure-based drug design.  Sequence-based anal. of this binding mode provides guidance for the rational design of inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXxFkkRUV7B7Vg90H21EOLACvtfcHk0lhs1jIoPaexww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleqs7Y%253D&md5=24b9225c52eff5cca4e295dad1c554c3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2010.00993.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2010.00993.x%26sid%3Dliteratum%253Aachs%26aulast%3DKutach%26aufirst%3DA.%2BK.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DLam%26aufirst%3DD.%26aulast%3DBelunis%26aufirst%3DC.%26aulast%3DJanson%26aufirst%3DC.%26aulast%3DLok%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DL.%2BN.%26aulast%3DLiu%26aufirst%3DC.%2BM.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DNovak%26aufirst%3DT.%2BJ.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DKuglstatter%26aufirst%3DA.%26atitle%3DCrystal%2520structures%2520of%2520IL-2-inducible%2520T%2520cell%2520kinase%2520complexed%2520with%2520inhibitors%253A%2520insights%2520into%2520rational%2520drug%2520design%2520and%2520activity%2520regulation%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D76%26spage%3D154%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Chen, W.; Loury, D. J.; Mody, T. D.; Verner, E.; Smyth, M. S.; Luo, W.</span><span> </span><span class="NLM_article-title">Preparation of Pyrazolo-pyrimidine Compounds as Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application WO 2011/046964,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=W.+Chen&author=D.+J.+Loury&author=T.+D.+Mody&author=E.+Verner&author=M.+S.+Smyth&author=W.+Luo&title=Preparation+of+Pyrazolo-pyrimidine+Compounds+as+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26atitle%3DPreparation%2520of%2520Pyrazolo-pyrimidine%2520Compounds%2520as%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Honigberg, L.; Verner, E.; Buggy, J.; Loury, D.; Chen, W.</span><span> </span><span class="NLM_article-title">Preparation of Substituted Pyrazolopyrimidinamines as Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application WO 2010/009342,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=L.+Honigberg&author=E.+Verner&author=J.+Buggy&author=D.+Loury&author=W.+Chen&title=Preparation+of+Substituted+Pyrazolopyrimidinamines+as+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%26atitle%3DPreparation%2520of%2520Substituted%2520Pyrazolopyrimidinamines%2520as%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Honigberg, L.; Verner, E.; Buggy, J. J.; Loury, D.; Chen, W.</span><span> </span><span class="NLM_article-title">Preparation of Substituted Pyrazolopyrimidinamines As Therapeutic Inhibitors of Bruton’s Tyrosine Kinase and Other Kinases</span>. Patent Application WO 2008/121742,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=L.+Honigberg&author=E.+Verner&author=J.+J.+Buggy&author=D.+Loury&author=W.+Chen&title=Preparation+of+Substituted+Pyrazolopyrimidinamines+As+Therapeutic+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase+and+Other+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%26atitle%3DPreparation%2520of%2520Substituted%2520Pyrazolopyrimidinamines%2520As%2520Therapeutic%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520and%2520Other%2520Kinases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Honigberg, L.; Verner, E.; Pan, Z.</span><span> </span><span class="NLM_article-title">Preparation of Substituted Pyrazolopyrimidinamines as Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application US 2008/0108636,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=L.+Honigberg&author=E.+Verner&author=Z.+Pan&title=Preparation+of+Substituted+Pyrazolopyrimidinamines+as+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%26atitle%3DPreparation%2520of%2520Substituted%2520Pyrazolopyrimidinamines%2520as%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Honigberg, L.; Verner, E.; Pan, Z.</span><span> </span><span class="NLM_article-title">Preparation of 1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives as Bruton’s Tyrosine Kinase Inhibitors</span>. Patent Application US 2008/0076921,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=L.+Honigberg&author=E.+Verner&author=Z.+Pan&title=Preparation+of+1H-Pyrazolo%5B3%2C4-d%5Dpyrimidine+Derivatives+as+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%26atitle%3DPreparation%2520of%25201H-Pyrazolo%255B3%252C4-d%255Dpyrimidine%2520Derivatives%2520as%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Pan, Z.; Li, S. J.; Schereens, H.; Honigberg, L.; Verner, E.</span><span> </span><span class="NLM_article-title">Inhibitor-Derived Reporter Molecules for Detection of Bruton’s Tyrosine Kinase and Their Uses</span>. Patent Application WO 2008/054827,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=Z.+Pan&author=S.+J.+Li&author=H.+Schereens&author=L.+Honigberg&author=E.+Verner&title=Inhibitor-Derived+Reporter+Molecules+for+Detection+of+Bruton%E2%80%99s+Tyrosine+Kinase+and+Their+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DInhibitor-Derived%2520Reporter%2520Molecules%2520for%2520Detection%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520and%2520Their%2520Uses%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span>ClinicalTrials.gov. Safety and Efficacy of PCI-32765 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (MCL) (PCYC-1104-CA). <a href="http://clinicaltrials.gov/ct2/show/NCT01236391" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01236391</a> (accessed Aug 25, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Safety+and+Efficacy+of+PCI-32765+in+Subjects+with+Relapsed%2FRefractory+Mantle+Cell+Lymphoma+%28MCL%29+%28PCYC-1104-CA%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01236391+%28accessed+Aug+25%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Byrd, J. C.; Blum, K. A.; Burger, J. A.; Coutre, S. E.; Sharman, J. R.; Furman, R. R.; Flinn, I. W.; Grant, B. W.; Richards, D. A.; Zhao, W.; Heerema, N. A.; Johnson, A. J.; Izumi, R.; Hamdy, A.; O’Brien, S. M.</span><span> </span><span class="NLM_article-title">Activity and Tolerability of the Bruton’s Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Interim Results of a Phase Ib/II Study</span>. Presented at the 2011 ASCO Annual Meeting, Chicago, IL,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Poster 6508.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+C.+Byrd&author=K.+A.+Blum&author=J.+A.+Burger&author=S.+E.+Coutre&author=J.+R.+Sharman&author=R.+R.+Furman&author=I.+W.+Flinn&author=B.+W.+Grant&author=D.+A.+Richards&author=W.+Zhao&author=N.+A.+Heerema&author=A.+J.+Johnson&author=R.+Izumi&author=A.+Hamdy&author=S.+M.+O%E2%80%99Brien&title=Activity+and+Tolerability+of+the+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+Inhibitor+PCI-32765+in+Patients+with+Chronic+Lymphocytic+Leukemia%2FSmall+Lymphocytic+Lymphoma+%28CLL%2FSLL%29%3A+Interim+Results+of+a+Phase+Ib%2FII+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DActivity%2520and%2520Tolerability%2520of%2520the%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520Inhibitor%2520PCI-32765%2520in%2520Patients%2520with%2520Chronic%2520Lymphocytic%2520Leukemia%252FSmall%2520Lymphocytic%2520Lymphoma%2520%2528CLL%252FSLL%2529%253A%2520Interim%2520Results%2520of%2520a%2520Phase%2520Ib%252FII%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Advani, R.; Porte Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.</span><span> </span><span class="NLM_article-title">The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study</span>. Presented at the 11th International Conference on Malignant Lymphoma, ICML, Palazzo dei Congressi, Lugano, Switzerland,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+Advani&author=J.+Porte+Sharman&author=S.+Smith&author=T.+Boyd&author=B.+Grant&author=K.+Kolibaba&author=R.+Furman&author=J.+Buggy&author=D.+Loury&author=E.+Hedrick&author=R.+Izumi&author=A.+Hamdy&author=N.+Fowler&title=The+Btk+Inhibitor+PCI-32765+Is+Highly+Active+and+Well+Tolerated+in+Patients+with+Relapsed%2FRefractory+B+Cell+Malignancies%3A+Final+Results+from+a+Phase+I+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%26atitle%3DThe%2520Btk%2520Inhibitor%2520PCI-32765%2520Is%2520Highly%2520Active%2520and%2520Well%2520Tolerated%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B%2520Cell%2520Malignancies%253A%2520Final%2520Results%2520from%2520a%2520Phase%2520I%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">O’Brien, S.; Burger, J. A.; Coutre, S. E.; Porte Sharman, J.; Furman, R. R.; Flinn, I. W.; Grant, B.; Richards, D.; Heerema, N.; Johnson, A. J.; Izumi, R.; Hamdy, A.; Blum, K. A.; Byrd, J. C.</span><span> </span><span class="NLM_article-title">The Btk Inhibitor PCI-32765 Is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study</span>. Presented at the 11th International Conference on Malignant Lymphoma, ICML, Palazzo dei Congressi, Lugano, Switzerland,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+O%E2%80%99Brien&author=J.+A.+Burger&author=S.+E.+Coutre&author=J.+Porte+Sharman&author=R.+R.+Furman&author=I.+W.+Flinn&author=B.+Grant&author=D.+Richards&author=N.+Heerema&author=A.+J.+Johnson&author=R.+Izumi&author=A.+Hamdy&author=K.+A.+Blum&author=J.+C.+Byrd&title=The+Btk+Inhibitor+PCI-32765+Is+Highly+Active+and+Tolerable+in+Patients+with+Poor-Risk+CLL%3A+Interim+Results+from+a+Phase+Ib%2FII+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DThe%2520Btk%2520Inhibitor%2520PCI-32765%2520Is%2520Highly%2520Active%2520and%2520Tolerable%2520in%2520Patients%2520with%2520Poor-Risk%2520CLL%253A%2520Interim%2520Results%2520from%2520a%2520Phase%2520Ib%252FII%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Pollyea, D. A.; Smith, S.; Fowler, N.; Boyd, T.; Smith, A. M.; Sirisawad, M.; Honigberg, L. A.; Hamdy, A.; Advani, R.</span><span> </span><span class="NLM_article-title">A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay</span>. Presented at the 51st ASH Annual Meeting and Exposition, New Orleans, LA,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Poster 3713.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=D.+A.+Pollyea&author=S.+Smith&author=N.+Fowler&author=T.+Boyd&author=A.+M.+Smith&author=M.+Sirisawad&author=L.+A.+Honigberg&author=A.+Hamdy&author=R.+Advani&title=A+Phase+I+Dose+Escalation+Study+of+the+Btk+Inhibitor+PCI-32765+in+Relapsed+and+Refractory+B+Cell+Non-Hodgkin+Lymphoma+and+Use+of+a+Novel+Fluorescent+Probe+Pharmacodynamic+Assay"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26atitle%3DA%2520Phase%2520I%2520Dose%2520Escalation%2520Study%2520of%2520the%2520Btk%2520Inhibitor%2520PCI-32765%2520in%2520Relapsed%2520and%2520Refractory%2520B%2520Cell%2520Non-Hodgkin%2520Lymphoma%2520and%2520Use%2520of%2520a%2520Novel%2520Fluorescent%2520Probe%2520Pharmacodynamic%2520Assay%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fowler, N.; Sharman, J. P.; Smith, S. S.; Boyd, T.; Grant, B.; Kolibaba, K. S.; Furman, R. R.; Buggy, J.; Loury, D.; Hamdy, A.; Advani, R.</span><span> </span><span class="NLM_article-title">The BTK Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity in Patients with Relapsed/Refractory B-Cell Malignancies: Results from a Phase I Study</span>. Presented at the 52nd ASH Annual Meeting and Exposition, Orlando, FL,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+Fowler&author=J.+P.+Sharman&author=S.+S.+Smith&author=T.+Boyd&author=B.+Grant&author=K.+S.+Kolibaba&author=R.+R.+Furman&author=J.+Buggy&author=D.+Loury&author=A.+Hamdy&author=R.+Advani&title=The+BTK+Inhibitor%2C+PCI-32765%2C+Induces+Durable+Responses+with+Minimal+Toxicity+in+Patients+with+Relapsed%2FRefractory+B-Cell+Malignancies%3A+Results+from+a+Phase+I+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DFowler%26aufirst%3DN.%26atitle%3DThe%2520BTK%2520Inhibitor%252C%2520PCI-32765%252C%2520Induces%2520Durable%2520Responses%2520with%2520Minimal%2520Toxicity%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B-Cell%2520Malignancies%253A%2520Results%2520from%2520a%2520Phase%2520I%2520Study%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">de Rooij, M. F. M.; Kuil, A.; Geest, C. R.; Eldering, E.; Chang, B. Y.; Buggy, J. J.; Pals, S. T.; Spaargaren, M.</span><span> </span><span class="NLM_article-title">The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia</span>.  <span class="citation_source-journal">Blood</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1182/blood-2011-11-390989</span> . Published Online: Jan 25,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1182%2Fblood-2011-11-390989" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+F.+M.+de+Rooij&author=A.+Kuil&author=C.+R.+Geest&author=E.+Eldering&author=B.+Y.+Chang&author=J.+J.+Buggy&author=S.+T.+Pals&author=M.+Spaargaren&title=The+clinically+active+BTK+inhibitor+PCI-32765+targets+B-cell+receptor-+and+chemokine-controlled+adhesion+and+migration+in+chronic+lymphocytic+leukemia&doi=10.1182%2Fblood-2011-11-390989"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-11-390989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-11-390989%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRooij%26aufirst%3DM.%2BF.%2BM.%26atitle%3DThe%2520clinically%2520active%2520BTK%2520inhibitor%2520PCI-32765%2520targets%2520B-cell%2520receptor-%2520and%2520chemokine-controlled%2520adhesion%2520and%2520migration%2520in%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26doi%3D10.1182%2Fblood-2011-11-390989%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span>ClinicalTrials.gov. Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <a href="http://clinicaltrials.gov/ct2/show/NCT01325701?term=PCI-32765&amp;rank=7" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01325701?term=PCI-32765&rank=7</a> (accessed Aug 25, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Safety+and+Efficacy+Study+of+Bruton%27s+Tyrosine+Kinase+Inhibitor+in+Subjects+with+Relapsed+or+Refractory+Diffuse+Large+B-Cell+Lymphoma.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01325701%3Fterm%3DPCI-32765%26rank%3D7+%28accessed+Aug+25%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span>ClinicalTrials.gov. Safety and Tolerability Study of PCI-32765 Combined with Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL). <a href="http://clinicaltrials.gov/ct2/show/NCT01292135" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01292135</a> (accessed Aug 25, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Safety+and+Tolerability+Study+of+PCI-32765+Combined+with+Fludarabine%2FCyclophosphamide%2FRituximab+%28FCR%29+and+Bendamustine%2FRituximab+%28BR%29+in+Chronic+Lymphocytic+Leukemia+%28CLL%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01292135+%28accessed+Aug+25%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakabayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamaki, K.</span><span> </span><span class="NLM_article-title">Predicting key example compounds in competitors’ patent applications using structural information alone</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci7002686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisV2qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=135-142&author=K.+Hattoriauthor=H.+Wakabayashiauthor=K.+Tamaki&title=Predicting+key+example+compounds+in+competitors%E2%80%99+patent+applications+using+structural+information+alone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Key Example Compounds in Competitors' Patent Applications Using Structural Information Alone</span></div><div class="casAuthors">Hattori, Kazunari; Wakabayashi, Hiroaki; Tamaki, Kenta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-142</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In drug discovery programs, predicting key example compds. in competitors' patent applications is important work for scientists working in the same or in related research areas.  In general, medicinal chemists are responsible for this work, and they attempt to guess the identity of key compds. based on information provided in patent applications, such as biol. data, scale of reaction, and/or optimization of the salt form for a particular compd.  However, this is sometimes made difficult by the lack of such information.  This paper describes a method for predicting key compds. in competitors' patent applications by using only structural information of example compds.  Based on the assumption that medicinal chemists usually carry out extensive structure-activity relationship (SAR) studies around key compds., the method identifies compds. located at the centers of densely populated regions in the patent examples' chem. space, as represented by Extended Connectivity Fingerprints (ECFPs).  For the validation of the method, a total of 30 patents contg. structures of launched drugs were selected to test whether or not the method is able to predict key compds. (the launched drugs).  In 17 out of the 30 patents (57%), the method was able to successfully predict the key compds.  The result indicates that our method could provide an alternative approach to predicting key compds. in cases where the conventional medicinal chemist's approach does not work well.  This method could also be used as a complement to the traditional medicinal chemist's approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_Rwj3qzEf7Vg90H21EOLACvtfcHk0lhJFrMIJQDRhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisV2qtA%253D%253D&md5=ae6a5758a22b2bf13072d2fcc8071aed</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fci7002686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci7002686%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DWakabayashi%26aufirst%3DH.%26aulast%3DTamaki%26aufirst%3DK.%26atitle%3DPredicting%2520key%2520example%2520compounds%2520in%2520competitors%25E2%2580%2599%2520patent%2520applications%2520using%2520structural%2520information%2520alone%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26spage%3D135%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiemann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francesco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jejurkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D. J.</span><span> </span><span class="NLM_article-title">PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in mouse models of arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">286</span><div class="note"><p class="first last"> (Abstract)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=286&issue=Suppl.+10&author=B.+Y.+Changauthor=P.+Thiemannauthor=M.+Francescoauthor=M.+M.+Huangauthor=M.+Sirisawadauthor=N.+Purroauthor=P.+Jejurkarauthor=C.+Maniauthor=D.+Tonevauthor=W.+Chenauthor=J.+J.+Buggyauthor=D.+J.+Loury&title=PCI-45292%2C+a+novel+Btk+inhibitor+with+optimized+pharmaceutical+properties%2C+demonstrates+potent+activities+in+mouse+models+of+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DThiemann%26aufirst%3DP.%26aulast%3DFrancesco%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DM.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DPurro%26aufirst%3DN.%26aulast%3DJejurkar%26aufirst%3DP.%26aulast%3DMani%26aufirst%3DC.%26aulast%3DTonev%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DLoury%26aufirst%3DD.%2BJ.%26atitle%3DPCI-45292%252C%2520a%2520novel%2520Btk%2520inhibitor%2520with%2520optimized%2520pharmaceutical%2520properties%252C%2520demonstrates%2520potent%2520activities%2520in%2520mouse%2520models%2520of%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26issue%3DSuppl.%252010%26spage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span>Pharmacyclics. Update on Preclinical Finding and Development Timeline for PCI-45292. <a href="http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=553831" class="extLink">http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=553831</a> (accessed Aug 25, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pharmacyclics.+Update+on+Preclinical+Finding+and+Development+Timeline+for+PCI-45292.+http%3A%2F%2Fir.pharmacyclics.com%2Freleasedetail.cfm%3FReleaseID%3D553831+%28accessed+Aug+25%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Kluge, A. F.; Petter, R. C.; Tester, R. W.; Qiao, L.; Niu, D.; Westlin, W. F.; Singh, J.; Mazdiyasni, H.</span><span> </span><span class="NLM_article-title">Heteroaryl Compounds and Uses Thereof</span>. Patent Application WO 2009/158571,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+F.+Kluge&author=R.+C.+Petter&author=R.+W.+Tester&author=L.+Qiao&author=D.+Niu&author=W.+F.+Westlin&author=J.+Singh&author=H.+Mazdiyasni&title=Heteroaryl+Compounds+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DHeteroaryl%2520Compounds%2520and%2520Uses%2520Thereof%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Singh, J.; Ghosh, S.; Kluge, A. F.; Petter, R. C.; Tester, R. W.</span><span> </span><span class="NLM_article-title">Heteroaryl Compounds and Uses Thereof</span>. Patent Application US 2010/0016296,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Singh&author=S.+Ghosh&author=A.+F.+Kluge&author=R.+C.+Petter&author=R.+W.+Tester&title=Heteroaryl+Compounds+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DHeteroaryl%2520Compounds%2520and%2520Uses%2520Thereof%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Singh, J.; Petter, R. C.; Tester, R. W.; Kluge, A. F.; Mazdiyasni, H.; Westlin, W. F.; Niu, D.; Qiao, L.</span><span> </span><span class="NLM_article-title">Heteroaryl Compounds and Uses Thereof</span>. Patent Application US 2010/0249092,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Singh&author=R.+C.+Petter&author=R.+W.+Tester&author=A.+F.+Kluge&author=H.+Mazdiyasni&author=W.+F.+Westlin&author=D.+Niu&author=L.+Qiao&title=Heteroaryl+Compounds+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DHeteroaryl%2520Compounds%2520and%2520Uses%2520Thereof%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Singh, J.; Petter, R. C.; Niu, D.</span><span> </span><span class="NLM_article-title">Algorithm for Designing Irreversible Inhibitors</span>. Patent Application WO 2010/028236,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Singh&author=R.+C.+Petter&author=D.+Niu&title=Algorithm+for+Designing+Irreversible+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DAlgorithm%2520for%2520Designing%2520Irreversible%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Evans, E.; Sheets, M.; Bernard, H.; Martin, T. S.; Nacht, M.; Zhu, Z.; Tester, R.; Mazdiyasni, H.; Chaturvedi, P.; Petter, R.; Westlin, W.; Singh, J.</span><span> </span><span class="NLM_article-title">Prolonged Inhibition of BCR Signaling and Suppression of B Cell Lymphoma through Irreversible Inhibition of Bruton’s Tyrosine Kinase</span>. Presented at the 50th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>Poster 2608.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Evans&author=M.+Sheets&author=H.+Bernard&author=T.+S.+Martin&author=M.+Nacht&author=Z.+Zhu&author=R.+Tester&author=H.+Mazdiyasni&author=P.+Chaturvedi&author=R.+Petter&author=W.+Westlin&author=J.+Singh&title=Prolonged+Inhibition+of+BCR+Signaling+and+Suppression+of+B+Cell+Lymphoma+through+Irreversible+Inhibition+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%26atitle%3DProlonged%2520Inhibition%2520of%2520BCR%2520Signaling%2520and%2520Suppression%2520of%2520B%2520Cell%2520Lymphoma%2520through%2520Irreversible%2520Inhibition%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Karp, R.; Evans, E.; Aslanian, S.; Chaturvedi, P.; Mazdiyasni, H.; Nacht, M.; Petter, R.; Sheets, M.; Singh, J.; Tester, R.; Westlin, W.</span><span> </span><span class="NLM_article-title">Inhibition of BTK with AVL-292 Translates to Protective Activity in Rodent Models of Rheumatoid Arthritis</span>. Presented at the 16th International IRA Conference Meeting, Chantilly, VA,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span>Poster A113.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+Karp&author=E.+Evans&author=S.+Aslanian&author=P.+Chaturvedi&author=H.+Mazdiyasni&author=M.+Nacht&author=R.+Petter&author=M.+Sheets&author=J.+Singh&author=R.+Tester&author=W.+Westlin&title=Inhibition+of+BTK+with+AVL-292+Translates+to+Protective+Activity+in+Rodent+Models+of+Rheumatoid+Arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520BTK%2520with%2520AVL-292%2520Translates%2520to%2520Protective%2520Activity%2520in%2520Rodent%2520Models%2520of%2520Rheumatoid%2520Arthritis%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Evans, E.; Tester, R; Mazdiyasni, H.; Ponader, S.; Tesar, B.; Chaturavedi, P.; Nacht, M.; Stiede, S.; Witowski, S.; Lounsbury, H.; Silver, B.; Burger, J.; Brown, J. R.; Mahadevan, D.; Sharman, J.; Harb, W.; Petter, R.; Singh, J.; Westlin, W.</span><span> </span><span class="NLM_article-title">Clinical Development of AVL-292: A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies</span>. Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, CA,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Poster 3485.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=E.+Evans&author=R+Tester&author=H.+Mazdiyasni&author=S.+Ponader&author=B.+Tesar&author=P.+Chaturavedi&author=M.+Nacht&author=S.+Stiede&author=S.+Witowski&author=H.+Lounsbury&author=B.+Silver&author=J.+Burger&author=J.+R.+Brown&author=D.+Mahadevan&author=J.+Sharman&author=W.+Harb&author=R.+Petter&author=J.+Singh&author=W.+Westlin&title=Clinical+Development+of+AVL-292%3A+A+Potent%2C+Selective+Covalent+Btk+Inhibitor+for+the+Treatment+of+B+Cell+Malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%26atitle%3DClinical%2520Development%2520of%2520AVL-292%253A%2520A%2520Potent%252C%2520Selective%2520Covalent%2520Btk%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520B%2520Cell%2520Malignancies%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Konteatis, Z.; Moffett, K.; Lee, Y.; Chao, W.</span><span> </span><span class="NLM_article-title">Pyrrolotriazine compounds</span>. Patent Application WO 2010/126960,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Z.+Konteatis&author=K.+Moffett&author=Y.+Lee&author=W.+Chao&title=Pyrrolotriazine+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKonteatis%26aufirst%3DZ.%26atitle%3DPyrrolotriazine%2520compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-<i>a</i>]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6258</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6258-6263&author=K.+H.+Kimauthor=A.+Madernaauthor=M.+E.+Schnuteauthor=M.+Hegenauthor=S.+Mohanauthor=J.+Miyashiroauthor=L.+Linauthor=E.+Liauthor=S.+Keeganauthor=J.+Lussierauthor=C.+Wrocklageauthor=C.+L.+Nickerson-Nutterauthor=A.+J.+Wittwerauthor=H.+Soutterauthor=N.+Caspersauthor=S.+Hanauthor=R.+Kurumbailauthor=K.+Dunussi-Joannopoulosauthor=J.+Douhanauthor=A.+Wissner&title=Imidazo%5B1%2C5-a%5Dquinoxalines+as+irreversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DSoutter%26aufirst%3DH.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DImidazo%255B1%252C5-a%255Dquinoxalines%2520as%2520irreversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6258%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Currie, K. S.; Desimone, R. W.; Pippin, D. A.; Darrow, J. W.; Mitchell, S. A.</span><span> </span><span class="NLM_article-title">Preparation of Imidazo[1,2-<i>a</i>]pyrazin-8-ylamines as Kinase Modulators, Particularly Btk Inhibitors, for Treating Btk-Related Diseases and Conditions</span>. Patent Application WO 2005/047290,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+S.+Currie&author=R.+W.+Desimone&author=D.+A.+Pippin&author=J.+W.+Darrow&author=S.+A.+Mitchell&title=Preparation+of+Imidazo%5B1%2C2-a%5Dpyrazin-8-ylamines+as+Kinase+Modulators%2C+Particularly+Btk+Inhibitors%2C+for+Treating+Btk-Related+Diseases+and+Conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPreparation%2520of%2520Imidazo%255B1%252C2-a%255Dpyrazin-8-ylamines%2520as%2520Kinase%2520Modulators%252C%2520Particularly%2520Btk%2520Inhibitors%252C%2520for%2520Treating%2520Btk-Related%2520Diseases%2520and%2520Conditions%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Currie, K. S.; Desimone, R. W.; Mitchell, S. A.; Pippin, D. A.; Darrow, J. W.; Qian, X.; Velleca, M.; Qian, D.</span><span> </span><span class="NLM_article-title">Preparation of Imidazo[1,2-<i>a</i>]pyrazin-8-ylamines for Inhibition of Bruton’s Tyrosine Kinase</span>. Patent Application WO 2005/014599,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+S.+Currie&author=R.+W.+Desimone&author=S.+A.+Mitchell&author=D.+A.+Pippin&author=J.+W.+Darrow&author=X.+Qian&author=M.+Velleca&author=D.+Qian&title=Preparation+of+Imidazo%5B1%2C2-a%5Dpyrazin-8-ylamines+for+Inhibition+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPreparation%2520of%2520Imidazo%255B1%252C2-a%255Dpyrazin-8-ylamines%2520for%2520Inhibition%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Currie, K. S.; Desimone, R. W.; Mitchell, S.; Pippin, D. A.</span><span> </span><span class="NLM_article-title">Preparation of Imidazo[1,2-<i>a</i>]pyrazin-8-ylamines as Bruton’s Tyrosine Kinase (Btk) Inhibitors for the Treatment of Cancer</span>. Patent Application WO 2005/005429,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+S.+Currie&author=R.+W.+Desimone&author=S.+Mitchell&author=D.+A.+Pippin&title=Preparation+of+Imidazo%5B1%2C2-a%5Dpyrazin-8-ylamines+as+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+Inhibitors+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPreparation%2520of%2520Imidazo%255B1%252C2-a%255Dpyrazin-8-ylamines%2520as%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Targeting B-cells in inflammatory disease</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=175-190&author=K.+S.+Currie&title=Targeting+B-cells+in+inflammatory+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DTargeting%2520B-cells%2520in%2520inflammatory%2520disease%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D175%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of a Novel Series of Highly Selective Inhibitors of Bruton’s Tyrosine Kinase</span>. Presented at the EFMC 21st International Symposium on Medicinal Chemistry, Brussels, Belgium,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=K.+S.+Currie&title=Discovery+and+Optimization+of+a+Novel+Series+of+Highly+Selective+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Novel%2520Series%2520of%2520Highly%2520Selective%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+effect+of+a+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+in+rat+collagen-induced+arthritis+and+mechanism-based+pharmacokinetic%2Fpharmacodynamic+modeling%3A+relationships+between+inhibition+of+BTK+phosphorylation+and+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0lgyw3E8JKuViQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520effect%2520of%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520in%2520rat%2520collagen-induced%2520arthritis%2520and%2520mechanism-based%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%253A%2520relationships%2520between%2520inhibition%2520of%2520BTK%2520phosphorylation%2520and%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D154%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coraggio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgardner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopaul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuebler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase (BTK) inhibitor</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">21742900</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=21742900&author=L.+Liuauthor=J.+Halladayauthor=Y.+Shinauthor=S.+Wongauthor=M.+Coraggioauthor=H.+Laauthor=M.+Baumgardnerauthor=H.+Leauthor=S.+Gopaulauthor=J.+Boggsauthor=P.+Kueblerauthor=J.+Davisauthor=C.+Liaoauthor=J.+Lubachauthor=A.+Deeseauthor=G.+Sowellauthor=K.+Currieauthor=W.+Youngauthor=C.+Khojastehauthor=C.+Hopauthor=H.+Wong&title=Significant+species+difference+in+amide+hydrolysis+of+GDC-0834%2C+a+novel+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DKuebler%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DLubach%26aufirst%3DJ.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DG.%26aulast%3DCurrie%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DW.%26aulast%3DKhojasteh%26aufirst%3DC.%26aulast%3DHop%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DSignificant%2520species%2520difference%2520in%2520amide%2520hydrolysis%2520of%2520GDC-0834%252C%2520a%2520novel%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26spage%3D21742900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dewdney, N. J.; Kondru, R. K.; Lou, Y.; Soth, M.; Gabriel, T.</span><span> </span><span class="NLM_article-title">BTK Protein Kinase Inhibitors</span>. Patent Application US 2009/0105209,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+J.+Dewdney&author=R.+K.+Kondru&author=Y.+Lou&author=M.+Soth&author=T.+Gabriel&title=BTK+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DBTK%2520Protein%2520Kinase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit60b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dewdney, N. J.; Lou, Y.; Soth, M.</span><span> </span><span class="NLM_article-title">Novel Imidazo[1,2-A]pyridine and Imidazo[1,2-B]pyridazine Derivatives</span>. Patent Application WO 2009/077334,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+J.+Dewdney&author=Y.+Lou&author=M.+Soth&title=Novel+Imidazo%5B1%2C2-A%5Dpyridine+and+Imidazo%5B1%2C2-B%5Dpyridazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DNovel%2520Imidazo%255B1%252C2-A%255Dpyridine%2520and%2520Imidazo%255B1%252C2-B%255Dpyridazine%2520Derivatives%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit60c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dewdney, N. J.; Kennedy-Smith, J.; Kondru, R. K.; Loe, B. E.; Lou, Y.; McIntosh, J.; Owens, T. D.; Soth, M.; Sweeney, Z. K.; Taygerly, J. P.G.</span><span> </span><span class="NLM_article-title">Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application US 2009/0306041,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+J.+Dewdney&author=J.+Kennedy-Smith&author=R.+K.+Kondru&author=B.+E.+Loe&author=Y.+Lou&author=J.+McIntosh&author=T.+D.+Owens&author=M.+Soth&author=Z.+K.+Sweeney&author=J+P.+G+Taygerly&title=Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DInhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit60d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Dewdney, N. J.; Lou, Y.; Sjogren, E. B.; Soth, M.</span><span> </span><span class="NLM_article-title">Novel Phenyl-imidazopyridines and Pyridazines</span>. Patent Application WO 2010/006947,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+J.+Dewdney&author=Y.+Lou&author=E.+B.+Sjogren&author=M.+Soth&title=Novel+Phenyl-imidazopyridines+and+Pyridazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DNovel%2520Phenyl-imidazopyridines%2520and%2520Pyridazines%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit60e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dewdney, N. J.; Lou, Y.; Sjogren, E. B.; Soth, M.; Sweeney, Z. K.</span><span> </span><span class="NLM_article-title">Novel Phenylpyrazinones as Kinase Inhibitors</span>. Patent Application WO 2010/000633,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+J.+Dewdney&author=Y.+Lou&author=E.+B.+Sjogren&author=M.+Soth&author=Z.+K.+Sweeney&title=Novel+Phenylpyrazinones+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DNovel%2520Phenylpyrazinones%2520as%2520Kinase%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit60f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Dewdney, N. J.; Hawley, R. C.; Kondru, R. K.; Lai, Y.; Lou, Y.</span><span> </span><span class="NLM_article-title">Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application WO 2010/122038,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+J.+Dewdney&author=R.+C.+Hawley&author=R.+K.+Kondru&author=Y.+Lai&author=Y.+Lou&title=Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DInhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit60g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Berthel, S.; Firooznia, F.; Fishlock, D.; Hong, J.; Lou, Y.; Lucas, M.; Owens, T. D.; Sarma, K.; Sweeney, Z. K.; Taygerly, J. P. G.</span><span> </span><span class="NLM_article-title">Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application US 2010/0222325,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Berthel&author=F.+Firooznia&author=D.+Fishlock&author=J.+Hong&author=Y.+Lou&author=M.+Lucas&author=T.+D.+Owens&author=K.+Sarma&author=Z.+K.+Sweeney&author=J.+P.+G.+Taygerly&title=Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBerthel%26aufirst%3DS.%26atitle%3DInhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Xu, D.; Kim, Y.; Postelnek, J.; Vu, M. D.; Hu, D.-Q.; Hsu, J.; Liao, C.; Zhang, J.; Pashine, A.; Srinivasan, D.; Woods, J.; Owens, T.; Lou, Y.; Hill, R.; Narula, S.; DeMartino, J.; Fine, J. S.</span><span> </span><span class="NLM_article-title">RN486 [6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2<i>H</i>-isoquinolin-1-one], a selective Bruton’s tyrosine kinase (Btk) inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span>.  <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A280%3ADC%252BC38zhtFymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90&author=D.+Xu&author=Y.+Kim&author=J.+Postelnek&author=M.+D.+Vu&author=D.-Q.+Hu&author=J.+Hsu&author=C.+Liao&author=J.+Zhang&author=A.+Pashine&author=D.+Srinivasan&author=J.+Woods&author=T.+Owens&author=Y.+Lou&author=R.+Hill&author=S.+Narula&author=J.+DeMartino&author=J.+S.+Fine&title=RN486+%5B6-cyclopropyl-8-fluoro-2-%282-hydroxymethyl-3-%7B1-methyl-5-%5B5-%284-methyl-piperazin-1-yl%29-pyridin-2-ylamino%5D-6-oxo-1%2C6-dihydro-pyridin-3-yl%7D-phenyl%29-2H-isoquinolin-1-one%5D%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents</span></div><div class="casAuthors">Xu Daigen; Kim Yong; Postelnek Jennifer; Vu Minh Diem; Hu Dong-Qing; Liao Cheng; Bradshaw Mike; Hsu Jonathan; Zhang Jun; Pashine Achal; Srinivasan Dinesh; Woods John; Levin Anita; O'Mahony Alison; Owens Timothy D; Lou Yan; Hill Ronald J; Narula Satwant; Demartino Julie; Fine Jay S</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic mutation and pharmacological inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor cross-linking-induced degranulation in mast cells (IC(50) = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α production in monocytes (IC(50) = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC(50) = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-molecule disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqSnPYc5dDCNj_Vg2vObihfW6udTcc2ebtpjqtIKWHQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zhtFymtQ%253D%253D&md5=a04c33939073dc33beda20c4b5e833d3</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26atitle%3DRN486%2520%255B6-cyclopropyl-8-fluoro-2-%25282-hydroxymethyl-3-%257B1-methyl-5-%255B5-%25284-methyl-piperazin-1-yl%2529-pyridin-2-ylamino%255D-6-oxo-1%252C6-dihydro-pyridin-3-yl%257D-phenyl%2529-2H-isoquinolin-1-one%255D%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Lindauer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span> </span><span class="NLM_article-title">Dasatinib</span> <span class="citation_source-journal">Recent Results Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1007%2F978-3-642-01222-8_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20072833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=83-102&author=M.+Lindauerauthor=A.+Hochhaus&title=Dasatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib</span></div><div class="casAuthors">Lindauer, Markus; Hochhaus, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">83-102</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">0080-0015</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Dasatinib, (former BMS 354825), is an orally available small-mol. multikinase inhibitor.  It potently inhibits BCR-ABL and SRC-family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-α and β, and ephrin receptor kinase.  Dasatinib is about 300 times more potent than imatinib in cells expressing unmutated BCR-ABL in vitro.  The drug has demonstrated activity against clin. relevant mutations, including those assocd. with poor prognosis during ongoing imatinib therapy.  Dasatinib is approved for the treatment of patients with BCR-ABL-pos. chronic myeloid leukemia (CML), resistant or intolerant to imatinib in chronic, accelerated, and blast phase.  It also is approved for the treatment of Philadelphia Chromosome pos. (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to imatinib.  A single daily dose of 100 mg in chronic phase CML results in high hematol. and mol. remission rates and prolongation of survival.  In accelerated and blastic phase as well as in ALL, 70 mg twice daily is recommended.  Complete hematol. and cytogenetic remissions (CR) frequently occur even in this patient group with poor prognosis.  Remissions however are very short.  Side effects of dasatinib are frequent but mostly moderate and manageable and include cytopenias and pleural effusions.  The role of dasatinib in other diseases, including solid tumors, has to be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbjaDV5Fc3frVg90H21EOLACvtfcHk0lj6RhV_JonhQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsLnK&md5=062b34461639470b554c895b74a295f7</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-01222-8_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-01222-8_7%26sid%3Dliteratum%253Aachs%26aulast%3DLindauer%26aufirst%3DM.%26aulast%3DHochhaus%26aufirst%3DA.%26atitle%3DDasatinib%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2010%26volume%3D184%26spage%3D83%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burckstummer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutze, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">13283</span><span class="NLM_x">–</span> <span class="NLM_lpage">13288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13283-13288&author=O.+Hantschelauthor=U.+Rixauthor=U.+Schmidtauthor=T.+Burckstummerauthor=M.+Kneidingerauthor=G.+Schutzeauthor=J.+Colingeauthor=K.+L.+Bennettauthor=W.+Ellmeierauthor=P.+Valentauthor=G.+Superti-Furga&title=The+Btk+tyrosine+kinase+is+a+major+target+of+the+Bcr-Abl+inhibitor+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBurckstummer%26aufirst%3DT.%26aulast%3DKneidinger%26aufirst%3DM.%26aulast%3DSchutze%26aufirst%3DG.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520Btk%2520tyrosine%2520kinase%2520is%2520a%2520major%2520target%2520of%2520the%2520Bcr-Abl%2520inhibitor%2520dasatinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D13283%26epage%3D13288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Sillaber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herndlhofer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschachler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jager, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span> </span><span class="NLM_article-title">Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily</span> <span class="citation_source-journal">Eur. J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">–</span> <span class="NLM_lpage">1109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=1098-1109&author=C.+Sillaberauthor=H.+Herrmannauthor=K.+Bennettauthor=U.+Rixauthor=C.+Baumgartnerauthor=A.+Bohmauthor=S.+Herndlhoferauthor=E.+Tschachlerauthor=G.+Superti-Furgaauthor=U.+Jagerauthor=P.+Valent&title=Immunosuppression+and+atypical+infections+in+CML+patients+treated+with+dasatinib+at+140+mg+daily"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSillaber%26aufirst%3DC.%26aulast%3DHerrmann%26aufirst%3DH.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DBohm%26aufirst%3DA.%26aulast%3DHerndlhofer%26aufirst%3DS.%26aulast%3DTschachler%26aufirst%3DE.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26aulast%3DJager%26aufirst%3DU.%26aulast%3DValent%26aufirst%3DP.%26atitle%3DImmunosuppression%2520and%2520atypical%2520infections%2520in%2520CML%2520patients%2520treated%2520with%2520dasatinib%2520at%2520140%2520mg%2520daily%26jtitle%3DEur.%2520J.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D39%26spage%3D1098%26epage%3D1109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Kneidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleixner, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vales, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupinek, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weghofer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schebesta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrtala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span> </span><span class="NLM_article-title">The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">3097</span><span class="NLM_x">–</span> <span class="NLM_lpage">3107</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=3097-3107&author=M.+Kneidingerauthor=U.+Schmidtauthor=U.+Rixauthor=K.+V.+Gleixnerauthor=A.+Valesauthor=C.+Baumgartnerauthor=C.+Lupinekauthor=M.+Weghoferauthor=K.+L.+Bennettauthor=H.+Herrmannauthor=A.+Schebestaauthor=W.+R.+Thomasauthor=S.+Vrtalaauthor=R.+Valentaauthor=F.+Y.+Leeauthor=W.+Ellmeierauthor=G.+Superti-Furgaauthor=P.+Valent&title=The+effects+of+dasatinib+on+IgE+receptor-dependent+activation+and+histamine+release+in+human+basophils"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKneidinger%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DGleixner%26aufirst%3DK.%2BV.%26aulast%3DVales%26aufirst%3DA.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DLupinek%26aufirst%3DC.%26aulast%3DWeghofer%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DHerrmann%26aufirst%3DH.%26aulast%3DSchebesta%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DW.%2BR.%26aulast%3DVrtala%26aufirst%3DS.%26aulast%3DValenta%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26aulast%3DValent%26aufirst%3DP.%26atitle%3DThe%2520effects%2520of%2520dasatinib%2520on%2520IgE%2520receptor-dependent%2520activation%2520and%2520histamine%2520release%2520in%2520human%2520basophils%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D3097%26epage%3D3107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Liu, Q.; Batt, D. G.; DeLucca, G. V.; Shi, Q.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Carbazole Carboxamide Compounds Useful as Kinase Inhibitors</span>. Patent Application US 2010/0160303,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Q.+Liu&author=D.+G.+Batt&author=G.+V.+DeLucca&author=Q.+Shi&author=A.+J.+Tebben&title=Carbazole+Carboxamide+Compounds+Useful+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DCarbazole%2520Carboxamide%2520Compounds%2520Useful%2520as%2520Kinase%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Liu, C.; Leftheris, K.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Fused Heterocyclic Compounds Useful for the Treatment of Proliferative, Allergic, Autoimmune or Inflammatory Diseases</span>. Patent Application WO 2008/116064,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Liu&author=K.+Leftheris&author=A.+J.+Tebben&title=Fused+Heterocyclic+Compounds+Useful+for+the+Treatment+of+Proliferative%2C+Allergic%2C+Autoimmune+or+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DFused%2520Heterocyclic%2520Compounds%2520Useful%2520for%2520the%2520Treatment%2520of%2520Proliferative%252C%2520Allergic%252C%2520Autoimmune%2520or%2520Inflammatory%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Liu, C.; Leftheris, K.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Fused Heterocyclic Compounds Useful as Kinase Modulators</span>. Patent Application WO 2010/011837,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+Liu&author=K.+Leftheris&author=A.+J.+Tebben&title=Fused+Heterocyclic+Compounds+Useful+as+Kinase+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DFused%2520Heterocyclic%2520Compounds%2520Useful%2520as%2520Kinase%2520Modulators%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Duan, J.; Jiang, B.; Lu, Z.</span><span> </span><span class="NLM_article-title">Azaindazoles as BTK Kinase Modulators and Use Thereof</span>. Patent Application WO 2011/019780,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Duan&author=B.+Jiang&author=Z.+Lu&title=Azaindazoles+as+BTK+Kinase+Modulators+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26atitle%3DAzaindazoles%2520as%2520BTK%2520Kinase%2520Modulators%2520and%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bui, M.; Conlon, P.; Erlanson, D. A.; Fan, J.; Guan, B.; Hopkins, B. T.; Ishchenko, A.; Jenkins, T. J.; Kumaravel, G.; Marcotte, D.; Powell, N.; Scott, D.; Taveras, A.; Wang, D.; Zhong, M.</span><span> </span><span class="NLM_article-title">Heteroaryl BTK Inhibitors</span>. Patent Application WO 2011/029043,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Bui&author=P.+Conlon&author=D.+A.+Erlanson&author=J.+Fan&author=B.+Guan&author=B.+T.+Hopkins&author=A.+Ishchenko&author=T.+J.+Jenkins&author=G.+Kumaravel&author=D.+Marcotte&author=N.+Powell&author=D.+Scott&author=A.+Taveras&author=D.+Wang&author=M.+Zhong&title=Heteroaryl+BTK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBui%26aufirst%3DM.%26atitle%3DHeteroaryl%2520BTK%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit70b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Erlanson, D. A.; Marcotte, D.; Kumaravel, G.; Fan, J.; Wang, D.; Cuervo, J. H.; Silvian, L.; Powell, N.; Bui, M.; Hopkins, B. T.; Taveras, A.; Guan, B.; Conlon, P.; Zhong, M.; Jenkins, T. J.; Scott, D.; Lugovskoy, A. A.</span><span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitors</span>. Patent Application WO 2011/029046,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+A.+Erlanson&author=D.+Marcotte&author=G.+Kumaravel&author=J.+Fan&author=D.+Wang&author=J.+H.+Cuervo&author=L.+Silvian&author=N.+Powell&author=M.+Bui&author=B.+T.+Hopkins&author=A.+Taveras&author=B.+Guan&author=P.+Conlon&author=M.+Zhong&author=T.+J.+Jenkins&author=D.+Scott&author=A.+A.+Lugovskoy&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38a','cit38b'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60a','cit60b','cit60c','cit60d','cit60e','cit60f','cit60g'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70a','cit70b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 61 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xuejun Zhang, Xijun Sheng, Jie Shen, Shoubo Zhang, Wenjie Sun, Chunli Shen, Yi Li, Jun Wang, Huqiang Lv, Minghui Cui, Yuchuan Zhu, Lei Huang, Dongling Hao, Zhibo Qi, Guanglong Sun, Weifeng Mao, Yan Pan, Liang Shen, Xin Li, Guoping Hu, Zhen Gong, Shuhua Han, Jian Li, Shuhui Chen, Ronghua Tu, Xuehai Wang, <span class="NLM_string-name hlFld-ContribAuthor">Chengde Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1863-1868. <a href="https://doi.org/10.1021/acsmedchemlett.9b00395" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00395%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252BEvaluation%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyridazinone%252Bas%252Ba%252BPotent%252Band%252BOrally%252BActive%252BIrreversible%252BBTK%252BInhibitor%26aulast%3DZhang%26aufirst%3DXuejun%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23082019%26date%3D11122019%26date%3D16122019%26date%3D11122019%26volume%3D11%26issue%3D10%26spage%3D1863%26epage%3D1868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard D. Caldwell, Hui Qiu, Ben C. Askew, Andrew T. Bender, Nadia Brugger, Montserrat Camps, Mohanraj Dhanabal, Vikram Dutt, Thomas Eichhorn, Anna S. Gardberg, Andreas Goutopoulos, Roland Grenningloh, Jared Head, Brian Healey, Brian L. Hodous, Bayard R. Huck, Theresa L. Johnson, Christopher Jones, Reinaldo C. Jones, Igor Mochalkin, Federica Morandi, Ngan Nguyen, Michael Meyring, Justin R. Potnick, Dusica Cvetinovic Santos, Ralf Schmidt, Brian Sherer, Adam Shutes, Klaus Urbahns, Ariele Viacava Follis, Ansgar A. Wegener, Simone C. Zimmerli, <span class="NLM_string-name hlFld-ContribAuthor">Lesley Liu-Bujalski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (17)
                                     , 7643-7655. <a href="https://doi.org/10.1021/acs.jmedchem.9b00794" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00794%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BEvobrutinib%25253A%252BAn%252BOral%25252C%252BPotent%25252C%252Band%252BHighly%252BSelective%25252C%252BCovalent%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDiseases%26aulast%3DCaldwell%26aufirst%3DRichard%2BD.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15052019%26date%3D15082019%26date%3D01082019%26volume%3D62%26issue%3D17%26spage%3D7643%26epage%3D7655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xia Yao, Xiuyun Sun, Shuyu Jin, Ling Yang, Hongjiang Xu, <span class="NLM_string-name hlFld-ContribAuthor">Yu Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6561-6574. <a href="https://doi.org/10.1021/acs.jmedchem.9b00329" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00329%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Aminoquinoline-3-carboxamide%252BDerivatives%252Bas%252BPotent%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DYao%26aufirst%3DXia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21022019%26date%3D12072019%26date%3D01072019%26volume%3D62%26issue%3D14%26spage%3D6561%26epage%3D6574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> James J.    Crawford    </span><span class="hlFld-ContribAuthor "> Haiming    Zhang </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 239-266. <a href="https://doi.org/10.1021/bk-2019-1332.ch009" title="DOI URL">https://doi.org/10.1021/bk-2019-1332.ch009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2019-1332.ch009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2019-1332.ch009%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BNon-Covalent%25252C%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252BFenebrutinib%252B%252528GDC-0853%252529%26aulast%3DCrawford%26aufirst%3DJames%2BJ.%26date%3D2019%26date%3D2019%26spage%3D239%26epage%3D266%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B2%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2019%26date%3D2019%26volume%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yu Xue, Peiran Song, Zilan Song, Aoli Wang, Linjiang Tong, Meiyu Geng, Jian Ding, Qingsong Liu, Liping Sun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ao Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 4608-4627. <a href="https://doi.org/10.1021/acs.jmedchem.8b00441" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00441%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4%25252C7-Diamino-5-%2525284-phenoxyphenyl%252529-6-methylene-pyrimido%25255B5%25252C4-b%25255Dpyrrolizines%252Bas%252BNovel%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DXue%26aufirst%3DYu%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D09052018%26date%3D01052018%26volume%3D61%26issue%3D10%26spage%3D4608%26epage%3D4627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James J. Crawford, Adam R. Johnson, Dinah L. Misner, Lisa D. Belmont, Georgette Castanedo, Regina Choy, Melis Coraggio, Liming Dong, Charles Eigenbrot, Rebecca Erickson, Nico Ghilardi, Jonathan Hau, Arna Katewa, Pawan Bir Kohli, Wendy Lee, Joseph W. Lubach, Brent S. McKenzie, Daniel F. Ortwine, Leah Schutt, Suzanne Tay, BinQing Wei, Karin Reif, Lichuan Liu, Harvey Wong, <span class="NLM_string-name hlFld-ContribAuthor">Wendy B. Young</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2227-2245. <a href="https://doi.org/10.1021/acs.jmedchem.7b01712" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01712</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BGDC-0853%25253A%252BA%252BPotent%25252C%252BSelective%25252C%252Band%252BNoncovalent%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bin%252BEarly%252BClinical%252BDevelopment%26aulast%3DCrawford%26aufirst%3DJames%2BJ.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D20112017%26date%3D23022018%26date%3D19022018%26volume%3D61%26issue%3D6%26spage%3D2227%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojing  Wang</span>, <span class="hlFld-ContribAuthor ">James  Barbosa</span>, <span class="hlFld-ContribAuthor ">Peter  Blomgren</span>, <span class="hlFld-ContribAuthor ">Meire C.  Bremer</span>, <span class="hlFld-ContribAuthor ">Jacob  Chen</span>, <span class="hlFld-ContribAuthor ">James J.  Crawford</span>, <span class="hlFld-ContribAuthor ">Wei  Deng</span>, <span class="hlFld-ContribAuthor ">Liming  Dong</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Steve  Gallion</span>, <span class="hlFld-ContribAuthor ">Jonathon  Hau</span>, <span class="hlFld-ContribAuthor ">Huiyong  Hu</span>, <span class="hlFld-ContribAuthor ">Adam R.  Johnson</span>, <span class="hlFld-ContribAuthor ">Arna  Katewa</span>, <span class="hlFld-ContribAuthor ">Jeffrey E.  Kropf</span>, <span class="hlFld-ContribAuthor ">Seung H.  Lee</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Joseph W.  Lubach</span>, <span class="hlFld-ContribAuthor ">Jen  Macaluso</span>, <span class="hlFld-ContribAuthor ">Pat  Maciejewski</span>, <span class="hlFld-ContribAuthor ">Scott A.  Mitchell</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Julie  DiPaolo</span>, <span class="hlFld-ContribAuthor ">Karin  Reif</span>, <span class="hlFld-ContribAuthor ">Heleen  Scheerens</span>, <span class="hlFld-ContribAuthor ">Aaron  Schmitt</span>, <span class="hlFld-ContribAuthor ">Harvey  Wong</span>, <span class="hlFld-ContribAuthor ">Jin-Ming  Xiong</span>, <span class="hlFld-ContribAuthor ">Jianjun  Xu</span>, <span class="hlFld-ContribAuthor ">Zhongdong  Zhao</span>, <span class="hlFld-ContribAuthor ">Fusheng  Zhou</span>, <span class="hlFld-ContribAuthor ">Kevin S.  Currie</span>, and <span class="hlFld-ContribAuthor ">Wendy B.  Young</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (6)
                                     , 608-613. <a href="https://doi.org/10.1021/acsmedchemlett.7b00103" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00103%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252BTricyclic%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252BImproved%252BDruglike%252BProperties%26aulast%3DWang%26aufirst%3DXiaojing%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D08032017%26date%3D03052017%26date%3D16052017%26date%3D08062017%26date%3D03052017%26volume%3D8%26issue%3D6%26spage%3D608%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul A.  Jackson</span>, <span class="hlFld-ContribAuthor ">John C.  Widen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Harki</span>, and <span class="hlFld-ContribAuthor ">Kay M.  Brummond</span>  . </span><span class="cited-content_cbyCitation_article-title">Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (3)
                                     , 839-885. <a href="https://doi.org/10.1021/acs.jmedchem.6b00788" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00788%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252BModifiers%25253A%252BA%252BChemical%252BPerspective%252Bon%252Bthe%252BReactivity%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B2-Unsaturated%252BCarbonyls%252Bwith%252BThiols%252Bvia%252BHetero-Michael%252BAddition%252BReactions%26aulast%3DJackson%26aufirst%3DPaul%2BA.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D25052016%26date%3D20122016%26date%3D09022017%26volume%3D60%26issue%3D3%26spage%3D839%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Yue  Jin</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Jinyong  Peng</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (12)
                                     , 1050-1055. <a href="https://doi.org/10.1021/acsmedchemlett.6b00235" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00235%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitors%252BBearing%252Ba%252BN%25252C9-Diphenyl-9H-purin-2-amine%252BScaffold%26aulast%3DGe%26aufirst%3DYang%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11062016%26date%3D21092016%26date%3D27092016%26date%3D08122016%26date%3D21092016%26volume%3D7%26issue%3D12%26spage%3D1050%26epage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam R.  Johnson</span>, <span class="hlFld-ContribAuthor ">Pawan Bir  Kohli</span>, <span class="hlFld-ContribAuthor ">Arna  Katewa</span>, <span class="hlFld-ContribAuthor ">Emily  Gogol</span>, <span class="hlFld-ContribAuthor ">Lisa D.  Belmont</span>, <span class="hlFld-ContribAuthor ">Regina  Choy</span>, <span class="hlFld-ContribAuthor ">Elicia  Penuel</span>, <span class="hlFld-ContribAuthor ">Luciana  Burton</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Christine  Yu</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Krista  Bowman</span>, <span class="hlFld-ContribAuthor ">Yvonne  Franke</span>, <span class="hlFld-ContribAuthor ">Christine  Tam</span>, <span class="hlFld-ContribAuthor ">Alberto  Estevez</span>, <span class="hlFld-ContribAuthor ">Kyle  Mortara</span>, <span class="hlFld-ContribAuthor ">Jiansheng  Wu</span>, <span class="hlFld-ContribAuthor ">Hong  Li</span>, <span class="hlFld-ContribAuthor ">May  Lin</span>, <span class="hlFld-ContribAuthor ">Philippe  Bergeron</span>, <span class="hlFld-ContribAuthor ">James J.  Crawford</span>, and <span class="hlFld-ContribAuthor ">Wendy B.  Young</span>  . </span><span class="cited-content_cbyCitation_article-title">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (10)
                                     , 2897-2907. <a href="https://doi.org/10.1021/acschembio.6b00480" title="DOI URL">https://doi.org/10.1021/acschembio.6b00480</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.6b00480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.6b00480%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DBattling%252BBtk%252BMutants%252BWith%252BNoncovalent%252BInhibitors%252BThat%252BOvercome%252BCys481%252Band%252BThr474%252BMutations%26aulast%3DJohnson%26aufirst%3DAdam%2BR.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D01062016%26date%3D29082016%26date%3D07092016%26date%3D21102016%26date%3D29082016%26volume%3D11%26issue%3D10%26spage%3D2897%26epage%3D2907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Deodial  Guiadeen</span>, <span class="hlFld-ContribAuthor ">Arto  Krikorian</span>, <span class="hlFld-ContribAuthor ">Xiaolei  Gao</span>, <span class="hlFld-ContribAuthor ">James  Wang</span>, <span class="hlFld-ContribAuthor ">Sobhana Babu  Boga</span>, <span class="hlFld-ContribAuthor ">Abdul-Basit  Alhassan</span>, <span class="hlFld-ContribAuthor ">Younong  Yu</span>, <span class="hlFld-ContribAuthor ">Henry  Vaccaro</span>, <span class="hlFld-ContribAuthor ">Shilan  Liu</span>, <span class="hlFld-ContribAuthor ">Chundao  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Wu</span>, <span class="hlFld-ContribAuthor ">Alan  Cooper</span>, <span class="hlFld-ContribAuthor ">Jos  de Man</span>, <span class="hlFld-ContribAuthor ">Allard  Kaptein</span>, <span class="hlFld-ContribAuthor ">Kevin  Maloney</span>, <span class="hlFld-ContribAuthor ">Viktor  Hornak</span>, <span class="hlFld-ContribAuthor ">Ying-Duo  Gao</span>, <span class="hlFld-ContribAuthor ">Thierry O.  Fischmann</span>, <span class="hlFld-ContribAuthor ">Hans  Raaijmakers</span>, <span class="hlFld-ContribAuthor ">Diep  Vu-Pham</span>, <span class="hlFld-ContribAuthor ">Jeremy  Presland</span>, <span class="hlFld-ContribAuthor ">My  Mansueto</span>, <span class="hlFld-ContribAuthor ">Zangwei  Xu</span>, <span class="hlFld-ContribAuthor ">Erica  Leccese</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang-Hoover</span>, <span class="hlFld-ContribAuthor ">Ian  Knemeyer</span>, <span class="hlFld-ContribAuthor ">Charles G.  Garlisi</span>, <span class="hlFld-ContribAuthor ">Nathan  Bays</span>, <span class="hlFld-ContribAuthor ">Peter  Stivers</span>, <span class="hlFld-ContribAuthor ">Philip E.  Brandish</span>, <span class="hlFld-ContribAuthor ">Alexandra  Hicks</span>, <span class="hlFld-ContribAuthor ">Ronald  Kim</span>, and <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (2)
                                     , 198-203. <a href="https://doi.org/10.1021/acsmedchemlett.5b00463" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B8-Amino-imidazo%25255B1%25252C5-a%25255Dpyrazines%252Bas%252BReversible%252BBTK%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DLiu%26aufirst%3DJian%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D01122015%26date%3D18122015%26date%3D30122015%26date%3D11022016%26date%3D19122015%26volume%3D7%26issue%3D2%26spage%3D198%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eunha  Kim</span>, <span class="hlFld-ContribAuthor ">Katherine S.  Yang</span>, <span class="hlFld-ContribAuthor ">Rainer H.  Kohler</span>, <span class="hlFld-ContribAuthor ">John M.  Dubach</span>, <span class="hlFld-ContribAuthor ">Hannes  Mikula</span>, and <span class="hlFld-ContribAuthor ">Ralph  Weissleder</span>  . </span><span class="cited-content_cbyCitation_article-title">Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2015,</strong> <em>26 </em>
                                    (8)
                                     , 1513-1518. <a href="https://doi.org/10.1021/acs.bioconjchem.5b00152" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.5b00152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.5b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.5b00152%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DOptimized%252BNear-IR%252BFluorescent%252BAgents%252Bfor%252Bin%252BVivo%252BImaging%252Bof%252BBtk%252BExpression%26aulast%3DKim%26aufirst%3DEunha%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D23032015%26date%3D26052015%26date%3D09062015%26date%3D19082015%26date%3D27052015%26volume%3D26%26issue%3D8%26spage%3D1513%26epage%3D1518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yupeng  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Discoidin Domain Receptor Kinase Inhibitors and Potential Medical Applications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (8)
                                     , 3287-3301. <a href="https://doi.org/10.1021/jm5012319" title="DOI URL">https://doi.org/10.1021/jm5012319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5012319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5012319%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BDiscoidin%252BDomain%252BReceptor%252BKinase%252BInhibitors%252Band%252BPotential%252BMedical%252BApplications%26aulast%3DLi%26aufirst%3DYupeng%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D10082014%26date%3D21012015%26date%3D23042015%26date%3D08012015%26volume%3D58%26issue%3D8%26spage%3D3287%26epage%3D3301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Lou</span>, <span class="hlFld-ContribAuthor ">Xiaochun  Han</span>, <span class="hlFld-ContribAuthor ">Andreas  Kuglstatter</span>, <span class="hlFld-ContribAuthor ">Rama K.  Kondru</span>, <span class="hlFld-ContribAuthor ">Zachary K.  Sweeney</span>, <span class="hlFld-ContribAuthor ">Michael  Soth</span>, <span class="hlFld-ContribAuthor ">Joel  McIntosh</span>, <span class="hlFld-ContribAuthor ">Renee  Litman</span>, <span class="hlFld-ContribAuthor ">Judy  Suh</span>, <span class="hlFld-ContribAuthor ">Buelent  Kocer</span>, <span class="hlFld-ContribAuthor ">Dana  Davis</span>, <span class="hlFld-ContribAuthor ">Jaehyeon  Park</span>, <span class="hlFld-ContribAuthor ">Sandra  Frauchiger</span>, <span class="hlFld-ContribAuthor ">Nolan  Dewdney</span>, <span class="hlFld-ContribAuthor ">Hasim  Zecic</span>, <span class="hlFld-ContribAuthor ">Joshua P.  Taygerly</span>, <span class="hlFld-ContribAuthor ">Keshab  Sarma</span>, <span class="hlFld-ContribAuthor ">Junbae  Hong</span>, <span class="hlFld-ContribAuthor ">Ronald J.  Hill</span>, <span class="hlFld-ContribAuthor ">Tobias  Gabriel</span>, <span class="hlFld-ContribAuthor ">David M.  Goldstein</span>, and <span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (1)
                                     , 512-516. <a href="https://doi.org/10.1021/jm500305p" title="DOI URL">https://doi.org/10.1021/jm500305p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500305p%26sid%3Dliteratum%253Aachs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDrug%252BDesign%252Bof%252BRN486%25252C%252Ba%252BPotent%252Band%252BSelective%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitor%25252C%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DLou%26aufirst%3DYan%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D03032014%26date%3D16042014%26date%3D08012015%26date%3D08042014%26volume%3D58%26issue%3D1%26spage%3D512%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xitao  Li</span>, <span class="hlFld-ContribAuthor ">Yingying  Zuo</span>, <span class="hlFld-ContribAuthor ">Guanghui  Tang</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Yiqing  Zhou</span>, <span class="hlFld-ContribAuthor ">Xueying  Wang</span>, <span class="hlFld-ContribAuthor ">Tianlin  Guo</span>, <span class="hlFld-ContribAuthor ">Mengying  Xia</span>, <span class="hlFld-ContribAuthor ">Ning  Ding</span>, and <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (12)
                                     , 5112-5128. <a href="https://doi.org/10.1021/jm4017762" title="DOI URL">https://doi.org/10.1021/jm4017762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4017762%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BSeries%252Bof%252B2%25252C5-Diaminopyrimidine%252BCovalent%252BIrreversible%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252Bin%252BVivo%252BAntitumor%252BActivity%26aulast%3DLi%26aufirst%3DXitao%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D16112013%26date%3D10062014%26date%3D26062014%26volume%3D57%26issue%3D12%26spage%3D5112%26epage%3D5128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun-Bae  Hong</span>, <span class="hlFld-ContribAuthor ">James P.  Davidson</span>, <span class="hlFld-ContribAuthor ">Qingwu  Jin</span>, <span class="hlFld-ContribAuthor ">Gary R.  Lee</span>, <span class="hlFld-ContribAuthor ">Michael  Matchett</span>, <span class="hlFld-ContribAuthor ">Erin  O’Brien</span>, <span class="hlFld-ContribAuthor ">Michael  Welch</span>, <span class="hlFld-ContribAuthor ">Bill  Bingenheimer</span>, and <span class="hlFld-ContribAuthor ">Keshab  Sarma</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of a Scalable Synthesis of a Bruton’s Tyrosine Kinase Inhibitor via C–N and C–C Bond Couplings as an End Game Strategy. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2014,</strong> <em>18 </em>
                                    (1)
                                     , 228-238. <a href="https://doi.org/10.1021/op4001077" title="DOI URL">https://doi.org/10.1021/op4001077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/op4001077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fop4001077%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BScalable%252BSynthesis%252Bof%252Ba%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bvia%252BC%2525E2%252580%252593N%252Band%252BC%2525E2%252580%252593C%252BBond%252BCouplings%252Bas%252Ban%252BEnd%252BGame%252BStrategy%26aulast%3DHong%26aufirst%3DJun-Bae%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D23042013%26date%3D02102013%26date%3D17012014%26date%3D27082013%26volume%3D18%26issue%3D1%26spage%3D228%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lady Mae  Alabanza</span>, <span class="hlFld-ContribAuthor ">Yan  Dong</span>, <span class="hlFld-ContribAuthor ">Ping  Wang</span>, <span class="hlFld-ContribAuthor ">James A.  Wright</span>, <span class="hlFld-ContribAuthor ">Yingchao  Zhang</span>, and <span class="hlFld-ContribAuthor ">Andrew J.  Briggs</span>  . </span><span class="cited-content_cbyCitation_article-title">A Practical Synthesis of an Aminopyridine as a Component of a BTK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2013,</strong> <em>17 </em>
                                    (5)
                                     , 876-880. <a href="https://doi.org/10.1021/op400046y" title="DOI URL">https://doi.org/10.1021/op400046y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/op400046y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fop400046y%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DA%252BPractical%252BSynthesis%252Bof%252Ban%252BAminopyridine%252Bas%252Ba%252BComponent%252Bof%252Ba%252BBTK%252BInhibitor%26aulast%3DAlabanza%26aufirst%3DLady%2BMae%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D20022013%26date%3D02052013%26date%3D17052013%26date%3D22042013%26volume%3D17%26issue%3D5%26spage%3D876%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lauren E.  Kueffer</span>, <span class="hlFld-ContribAuthor ">Raji E.  Joseph</span>, <span class="hlFld-ContribAuthor ">Amy H.  Andreotti</span>. </span><span class="cited-content_cbyCitation_article-title">Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.655489" title="DOI URL">https://doi.org/10.3389/fcell.2021.655489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.655489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.655489%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DReining%252Bin%252BBTK%25253A%252BInterdomain%252BInteractions%252Band%252BTheir%252BImportance%252Bin%252Bthe%252BRegulatory%252BControl%252Bof%252BBTK%26aulast%3DKueffer%26aufirst%3DLauren%2BE.%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Qiu</span>, <span class="hlFld-ContribAuthor ">Zahid  Ali</span>, <span class="hlFld-ContribAuthor ">Andrew  Bender</span>, <span class="hlFld-ContribAuthor ">Richard  Caldwell</span>, <span class="hlFld-ContribAuthor ">Yi-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Zhizhou  Fang</span>, <span class="hlFld-ContribAuthor ">Anna  Gardberg</span>, <span class="hlFld-ContribAuthor ">Nina  Glaser</span>, <span class="hlFld-ContribAuthor ">Anja  Goettsche</span>, <span class="hlFld-ContribAuthor ">Andreas  Goutopoulos</span>, <span class="hlFld-ContribAuthor ">Roland  Grenningloh</span>, <span class="hlFld-ContribAuthor ">Bettina  Hanschke</span>, <span class="hlFld-ContribAuthor ">Jared  Head</span>, <span class="hlFld-ContribAuthor ">Theresa  Johnson</span>, <span class="hlFld-ContribAuthor ">Christopher  Jones</span>, <span class="hlFld-ContribAuthor ">Reinaldo  Jones</span>, <span class="hlFld-ContribAuthor ">Shashank  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Christine  Maurer</span>, <span class="hlFld-ContribAuthor ">Federica  Morandi</span>, <span class="hlFld-ContribAuthor ">Constantin  Neagu</span>, <span class="hlFld-ContribAuthor ">Sven  Poetzsch</span>, <span class="hlFld-ContribAuthor ">Justin  Potnick</span>, <span class="hlFld-ContribAuthor ">Ralf  Schmidt</span>, <span class="hlFld-ContribAuthor ">Katherine  Roe</span>, <span class="hlFld-ContribAuthor ">Ariele  Viacava Follis</span>, <span class="hlFld-ContribAuthor ">Carolyn  Wing</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Zhu</span>, <span class="hlFld-ContribAuthor ">Brian  Sherer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>40 </em>, 116163. <a href="https://doi.org/10.1016/j.bmc.2021.116163" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116163%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bselective%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DQiu%26aufirst%3DHui%26date%3D2021%26volume%3D40%26spage%3D116163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atli  Thorarensen</span>, <span class="hlFld-ContribAuthor ">Paul  Balbo</span>, <span class="hlFld-ContribAuthor ">Mary E.  Banker</span>, <span class="hlFld-ContribAuthor ">Robert M.  Czerwinski</span>, <span class="hlFld-ContribAuthor ">Max  Kuhn</span>, <span class="hlFld-ContribAuthor ">Tristan S.  Maurer</span>, <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Arthur J.  Wittwer</span>. </span><span class="cited-content_cbyCitation_article-title">The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115865. <a href="https://doi.org/10.1016/j.bmc.2020.115865" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115865</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115865%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Badvantages%252Bof%252Bdescribing%252Bcovalent%252Binhibitor%252Bin%252Bvitro%252Bpotencies%252Bby%252BIC50%252Bat%252Ba%252Bfixed%252Btime%252Bpoint.%252BIC50%252Bdetermination%252Bof%252Bcovalent%252Binhibitors%252Bprovides%252Bmeaningful%252Bdata%252Bto%252Bmedicinal%252Bchemistry%252Bfor%252BSAR%252Boptimization%26aulast%3DThorarensen%26aufirst%3DAtli%26date%3D2021%26volume%3D29%26spage%3D115865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olivier R.P.  David</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5-6 Systems With One Bridgehead (Ring Junction) Nitrogen Atom: Three Extra 1-Heteroatom 1:2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00058-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00058-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00058-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00058-5%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5-6%252BSystems%252BWith%252BOne%252BBridgehead%252B%252528Ring%252BJunction%252529%252BNitrogen%252BAtom%25253A%252BThree%252BExtra%252B1-Heteroatom%252B1%25253A2%26aulast%3DDavid%26aufirst%3DOlivier%2BR.P.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Bayesian machine learning to discover Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2020,</strong> <em>96 </em>
                                    (4)
                                     , 1114-1122. <a href="https://doi.org/10.1111/cbdd.13656" title="DOI URL">https://doi.org/10.1111/cbdd.13656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13656%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DBayesian%252Bmachine%252Blearning%252Bto%252Bdiscover%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DWang%26aufirst%3DJian%26date%3D2020%26date%3D2020%26volume%3D96%26issue%3D4%26spage%3D1114%26epage%3D1122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanyan  Diao</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Fang</span>, <span class="hlFld-ContribAuthor ">Peiran  Song</span>, <span class="hlFld-ContribAuthor ">Mengzhen  Lai</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Yongjia  Hao</span>, <span class="hlFld-ContribAuthor ">Dou  Dou</span>, <span class="hlFld-ContribAuthor ">Yingqiang  Liu</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (15)
                                     , 3390-3395. <a href="https://doi.org/10.1016/j.bmc.2019.06.023" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BBiological%252Bevaluation%252Bof%252Bpyrimido%25255B4%25252C5-d%25255Dpyrimidine-2%25252C4%2525281H%25252C3H%252529-dione%252Bderivatives%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DDiao%26aufirst%3DYanyan%26date%3D2019%26volume%3D27%26issue%3D15%26spage%3D3390%26epage%3D3395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shenqiu  Wang</span>, <span class="hlFld-ContribAuthor ">Sayan  Mondal</span>, <span class="hlFld-ContribAuthor ">Chunying  Zhao</span>, <span class="hlFld-ContribAuthor ">Marjan  Berishaj</span>, <span class="hlFld-ContribAuthor ">Phani  Ghanakota</span>, <span class="hlFld-ContribAuthor ">Connie Lee  Batlevi</span>, <span class="hlFld-ContribAuthor ">Ahmet  Dogan</span>, <span class="hlFld-ContribAuthor ">Venkatraman E.  Seshan</span>, <span class="hlFld-ContribAuthor ">Robert  Abel</span>, <span class="hlFld-ContribAuthor ">Michael R.  Green</span>, <span class="hlFld-ContribAuthor ">Anas  Younes</span>, <span class="hlFld-ContribAuthor ">Hans-Guido  Wendel</span>. </span><span class="cited-content_cbyCitation_article-title">Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. </span><span class="cited-content_cbyCitation_journal-name">JCI Insight</span><span> <strong>2019,</strong> <em>4 </em>
                                    (12)
                                     <a href="https://doi.org/10.1172/jci.insight.127566" title="DOI URL">https://doi.org/10.1172/jci.insight.127566</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1172/jci.insight.127566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1172%2Fjci.insight.127566%26sid%3Dliteratum%253Aachs%26jtitle%3DJCI%2520Insight%26atitle%3DNoncovalent%252Binhibitors%252Breveal%252BBTK%252Bgatekeeper%252Band%252Bauto-inhibitory%252Bresidues%252Bthat%252Bcontrol%252Bits%252Btransforming%252Bactivity%26aulast%3DWang%26aufirst%3DShenqiu%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francisco  Lopez-Tapia</span>, <span class="hlFld-ContribAuthor ">Yan  Lou</span>, <span class="hlFld-ContribAuthor ">Christine  Brotherton-Pleiss</span>, <span class="hlFld-ContribAuthor ">Andreas  Kuglstatter</span>, <span class="hlFld-ContribAuthor ">Sung-Sau  So</span>, <span class="hlFld-ContribAuthor ">Rama  Kondru</span>. </span><span class="cited-content_cbyCitation_article-title">A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (9)
                                     , 1074-1078. <a href="https://doi.org/10.1016/j.bmcl.2019.03.001" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.03.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DA%252Bpotent%252Bseven-membered%252Bcyclic%252BBTK%252B%252528Bruton%252527s%252Btyrosine%252BKinase%252529%252Bchiral%252Binhibitor%252Bconceived%252Bby%252Bstructure-based%252Bdrug%252Bdesign%252Bto%252Block%252Bits%252Bbioactive%252Bconformation%26aulast%3DLopez-Tapia%26aufirst%3DFrancisco%26date%3D2019%26volume%3D29%26issue%3D9%26spage%3D1074%26epage%3D1078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Jun  He</span>, <span class="hlFld-ContribAuthor ">Jiali  Zhu</span>, <span class="hlFld-ContribAuthor ">Weimin  Li</span>, <span class="hlFld-ContribAuthor ">Ting  Niu</span>, <span class="hlFld-ContribAuthor ">Mingli  Xiang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>169 </em>, 121-143. <a href="https://doi.org/10.1016/j.ejmech.2019.02.077" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.077%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252B7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-amine%252Bderivatives%252Bas%252Bpotent%25252C%252Bselective%252Band%252Breversible%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DZhang%26aufirst%3DChufeng%26date%3D2019%26volume%3D169%26spage%3D121%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Nan  Ma</span>, <span class="hlFld-ContribAuthor ">Rui  Wu</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Zhengqiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">A novel reactive turn-on probe capable of selective profiling and no-wash imaging of Bruton's tyrosine kinase in live cells. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (24)
                                     , 3473-3476. <a href="https://doi.org/10.1039/C9CC01059A" title="DOI URL">https://doi.org/10.1039/C9CC01059A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC01059A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC01059A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DA%252Bnovel%252Breactive%252Bturn-on%252Bprobe%252Bcapable%252Bof%252Bselective%252Bprofiling%252Band%252Bno-wash%252Bimaging%252Bof%252BBruton%252527s%252Btyrosine%252Bkinase%252Bin%252Blive%252Bcells%26aulast%3DWang%26aufirst%3DXin%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D24%26spage%3D3473%26epage%3D3476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Zheng</span>, <span class="hlFld-ContribAuthor ">Qun  Hao</span>, <span class="hlFld-ContribAuthor ">Kuaile  Lin</span>, <span class="hlFld-ContribAuthor ">Jing  Pan</span>, <span class="hlFld-ContribAuthor ">Yingxia  Li</span>, <span class="hlFld-ContribAuthor ">Weicheng  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (2)
                                     , 225-229. <a href="https://doi.org/10.1016/j.bmcl.2018.11.051" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.11.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.11.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.11.051%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B1-substituted%252B3-%2525283-phenoxyprop-1-yn-1-yl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-amines%252Bas%252Bpotent%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%26aulast%3DZheng%26aufirst%3DNan%26date%3D2019%26volume%3D29%26issue%3D2%26spage%3D225%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingjie  Liu</span>, <span class="hlFld-ContribAuthor ">Douglas G.  Batt</span>, <span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Jonathan S.  Lippy</span>, <span class="hlFld-ContribAuthor ">Mark A.  Pattoli</span>, <span class="hlFld-ContribAuthor ">Neha  Surti</span>, <span class="hlFld-ContribAuthor ">Songmei  Xu</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">James R.  Burke</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (18)
                                     , 3080-3084. <a href="https://doi.org/10.1016/j.bmcl.2018.07.041" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.07.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.07.041%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DConversion%252Bof%252Bcarbazole%252Bcarboxamide%252Bbased%252Breversible%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binto%252Bpotent%25252C%252Bselective%252Birreversible%252Binhibitors%252Bin%252Bthe%252Bcarbazole%25252C%252Btetrahydrocarbazole%25252C%252Band%252Ba%252Bnew%252B2%25252C3-dimethylindole%252Bseries%26aulast%3DLiu%26aufirst%3DQingjie%26date%3D2018%26volume%3D28%26issue%3D18%26spage%3D3080%26epage%3D3084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Qiu</span>, <span class="hlFld-ContribAuthor ">Lesley  Liu-Bujalski</span>, <span class="hlFld-ContribAuthor ">Richard D  Caldwell</span>, <span class="hlFld-ContribAuthor ">Ariele Viacava  Follis</span>, <span class="hlFld-ContribAuthor ">Anna  Gardberg</span>, <span class="hlFld-ContribAuthor ">Andreas  Goutopoulos</span>, <span class="hlFld-ContribAuthor ">Roland  Grenningloh</span>, <span class="hlFld-ContribAuthor ">Jared  Head</span>, <span class="hlFld-ContribAuthor ">Theresa  Johnson</span>, <span class="hlFld-ContribAuthor ">Reinaldo  Jones</span>, <span class="hlFld-ContribAuthor ">Igor  Mochalkin</span>, <span class="hlFld-ContribAuthor ">Federica  Morandi</span>, <span class="hlFld-ContribAuthor ">Constantin  Neagu</span>, <span class="hlFld-ContribAuthor ">Brian  Sherer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (17)
                                     , 2939-2944. <a href="https://doi.org/10.1016/j.bmcl.2018.07.008" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.07.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.07.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bpotent%25252C%252Bhighly%252Bselective%252Bcovalent%252Birreversible%252BBTK%252Binhibitors%252Bfrom%252Ba%252Bfragment%252Bhit%26aulast%3DQiu%26aufirst%3DHui%26date%3D2018%26volume%3D28%26issue%3D17%26spage%3D2939%26epage%3D2944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandro  Corti</span>, <span class="hlFld-ContribAuthor ">Mario  Milani</span>, <span class="hlFld-ContribAuthor ">Daniele  Lecis</span>, <span class="hlFld-ContribAuthor ">Pierfausto  Seneci</span>, <span class="hlFld-ContribAuthor ">Matteo  Rosa</span>, <span class="hlFld-ContribAuthor ">Eloise  Mastrangelo</span>, <span class="hlFld-ContribAuthor ">Federica  Cossu</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐based design and molecular profiling of Smac‐mimetics selective for cellular
              IAP
              s. </span><span class="cited-content_cbyCitation_journal-name">The FEBS Journal</span><span> <strong>2018,</strong> <em>285 </em>
                                    (17)
                                     , 3286-3298. <a href="https://doi.org/10.1111/febs.14616" title="DOI URL">https://doi.org/10.1111/febs.14616</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/febs.14616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffebs.14616%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FEBS%2520Journal%26atitle%3DStructure%2525E2%252580%252590based%252Bdesign%252Band%252Bmolecular%252Bprofiling%252Bof%252BSmac%2525E2%252580%252590mimetics%252Bselective%252Bfor%252Bcellular%252BIAP%252Bs%26aulast%3DCorti%26aufirst%3DAlessandro%26date%3D2018%26date%3D2018%26volume%3D285%26issue%3D17%26spage%3D3286%26epage%3D3298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Zheng</span>, <span class="hlFld-ContribAuthor ">Jing  Pan</span>, <span class="hlFld-ContribAuthor ">Qun  Hao</span>, <span class="hlFld-ContribAuthor ">Yingxia  Li</span>, <span class="hlFld-ContribAuthor ">Weicheng  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (8)
                                     , 2165-2172. <a href="https://doi.org/10.1016/j.bmc.2018.03.017" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.03.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.03.017%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B3-substituted%252Bpyrazolopyrimidine%252Bderivatives%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%26aulast%3DZheng%26aufirst%3DNan%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D2165%26epage%3D2172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linyi  Liu</span>, <span class="hlFld-ContribAuthor ">Bingyu  Shi</span>, <span class="hlFld-ContribAuthor ">Xiangqian  Wang</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (3)
                                     , 343-356. <a href="https://doi.org/10.4155/fmc-2017-0145" title="DOI URL">https://doi.org/10.4155/fmc-2017-0145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0145%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DStrategies%252Bto%252Bovercome%252Bresistance%252Bmutations%252Bof%252BBruton%252527s%252Btyrosine%252Bkinase%252Binhibitor%252Bibrutinib%26aulast%3DLiu%26aufirst%3DLinyi%26date%3D2018%26volume%3D10%26issue%3D3%26spage%3D343%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sobhana Babu  Boga</span>, <span class="hlFld-ContribAuthor ">Abdul-Basit  Alhassan</span>, <span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Deodial  Guiadeen</span>, <span class="hlFld-ContribAuthor ">Arto  Krikorian</span>, <span class="hlFld-ContribAuthor ">Xiaolei  Gao</span>, <span class="hlFld-ContribAuthor ">James  Wang</span>, <span class="hlFld-ContribAuthor ">Younong  Yu</span>, <span class="hlFld-ContribAuthor ">Rajan  Anand</span>, <span class="hlFld-ContribAuthor ">Shilan  Liu</span>, <span class="hlFld-ContribAuthor ">Chundao  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Wu</span>, <span class="hlFld-ContribAuthor ">Jiaqiang  Cai</span>, <span class="hlFld-ContribAuthor ">Hugh  Zhu</span>, <span class="hlFld-ContribAuthor ">Jagdish  Desai</span>, <span class="hlFld-ContribAuthor ">Kevin  Maloney</span>, <span class="hlFld-ContribAuthor ">Ying-Duo  Gao</span>, <span class="hlFld-ContribAuthor ">Thierry O.  Fischmann</span>, <span class="hlFld-ContribAuthor ">Jeremy  Presland</span>, <span class="hlFld-ContribAuthor ">My  Mansueto</span>, <span class="hlFld-ContribAuthor ">Zangwei  Xu</span>, <span class="hlFld-ContribAuthor ">Erica  Leccese</span>, <span class="hlFld-ContribAuthor ">Ian  Knemeyer</span>, <span class="hlFld-ContribAuthor ">Charles G.  Garlisi</span>, <span class="hlFld-ContribAuthor ">Nathan  Bays</span>, <span class="hlFld-ContribAuthor ">Peter  Stivers</span>, <span class="hlFld-ContribAuthor ">Philip E.  Brandish</span>, <span class="hlFld-ContribAuthor ">Alexandra  Hicks</span>, <span class="hlFld-ContribAuthor ">Alan  Cooper</span>, <span class="hlFld-ContribAuthor ">Ronald M.  Kim</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (16)
                                     , 3939-3943. <a href="https://doi.org/10.1016/j.bmcl.2017.03.040" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.03.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.03.040%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B3-morpholino-imidazole%25255B1%25252C5-a%25255Dpyrazine%252BBTK%252Binhibitors%252Bfor%252Brheumatoid%252Barthritis%26aulast%3DBoga%26aufirst%3DSobhana%2BBabu%26date%3D2017%26volume%3D27%26issue%3D16%26spage%3D3939%26epage%3D3943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John W.  Cuozzo</span>, <span class="hlFld-ContribAuthor ">Paolo A.  Centrella</span>, <span class="hlFld-ContribAuthor ">Diana  Gikunju</span>, <span class="hlFld-ContribAuthor ">Sevan  Habeshian</span>, <span class="hlFld-ContribAuthor ">Christopher D.  Hupp</span>, <span class="hlFld-ContribAuthor ">Anthony D.  Keefe</span>, <span class="hlFld-ContribAuthor ">Eric A.  Sigel</span>, <span class="hlFld-ContribAuthor ">Holly H.  Soutter</span>, <span class="hlFld-ContribAuthor ">Heather A.  Thomson</span>, <span class="hlFld-ContribAuthor ">Ying  Zhang</span>, <span class="hlFld-ContribAuthor ">Matthew A.  Clark</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2017,</strong> <em>18 </em>
                                    (9)
                                     , 864-871. <a href="https://doi.org/10.1002/cbic.201600573" title="DOI URL">https://doi.org/10.1002/cbic.201600573</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.201600573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.201600573%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252BBTK%252BInhibitor%252Bwith%252Ba%252BNovel%252BBinding%252BMode%252Bby%252BUsing%252BParallel%252BSelections%252Bwith%252Ba%252BDNA-Encoded%252BChemical%252BLibrary%26aulast%3DCuozzo%26aufirst%3DJohn%2BW.%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D9%26spage%3D864%26epage%3D871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolei  Gao</span>, <span class="hlFld-ContribAuthor ">James  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Deodial  Guiadeen</span>, <span class="hlFld-ContribAuthor ">Arto  Krikorian</span>, <span class="hlFld-ContribAuthor ">Sobhana Babu  Boga</span>, <span class="hlFld-ContribAuthor ">Abdul-Basit  Alhassan</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Younong  Yu</span>, <span class="hlFld-ContribAuthor ">Rajan  Anand</span>, <span class="hlFld-ContribAuthor ">Shilan  Liu</span>, <span class="hlFld-ContribAuthor ">Chundao  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Wu</span>, <span class="hlFld-ContribAuthor ">Jiaqiang  Cai</span>, <span class="hlFld-ContribAuthor ">Alan  Cooper</span>, <span class="hlFld-ContribAuthor ">Hugh  Zhu</span>, <span class="hlFld-ContribAuthor ">Kevin  Maloney</span>, <span class="hlFld-ContribAuthor ">Ying-Duo  Gao</span>, <span class="hlFld-ContribAuthor ">Thierry O.  Fischmann</span>, <span class="hlFld-ContribAuthor ">Jeremy  Presland</span>, <span class="hlFld-ContribAuthor ">My  Mansueto</span>, <span class="hlFld-ContribAuthor ">Zangwei  Xu</span>, <span class="hlFld-ContribAuthor ">Erica  Leccese</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang-Hoover</span>, <span class="hlFld-ContribAuthor ">Ian  Knemeyer</span>, <span class="hlFld-ContribAuthor ">Charles G.  Garlisi</span>, <span class="hlFld-ContribAuthor ">Nathan  Bays</span>, <span class="hlFld-ContribAuthor ">Peter  Stivers</span>, <span class="hlFld-ContribAuthor ">Philip E.  Brandish</span>, <span class="hlFld-ContribAuthor ">Alexandra  Hicks</span>, <span class="hlFld-ContribAuthor ">Ronald  Kim</span>, <span class="hlFld-ContribAuthor ">Joeseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel BTK inhibitors with carboxylic acids. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (6)
                                     , 1471-1477. <a href="https://doi.org/10.1016/j.bmcl.2016.11.079" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.11.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.11.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.11.079%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252BBTK%252Binhibitors%252Bwith%252Bcarboxylic%252Bacids%26aulast%3DGao%26aufirst%3DXiaolei%26date%3D2017%26volume%3D27%26issue%3D6%26spage%3D1471%26epage%3D1477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Lou</span>, <span class="hlFld-ContribAuthor ">Francisco  Lopez</span>, <span class="hlFld-ContribAuthor ">Yongying  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiaochun  Han</span>, <span class="hlFld-ContribAuthor ">Chris  Brotherton</span>, <span class="hlFld-ContribAuthor ">Roland  Billedeau</span>, <span class="hlFld-ContribAuthor ">Steve  Gabriel</span>, <span class="hlFld-ContribAuthor ">Shelly  Gleason</span>, <span class="hlFld-ContribAuthor ">David M.  Goldstein</span>, <span class="hlFld-ContribAuthor ">Ramona  Hilgenkamp</span>, <span class="hlFld-ContribAuthor ">Buelent  Kocer</span>, <span class="hlFld-ContribAuthor ">Lucja  Orzechowski</span>, <span class="hlFld-ContribAuthor ">Jenny  Tan</span>, <span class="hlFld-ContribAuthor ">Peter  Wovkulich</span>, <span class="hlFld-ContribAuthor ">Bo  Wen</span>, <span class="hlFld-ContribAuthor ">David  Fry</span>, <span class="hlFld-ContribAuthor ">Paola  Di Lello</span>, <span class="hlFld-ContribAuthor ">Lucy  Chen</span>, <span class="hlFld-ContribAuthor ">Fang-jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Jennifer  Fretland</span>, <span class="hlFld-ContribAuthor ">Anjali  Nangia</span>, <span class="hlFld-ContribAuthor ">Tian  Yang</span>, <span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>. </span><span class="cited-content_cbyCitation_article-title">Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton’s tyrosine kinase (BTK). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (3)
                                     , 632-635. <a href="https://doi.org/10.1016/j.bmcl.2016.11.092" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.11.092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.11.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.11.092%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMitigation%252Bof%252Breactive%252Bmetabolite%252Bformation%252Bfor%252Ba%252Bseries%252Bof%252B3-amino-2-pyridone%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%26aulast%3DLou%26aufirst%3DYan%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D632%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingying  Zuo</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Inhibitors of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 75-104. <a href="https://doi.org/10.1007/7355_2017_6" title="DOI URL">https://doi.org/10.1007/7355_2017_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_6%26sid%3Dliteratum%253Aachs%26atitle%3DSmall-Molecule%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DZuo%26aufirst%3DYingying%26date%3D2017%26spage%3D75%26epage%3D104%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>, <span class="hlFld-ContribAuthor ">Yan  Lou</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Kinase Inhibitors for Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 76-103. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12399-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12399-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12399-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12399-6%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BKinase%252BInhibitors%252Bfor%252BCancer%26aulast%3DOwens%26aufirst%3DTimothy%2BD.%26date%3D2017%26spage%3D76%26epage%3D103%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Letícia  Santos-Garcia</span>, <span class="hlFld-ContribAuthor ">Letícia C.  Assis</span>, <span class="hlFld-ContribAuthor ">Daniela R.  Silva</span>, <span class="hlFld-ContribAuthor ">Teodorico C.  Ramalho</span>, <span class="hlFld-ContribAuthor ">Elaine F.F.  da Cunha</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR analysis of nicotinamidic compounds and design of potential Bruton’s tyrosine kinase (Btk) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2016,</strong> <em>34 </em>
                                    (7)
                                     , 1421-1440. <a href="https://doi.org/10.1080/07391102.2015.1070750" title="DOI URL">https://doi.org/10.1080/07391102.2015.1070750</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2015.1070750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2015.1070750%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DQSAR%252Banalysis%252Bof%252Bnicotinamidic%252Bcompounds%252Band%252Bdesign%252Bof%252Bpotential%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528Btk%252529%252Binhibitors%26aulast%3DSantos-Garcia%26aufirst%3DLet%25C3%25ADcia%26date%3D2016%26date%3D2016%26volume%3D34%26issue%3D7%26spage%3D1421%26epage%3D1440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rohit  Bavi</span>, <span class="hlFld-ContribAuthor ">Raj  Kumar</span>, <span class="hlFld-ContribAuthor ">Light  Choi</span>, <span class="hlFld-ContribAuthor ">Keun  Woo Lee</span>, . </span><span class="cited-content_cbyCitation_article-title">Exploration of Novel Inhibitors for Bruton’s Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2016,</strong> <em>11 </em>
                                    (1)
                                     , e0147190. <a href="https://doi.org/10.1371/journal.pone.0147190" title="DOI URL">https://doi.org/10.1371/journal.pone.0147190</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0147190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0147190%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DExploration%252Bof%252BNovel%252BInhibitors%252Bfor%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bby%252B3D%252BQSAR%252BModeling%252Band%252BMolecular%252BDynamics%252BSimulation%26aulast%3DBavi%26aufirst%3DRohit%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D1%26spage%3De0147190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adebayo A  Adeniyi</span>, <span class="hlFld-ContribAuthor ">Ramesh  Muthusamy</span>, <span class="hlFld-ContribAuthor ">Mahmoud ES  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">New drug design with covalent modifiers. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2016,</strong> <em>11 </em>
                                    (1)
                                     , 79-90. <a href="https://doi.org/10.1517/17460441.2016.1115478" title="DOI URL">https://doi.org/10.1517/17460441.2016.1115478</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17460441.2016.1115478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17460441.2016.1115478%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DNew%252Bdrug%252Bdesign%252Bwith%252Bcovalent%252Bmodifiers%26aulast%3DAdeniyi%26aufirst%3DAdebayo%2BA%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D1%26spage%3D79%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Xinge  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Qiu  Jin</span>, <span class="hlFld-ContribAuthor ">Gang  Wu</span>, <span class="hlFld-ContribAuthor ">Yazhou  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Tang</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton’s tyrosine kinase (BTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (19)
                                     , 6250-6257. <a href="https://doi.org/10.1016/j.bmc.2015.08.039" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.08.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.08.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.08.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B7-substituted%252B3-%2525284-phenoxyphenyl%252529thieno%25255B3%25252C2-c%25255Dpyridin-4-amines%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%26aulast%3DXin%26aufirst%3DMinhang%26date%3D2015%26volume%3D23%26issue%3D19%26spage%3D6250%26epage%3D6257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinge  Zhao</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yazhou  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Qiu  Jin</span>, <span class="hlFld-ContribAuthor ">Feng  Tang</span>, <span class="hlFld-ContribAuthor ">Gang  Wu</span>, <span class="hlFld-ContribAuthor ">Yong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thieno[3,2- c ]pyridin-4-amines as novel Bruton’s tyrosine kinase (BTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (17)
                                     , 6059-6068. <a href="https://doi.org/10.1016/j.bmc.2015.05.043" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.05.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.05.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.05.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthieno%25255B3%25252C2-%252Bc%252B%25255Dpyridin-4-amines%252Bas%252Bnovel%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%26aulast%3DZhao%26aufirst%3DXinge%26date%3D2015%26volume%3D23%26issue%3D17%26spage%3D6059%26epage%3D6068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinge  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Yazhou  Wang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Qiu  Jin</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Cai</span>, <span class="hlFld-ContribAuthor ">Feng  Tang</span>, <span class="hlFld-ContribAuthor ">Yong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[2,3-b]pyridine derivatives as potent Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (15)
                                     , 4344-4353. <a href="https://doi.org/10.1016/j.bmc.2015.06.023" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPyrrolo%25255B2%25252C3-b%25255Dpyridine%252Bderivatives%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DZhao%26aufirst%3DXinge%26date%3D2015%26volume%3D23%26issue%3D15%26spage%3D4344%26epage%3D4353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J Michael  Bradshaw</span>, <span class="hlFld-ContribAuthor ">Jesse M  McFarland</span>, <span class="hlFld-ContribAuthor ">Ville O  Paavilainen</span>, <span class="hlFld-ContribAuthor ">Angelina  Bisconte</span>, <span class="hlFld-ContribAuthor ">Danny  Tam</span>, <span class="hlFld-ContribAuthor ">Vernon T  Phan</span>, <span class="hlFld-ContribAuthor ">Sergei  Romanov</span>, <span class="hlFld-ContribAuthor ">David  Finkle</span>, <span class="hlFld-ContribAuthor ">Jin  Shu</span>, <span class="hlFld-ContribAuthor ">Vaishali  Patel</span>, <span class="hlFld-ContribAuthor ">Tony  Ton</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Li</span>, <span class="hlFld-ContribAuthor ">David G  Loughhead</span>, <span class="hlFld-ContribAuthor ">Philip A  Nunn</span>, <span class="hlFld-ContribAuthor ">Dane E  Karr</span>, <span class="hlFld-ContribAuthor ">Mary E  Gerritsen</span>, <span class="hlFld-ContribAuthor ">Jens Oliver  Funk</span>, <span class="hlFld-ContribAuthor ">Timothy D  Owens</span>, <span class="hlFld-ContribAuthor ">Erik  Verner</span>, <span class="hlFld-ContribAuthor ">Ken A  Brameld</span>, <span class="hlFld-ContribAuthor ">Ronald J  Hill</span>, <span class="hlFld-ContribAuthor ">David M  Goldstein</span>, <span class="hlFld-ContribAuthor ">Jack  Taunton</span>. </span><span class="cited-content_cbyCitation_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2015,</strong> <em>11 </em>
                                    (7)
                                     , 525-531. <a href="https://doi.org/10.1038/nchembio.1817" title="DOI URL">https://doi.org/10.1038/nchembio.1817</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchembio.1817%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DProlonged%252Band%252Btunable%252Bresidence%252Btime%252Busing%252Breversible%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DBradshaw%26aufirst%3DJ%2BMichael%26date%3D2015%26date%3D2015%26volume%3D11%26issue%3D7%26spage%3D525%26epage%3D531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Turetsky</span>, <span class="hlFld-ContribAuthor ">Eunha  Kim</span>, <span class="hlFld-ContribAuthor ">Rainer H.  Kohler</span>, <span class="hlFld-ContribAuthor ">Miles A.  Miller</span>, <span class="hlFld-ContribAuthor ">Ralph  Weissleder</span>. </span><span class="cited-content_cbyCitation_article-title">Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2015,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep04782" title="DOI URL">https://doi.org/10.1038/srep04782</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep04782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep04782%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DSingle%252Bcell%252Bimaging%252Bof%252BBruton%252527s%252BTyrosine%252BKinase%252Busing%252Ban%252Birreversible%252Binhibitor%26aulast%3DTuretsky%26aufirst%3DAnna%26date%3D2015%26date%3D2014%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wendy B.  Young</span>, <span class="hlFld-ContribAuthor ">James  Barbosa</span>, <span class="hlFld-ContribAuthor ">Peter  Blomgren</span>, <span class="hlFld-ContribAuthor ">Meire C.  Bremer</span>, <span class="hlFld-ContribAuthor ">James J.  Crawford</span>, <span class="hlFld-ContribAuthor ">Donna  Dambach</span>, <span class="hlFld-ContribAuthor ">Steve  Gallion</span>, <span class="hlFld-ContribAuthor ">Sarah G.  Hymowitz</span>, <span class="hlFld-ContribAuthor ">Jeffrey E.  Kropf</span>, <span class="hlFld-ContribAuthor ">Seung H.  Lee</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Joseph W.  Lubach</span>, <span class="hlFld-ContribAuthor ">Jen  Macaluso</span>, <span class="hlFld-ContribAuthor ">Pat  Maciejewski</span>, <span class="hlFld-ContribAuthor ">Brigitte  Maurer</span>, <span class="hlFld-ContribAuthor ">Scott A.  Mitchell</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Julie  Di Paolo</span>, <span class="hlFld-ContribAuthor ">Karin  Reif</span>, <span class="hlFld-ContribAuthor ">Heleen  Scheerens</span>, <span class="hlFld-ContribAuthor ">Aaron  Schmitt</span>, <span class="hlFld-ContribAuthor ">C. Gregory  Sowell</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Wang</span>, <span class="hlFld-ContribAuthor ">Harvey  Wong</span>, <span class="hlFld-ContribAuthor ">Jin-Ming  Xiong</span>, <span class="hlFld-ContribAuthor ">Jianjun  Xu</span>, <span class="hlFld-ContribAuthor ">Zhongdong  Zhao</span>, <span class="hlFld-ContribAuthor ">Kevin S.  Currie</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (6)
                                     , 1333-1337. <a href="https://doi.org/10.1016/j.bmcl.2015.01.032" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.01.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPotent%252Band%252Bselective%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%25253A%252BDiscovery%252Bof%252BGDC-0834%26aulast%3DYoung%26aufirst%3DWendy%2BB.%26date%3D2015%26volume%3D25%26issue%3D6%26spage%3D1333%26epage%3D1337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinge  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Yazhou  Wang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Qiu  Jin</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Cai</span>, <span class="hlFld-ContribAuthor ">Feng  Tang</span>, <span class="hlFld-ContribAuthor ">Yong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel Bruton’s tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (4)
                                     , 891-901. <a href="https://doi.org/10.1016/j.bmc.2014.10.043" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.10.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.10.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.10.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%252Bbearing%252Ba%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bscaffold%26aulast%3DZhao%26aufirst%3DXinge%26date%3D2015%26volume%3D23%26issue%3D4%26spage%3D891%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belen'kii</span>, <span class="hlFld-ContribAuthor ">Yu B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XIII, 2012–2013. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 193-363. <a href="https://doi.org/10.1016/bs.aihch.2015.04.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2015.04.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2015.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2015.04.002%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXIII%25252C%252B2012%2525E2%252580%2525932013%26aulast%3DBelen%2527kii%26aufirst%3DLeonid%2BI.%26date%3D2015%26spage%3D193%26epage%3D363%26pub%3DElsevier%26date%3D2015%26volume%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinge  Zhao</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Yanliang  Ren</span>, <span class="hlFld-ContribAuthor ">Qiu  Jin</span>, <span class="hlFld-ContribAuthor ">Feng  Tang</span>, <span class="hlFld-ContribAuthor ">Hailong  Jiang</span>, <span class="hlFld-ContribAuthor ">Yazhou  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Shifu  Mo</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (2)
                                     , 348-364. <a href="https://doi.org/10.1016/j.bmc.2014.11.006" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.11.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.11.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252B5-phenylpyridin-2%2525281H%252529-one%252Bderivatives%252Bas%252Bpotent%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DZhao%26aufirst%3DXinge%26date%3D2015%26volume%3D23%26issue%3D2%26spage%3D348%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">W  Guo</span>, <span class="hlFld-ContribAuthor ">R  Liu</span>, <span class="hlFld-ContribAuthor ">G  Bhardwaj</span>, <span class="hlFld-ContribAuthor ">J C  Yang</span>, <span class="hlFld-ContribAuthor ">C  Changou</span>, <span class="hlFld-ContribAuthor ">A-H  Ma</span>, <span class="hlFld-ContribAuthor ">A  Mazloom</span>, <span class="hlFld-ContribAuthor ">S  Chintapalli</span>, <span class="hlFld-ContribAuthor ">K  Xiao</span>, <span class="hlFld-ContribAuthor ">W  Xiao</span>, <span class="hlFld-ContribAuthor ">P  Kumaresan</span>, <span class="hlFld-ContribAuthor ">E  Sanchez</span>, <span class="hlFld-ContribAuthor ">C-T  Yeh</span>, <span class="hlFld-ContribAuthor ">C P  Evans</span>, <span class="hlFld-ContribAuthor ">R  Patterson</span>, <span class="hlFld-ContribAuthor ">K S  Lam</span>, <span class="hlFld-ContribAuthor ">H-J  Kung</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2014,</strong> <em>5 </em>
                                    (9)
                                     , e1409-e1409. <a href="https://doi.org/10.1038/cddis.2014.343" title="DOI URL">https://doi.org/10.1038/cddis.2014.343</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/cddis.2014.343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fcddis.2014.343%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DTargeting%252BBtk%25252FEtk%252Bof%252Bprostate%252Bcancer%252Bcells%252Bby%252Ba%252Bnovel%252Bdual%252Binhibitor%26aulast%3DGuo%26aufirst%3DW%26date%3D2014%26date%3D2014%26volume%3D5%26issue%3D9%26spage%3De1409%26epage%3De1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing  Shi</span>, <span class="hlFld-ContribAuthor ">Andrew  Tebben</span>, <span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>, <span class="hlFld-ContribAuthor ">Hedy  Li</span>, <span class="hlFld-ContribAuthor ">Chunjian  Liu</span>, <span class="hlFld-ContribAuthor ">James  Lin</span>, <span class="hlFld-ContribAuthor ">Steve  Spergel</span>, <span class="hlFld-ContribAuthor ">James R.  Burke</span>, <span class="hlFld-ContribAuthor ">Kim W.  McIntyre</span>, <span class="hlFld-ContribAuthor ">Gilbert C.  Olini</span>, <span class="hlFld-ContribAuthor ">Joann  Strnad</span>, <span class="hlFld-ContribAuthor ">Neha  Surti</span>, <span class="hlFld-ContribAuthor ">Jodi K.  Muckelbauer</span>, <span class="hlFld-ContribAuthor ">Chiehying  Chang</span>, <span class="hlFld-ContribAuthor ">Yongmi  An</span>, <span class="hlFld-ContribAuthor ">Lin  Cheng</span>, <span class="hlFld-ContribAuthor ">Qian  Ruan</span>, <span class="hlFld-ContribAuthor ">Katerina  Leftheris</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">Joseph  Tino</span>, <span class="hlFld-ContribAuthor ">George V.  De Lucca</span>. </span><span class="cited-content_cbyCitation_article-title">Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (9)
                                     , 2206-2211. <a href="https://doi.org/10.1016/j.bmcl.2014.02.075" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.02.075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.02.075%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPurine%252Bderivatives%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%252Bfor%252Bautoimmune%252Bdiseases%26aulast%3DShi%26aufirst%3DQing%26date%3D2014%26volume%3D24%26issue%3D9%26spage%3D2206%26epage%3D2211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Xing</span>, <span class="hlFld-ContribAuthor ">Adrian  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Bruton's TK inhibitors: structural insights and evolution of clinical candidates. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2014,</strong> <em>6 </em>
                                    (6)
                                     , 675-695. <a href="https://doi.org/10.4155/fmc.14.24" title="DOI URL">https://doi.org/10.4155/fmc.14.24</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.14.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.14.24%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DBruton%252527s%252BTK%252Binhibitors%25253A%252Bstructural%252Binsights%252Band%252Bevolution%252Bof%252Bclinical%252Bcandidates%26aulast%3DXing%26aufirst%3DLi%26date%3D2014%26volume%3D6%26issue%3D6%26spage%3D675%26epage%3D695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Mah</span>, <span class="hlFld-ContribAuthor ">Jason R.  Thomas</span>, <span class="hlFld-ContribAuthor ">Cynthia M.  Shafer</span>. </span><span class="cited-content_cbyCitation_article-title">Drug discovery considerations in the development of covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (1)
                                     , 33-39. <a href="https://doi.org/10.1016/j.bmcl.2013.10.003" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDrug%252Bdiscovery%252Bconsiderations%252Bin%252Bthe%252Bdevelopment%252Bof%252Bcovalent%252Binhibitors%26aulast%3DMah%26aufirst%3DRobert%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D33%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dramane  Lainé</span>, <span class="hlFld-ContribAuthor ">Matthew  Lucas</span>, <span class="hlFld-ContribAuthor ">Francisco  Lopez-Tapia</span>, <span class="hlFld-ContribAuthor ">Stephen  Lynch</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Potential of Kinases in Asthma. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 255-288. <a href="https://doi.org/10.1002/9783527677252.ch11" title="DOI URL">https://doi.org/10.1002/9783527677252.ch11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527677252.ch11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527677252.ch11%26sid%3Dliteratum%253Aachs%26atitle%3DTherapeutic%252BPotential%252Bof%252BKinases%252Bin%252BAsthma%26aulast%3DLain%25C3%25A9%26aufirst%3DDramane%26date%3D2013%26date%3D2013%26spage%3D255%26epage%3D288%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DMedicinal%252BChemistry%252BApproaches%252Bto%252BPersonalized%252BMedicine%26aulast%3DLackey%26aufirst%3DKaren%26date%3D2013%26volume%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan  Hsu</span>, <span class="hlFld-ContribAuthor ">Jun  Zhang</span>, <span class="hlFld-ContribAuthor ">Chris  Kitson</span>, <span class="hlFld-ContribAuthor ">Seng-Lai  Tan</span>, <span class="hlFld-ContribAuthor ">Satwant  Narula</span>, <span class="hlFld-ContribAuthor ">Julie A.  DeMartino</span>, <span class="hlFld-ContribAuthor ">Cheng  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Pharmacodynamic Assay Based on PLCγ2 Phosphorylation for Quantifying Spleen Tyrosine Kinase (SYK)–Bruton’s Tyrosine Kinase (BTK) Signaling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Screening</span><span> <strong>2013,</strong> <em>18 </em>
                                    (8)
                                     , 890-898. <a href="https://doi.org/10.1177/1087057113489881" title="DOI URL">https://doi.org/10.1177/1087057113489881</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1087057113489881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1087057113489881%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Screening%26atitle%3DDevelopment%252Bof%252Ba%252BPharmacodynamic%252BAssay%252BBased%252Bon%252BPLC%2525CE%2525B32%252BPhosphorylation%252Bfor%252BQuantifying%252BSpleen%252BTyrosine%252BKinase%252B%252528SYK%252529%2525E2%252580%252593Bruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BSignaling%26aulast%3DHsu%26aufirst%3DJonathan%26date%3D2013%26date%3D2013%26volume%3D18%26issue%3D8%26spage%3D890%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seng-Lai  Tan</span>, <span class="hlFld-ContribAuthor ">Cheng  Liao</span>, <span class="hlFld-ContribAuthor ">Matthew C.  Lucas</span>, <span class="hlFld-ContribAuthor ">Christopher  Stevenson</span>, <span class="hlFld-ContribAuthor ">Julie A.  DeMartino</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2013,</strong> <em>138 </em>
                                    (2)
                                     , 294-309. <a href="https://doi.org/10.1016/j.pharmthera.2013.02.001" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2013.02.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2013.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2013.02.001%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTargeting%252Bthe%252BSYK%2525E2%252580%252593BTK%252Baxis%252Bfor%252Bthe%252Btreatment%252Bof%252Bimmunological%252Band%252Bhematological%252Bdisorders%26aulast%3DTan%26aufirst%3DSeng-Lai%26date%3D2013%26volume%3D138%26issue%3D2%26spage%3D294%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, <span class="hlFld-ContribAuthor ">Roberta R.  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2012,</strong> <em>84 </em>
                                    (11)
                                     , 1388-1399. <a href="https://doi.org/10.1016/j.bcp.2012.07.031" title="DOI URL">https://doi.org/10.1016/j.bcp.2012.07.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2012.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2012.07.031%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DClinical%252Bperspectives%252Bfor%252Birreversible%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252Bcancer%26aulast%3DCarmi%26aufirst%3DCaterina%26date%3D2012%26volume%3D84%26issue%3D11%26spage%3D1388%26epage%3D1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Analysis of corresponding amino acid residues in kinome at the positions aligned with T474 (gatekeeper) and C481 of BTK. <i>X</i>-axis refers to the identity of the amino acid, and <i>Y</i>-axis is the corresponding total count in the human kinome. For BTK, C481 ranks as the most uncommon residue whereas T474 ranks as the 17th.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. BTK inhibitors <b>10</b>, <b>11</b>, and <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Amino acids in the ATP binding pocket of BTK targeted for the design of selective inhibitors. Shown in yellow is a ribbon representation of the protein component of the BTK crystal structure bound with <b>9</b>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Side chains of amino acids targeted for selectivity design are shown in ball-and-stick representation: the gatekeeper residue T474 (cyan), C481 (green), and the specificity pocket (pink). For orientation, an ATP molecule (carbon atoms in gray) has been modeled into the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structures of BTK-inhibitor complexes: (A) compound <b>2</b> at 1.94 Å resolution; (B) compound <b>9</b> at 1.8 Å resolution. Inhibitors are displayed in green and selected amino acids in yellow. Black dashes indicate hydrogen bonds. A structurally important water molecule is drawn in cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative BTK inhibitors from Pharmacyclics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative BTK inhibitors from Avila.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representative BTK inhibitors reported by Locus Pharmaceuticals and Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. CGI/Genentech’s BTK inhibitors <b>25</b> and <b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Representative BTK inhibitors reported by Roche.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Representative BTK inhibitors reported by BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/medium/jm-2012-00035p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Representative BTK inhibitors reported by Biogen Idec.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm300035p/production/images/large/jm-2012-00035p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300035p&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i29">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 70 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Vetrie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorechovsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinter, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarstrom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinnon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobrow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentley, D. R.</span><span> </span><span class="NLM_article-title">The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">226</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=1993&pages=226-233&author=D.+Vetrieauthor=I.+Vorechovskyauthor=P.+Siderasauthor=J.+Hollandauthor=A.+Daviesauthor=F.+Flinterauthor=L.+Hammarstromauthor=C.+Kinnonauthor=R.+Levinskyauthor=M.+Bobrowauthor=C.+I.+E.+Smithauthor=D.+R.+Bentley&title=The+gene+involved+in+X-linked+agammaglobulinaemia+is+a+member+of+the+src+family+of+protein-tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVetrie%26aufirst%3DD.%26aulast%3DVorechovsky%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DFlinter%26aufirst%3DF.%26aulast%3DHammarstrom%26aufirst%3DL.%26aulast%3DKinnon%26aufirst%3DC.%26aulast%3DLevinsky%26aufirst%3DR.%26aulast%3DBobrow%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DBentley%26aufirst%3DD.%2BR.%26atitle%3DThe%2520gene%2520involved%2520in%2520X-linked%2520agammaglobulinaemia%2520is%2520a%2520member%2520of%2520the%2520src%2520family%2520of%2520protein-tyrosine%2520kinases%26jtitle%3DNature%26date%3D1993%26volume%3D361%26spage%3D226%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Smith, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humire-Greiff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniar, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjellen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarstrom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetrie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorechovsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideras, P.</span><span> </span><span class="NLM_article-title">Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=8283037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1994&pages=557-565&author=C.+I.+Smithauthor=B.+Baskinauthor=P.+Humire-Greiffauthor=J.+N.+Zhouauthor=P.+G.+Olssonauthor=H.+S.+Maniarauthor=P.+Kjellenauthor=J.+D.+Lambrisauthor=B.+Christenssonauthor=L.+Hammarstromauthor=D.+Bentleyauthor=D.+Vetrieauthor=K.+B.+Islamauthor=I.+Vorechovskyauthor=P.+Sideras&title=Expression+of+Bruton%E2%80%99s+agammaglobulinemia+tyrosine+kinase+gene%2C+BTK%2C+is+selectively+down-regulated+in+T+lymphocytes+and+plasma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span></div><div class="casAuthors">Smith, C. I. Edvard; Baskin, Berivan; Humire-Greiff, Patricia; Zhou, Jian Nian; Olsson, Per G.; Maniar, Hina S.; Kjellen, Peter; Lambris, John D.; Christensson, Birger; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">557-65</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">The gene mutated in the human disease, X-linked agammaglobulinemia (XLA), is related to the Src gene family of cytoplasmic protein-tyrosine kinases and is designated Btk (Bruton's agammaglobulinemia tyrosine kinase; formerly Atk/Bpk; the human gene is denoted BTK, using capital letters according to the kinase nomenclature).  The authors have recently reported that this gene is expressed in B lymphocytes and that the specific mRNA was undetectable in T cells using Northern blotting.  Further analyses of different sources of B and T lymphocytes confirmed this pattern.  However, BTK transcripts were undetectable in four plasmacytoma lines.  Moreover, as virtually normal amts. of BTK transcripts were found in PBMC from two patients carrying a point mutation in BTK, despite low B cell nos., the authors anticipated that the gene would also be expressed in cells of other lineages.  The erythroleukemia cell line K-562, the promyelocytic line HL-60 and the histiocytic lymphoma line U-937 were found to have BTK mRNA levels comparable to B cells.  BTK mRNA was also detected in monocytes from healthy donors as well as in the human immature basophilic cell line KU812, in the human mast cell leukemia cell line HMC-1 and in the CD34 expressing myeloblast KG-1.  A similar expression pattern was obtained when BTK protein was analyzed by immunopptn. and Western blotting.  Using a polymerase chain reaction-based anal., a small amt. (less than 1% of the level in B cells) of BTK mRNA was identified in T lymphocytes.  The authors' findings are compatible with a general expression of the BTK gene in hematopoietic cells, except in T lymphocytes and plasma cells, in which the transcript level is selectively down-regulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKw_P8osJHjLVg90H21EOLACvtfcHk0liuTdI7EIxAGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D&md5=c18d78dc39ed08bd0c1fb784cbf549a1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHumire-Greiff%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%2BN.%26aulast%3DOlsson%26aufirst%3DP.%2BG.%26aulast%3DManiar%26aufirst%3DH.%2BS.%26aulast%3DKjellen%26aufirst%3DP.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DHammarstrom%26aufirst%3DL.%26aulast%3DBentley%26aufirst%3DD.%26aulast%3DVetrie%26aufirst%3DD.%26aulast%3DIslam%26aufirst%3DK.%2BB.%26aulast%3DVorechovsky%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26atitle%3DExpression%2520of%2520Bruton%25E2%2580%2599s%2520agammaglobulinemia%2520tyrosine%2520kinase%2520gene%252C%2520BTK%252C%2520is%2520selectively%2520down-regulated%2520in%2520T%2520lymphocytes%2520and%2520plasma%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D1994%26volume%3D152%26spage%3D557%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Conley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbs, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigoriadou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coustan-Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campana, D.</span><span> </span><span class="NLM_article-title">Primary B cell immunodeficiencies: comparisons and contrasts</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1146%2Fannurev.immunol.021908.132649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19302039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=199-227&author=M.+E.+Conleyauthor=A.+K.+Dobbsauthor=D.+M.+Farmerauthor=S.+Kilicauthor=K.+Parisauthor=S.+Grigoriadouauthor=E.+Coustan-Smithauthor=V.+Howardauthor=D.+Campana&title=Primary+B+cell+immunodeficiencies%3A+comparisons+and+contrasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Primary B cell immunodeficiencies: comparisons and contrasts</span></div><div class="casAuthors">Conley, Mary Ellen; Dobbs, A. Kerry; Farmer, Dana M.; Kilic, Sebnem; Paris, Kenneth; Grigoriadou, Sofia; Coustan-Smith, Elaine; Howard, Vanessa; Campana, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">199-227</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Sophisticated genetic tools have made possible the identification of the genes responsible for most well-described immunodeficiencies in the past 15 years.  Mutations in Btk, components of the pre-B cell and B cell receptor (λ5, Igα, Igβ), or the scaffold protein BLNK account for approx. 90% of patients with defects in early B cell development.  Hyper-IgM syndromes result from mutations in CD40 ligand, CD40, AID, or UNG in 70-80% of affected patients.  Rare defects in ICOS or CD19 can result in a clin. picture that is consistent with common variable immunodeficiency, and as many as 10% of patients with this disorder have heterozygous amino acid substitutions in TACI.  For all these disorders, there is considerable clin. heterogeneity in patients with the same mutation.  Identifying the genetic and environmental factors that influence the clin. phenotype may enhance patient care and the understanding of normal B cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_hgfd2bSrJ7Vg90H21EOLACvtfcHk0liupjm075-SCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D&md5=83216a7a297af38c2efdf9d3e79a1213</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132649%26sid%3Dliteratum%253Aachs%26aulast%3DConley%26aufirst%3DM.%2BE.%26aulast%3DDobbs%26aufirst%3DA.%2BK.%26aulast%3DFarmer%26aufirst%3DD.%2BM.%26aulast%3DKilic%26aufirst%3DS.%26aulast%3DParis%26aufirst%3DK.%26aulast%3DGrigoriadou%26aufirst%3DS.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DHoward%26aufirst%3DV.%26aulast%3DCampana%26aufirst%3DD.%26atitle%3DPrimary%2520B%2520cell%2520immunodeficiencies%253A%2520comparisons%2520and%2520contrasts%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D199%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Gürcan, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keskin, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J. N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitzberg, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shekhani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. R.</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2Fj.intimp.2008.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19000786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FmtF2ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=G%C3%BCrcan%2C+H.+M.%3B+Keskin%2C+D.+B.%3B+Stern%2C+J.+N.+H.%3B+Nitzberg%2C+M.+A.%3B+Shekhani%2C+H.%3B+Ahmed%2C+A.+R.Int.+Immunopharmacol.+2009%2C+9%2C+10%E2%80%9325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the current use of rituximab in autoimmune diseases</span></div><div class="casAuthors">Gurcan Hakan M; Keskin Derin B; Stern Joel N H; Nitzberg Matthew A; Shekhani Haris; Ahmed A Razzaque</div><div class="citationInfo"><span class="NLM_cas:title">International immunopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-25</span>
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    </div><div class="casAbstract">Rituximab is a human/murine chimeric monoclonal antibody primarily used for treating non-Hodgkin's B-cell lymphoma.  Recently it has also been used in the treatment of several autoimmune diseases.  A literature review was conducted to determine the efficacy of rituximab in the treatment of some of these autoimmune diseases.  Multiple mechanisms proposed for the rituximab mediated B cell depletion are also discussed.  The efficacy of rituximab is well-established and it is FDA approved for treatment of Rheumatoid arthritis.  In this review, data on the use of rituximab is presented from 92 studies involving 1197 patients with the following diseases: systemic lupus erythematosus, idiopathic thrombocytopenic purpura, anti-neutrophil cytoplasmic antibody associated vasculitis, Grave's disease, autoimmune hemolytic anemia, pemphigus vulgaris, hemophilia A, cold agglutinin disease, Sjogren's syndrome, graft vs. host disease, thrombotic thrombocytopenic purpura, cryoglobulinemia, IgM mediated neuropathy, multiple sclerosis, neuromyelitis optica, idiopathic membranous nephropathy, dermatomyositis, and opsoclonus myoclonus.  The efficacy varies among different autoimmune diseases.  The cumulative data would suggest that in the vast majority of studies in this review, RTX has a beneficial role in their treatment.  While rituximab is very effective in the depletion of B cells, current research suggests it may also influence other cells of the immune system by re-establishing immune homeostasis and tolerance.  The safety profile of RTX reveals that most reactions are infusion related.  In patients with autoimmune diseases the incidence of serious and severe side effects is low.  Systemic infection still remains a major concern and may result in death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSN4idF-uziT9XdcedVHT5tfW6udTcc2ebNJbqMSSRvvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FmtF2ksg%253D%253D&md5=5dd07b14f6c46a71b64cad7afe9dfc04</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2008.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2008.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCrcan%26aufirst%3DH.%2BM.%26aulast%3DKeskin%26aufirst%3DD.%2BB.%26aulast%3DStern%26aufirst%3DJ.%2BN.%2BH.%26aulast%3DNitzberg%26aufirst%3DM.%2BA.%26aulast%3DShekhani%26aufirst%3DH.%26aulast%3DAhmed%26aufirst%3DA.%2BR.%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2009%26volume%3D9%26spage%3D10%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesser, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeland, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braziel, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubbs, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">463</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+Yangauthor=W.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+active+B-cell-receptor+signalling+in+diffuse+large+B-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520active%2520B-cell-receptor%2520signalling%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backesjo, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faryal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aints, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglof, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.+M.+Backesjoauthor=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Berglofauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0lj9qwVGWPU8lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBackesjo%26aufirst%3DC.%2BM.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBerglof%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Pan, Z.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase as a drug discovery target</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1358%2Fdnp.2008.21.7.1255308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19259548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOgurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=357-362&author=Z.+Pan&title=Bruton%E2%80%99s+tyrosine+kinase+as+a+drug+discovery+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase as a drug discovery target</span></div><div class="casAuthors">Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (Btk) is an important mediator in multiple signal transduction pathways.  Fifteen years of research have revealed a complex role for Btk in hematopoietic cells.  These studies suggest that Btk may be a promising target for therapeutic intervention for several complicated diseases.  Inhibitors targeting the Btk kinase domain have been developed and show clear beneficial effects in animal models of rheumatoid arthritis, lymphoma and other diseases.  Here, an overview of these studies is presented with an emphasis on results stemming from medicinal chem. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Pn8DtrLdQ7Vg90H21EOLACvtfcHk0lj9qwVGWPU8lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOgurnP&md5=dbb3e077ce56474a93b83c3be3783334</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2008.21.7.1255308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2008.21.7.1255308%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520as%2520a%2520drug%2520discovery%2520target%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2008%26volume%3D21%26spage%3D357%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beasley, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appell, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span> </span><span class="NLM_article-title">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">903</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1517%2F14728222.12.7.883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=18554156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=883-903&author=L.+L.+Rokoszauthor=J.+R.+Beasleyauthor=C.+D.+Carrollauthor=T.+Linauthor=J.+Zhaoauthor=K.+C.+Appellauthor=M.+L.+Webb&title=Kinase+inhibitors+as+drugs+for+chronic+inflammatory+and+immunological+diseases%3A+progress+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span></div><div class="casAuthors">Rokosz, Laura L.; Beasley, James R.; Carroll, Carolyn DiIanni; Lin, Tsung; Zhao, Jiuqiao; Appell, Kenneth C.; Webb, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  At the time of writing, there are seven marketed kinase inhibitor drugs.  The first kinase inhibitor, imatinib mesilate (Gleevec, Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases.  The most recent kinase inhibitor to come to market, disatinib (Sprycel, Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase.  To date, kinase inhibitor drugs are approved for oncol. and demonstrate that it is possible to develop compds. with relative selectivity for the target kinase against the broader kinome.  However, the use of kinase inhibitors in chronic inflammatory and immunol. diseases may require greater selectivity for the target kinase.  This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq458NGQKTbcbVg90H21EOLACvtfcHk0ljX2AO1-4Y26w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D&md5=6db3fdcc34b3ec97394c9dc6cdca8b99</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.7.883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.7.883%26sid%3Dliteratum%253Aachs%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DBeasley%26aufirst%3DJ.%2BR.%26aulast%3DCarroll%26aufirst%3DC.%2BD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DKinase%2520inhibitors%2520as%2520drugs%2520for%2520chronic%2520inflammatory%2520and%2520immunological%2520diseases%253A%2520progress%2520and%2520challenges%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26spage%3D883%26epage%3D903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Uckun, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbles, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassilev, A. O.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase as a new therapeutic target</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">632</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=624-632&author=F.+M.+Uckunauthor=H.+E.+Tibblesauthor=A.+O.+Vassilev&title=Bruton%E2%80%99s+tyrosine+kinase+as+a+new+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUckun%26aufirst%3DF.%2BM.%26aulast%3DTibbles%26aufirst%3DH.%2BE.%26aulast%3DVassilev%26aufirst%3DA.%2BO.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520as%2520a%2520new%2520therapeutic%2520target%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D624%26epage%3D632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0ljX2AO1-4Y26w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Thaimattam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miglani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, J.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors: structural insights into selectivity</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2751</span><span class="NLM_x">–</span> <span class="NLM_lpage">2765</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.2174%2F138161207781757042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=17897021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGmt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2751-2765&author=R.+Thaimattamauthor=R.+Banerjeeauthor=R.+Miglaniauthor=J.+Iqbal&title=Protein+kinase+inhibitors%3A+structural+insights+into+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors: structural insights into selectivity</span></div><div class="casAuthors">Thaimattam, Ram; Banerjee, Rahul; Miglani, Rajni; Iqbal, Javed</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2751-2765</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in many diseases like cancer, inflammation, cardiovascular disease, and diabetes.  They have become attractive target classes for drug development, making kinase inhibitors as important class of therapeutics.  The success of small-mol. ATP-competitive kinase inhibitors such as Gleevec, Iressa, and Tarceva has attracted much attention in the recent past.  Kinases make use of ATP for phosphorylation of a specific residue(s) on their protein substrates.  More than 400 x-ray structures of about 70 different kinases are publicly available.  These structures provide insights into selectivity and mechanisms of inhibition.  However, prediction of binding specificity of kinase inhibitors based on structural information alone appears to be insufficient.  Here, we will review these observations to gain insights into the rules that govern protein kinase inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBCSBUk5vhbVg90H21EOLACvtfcHk0ljr-LAjhDoCyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGmt7jN&md5=b4bffab06eddc7d04f7b0f5a4ad3fad4</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.2174%2F138161207781757042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207781757042%26sid%3Dliteratum%253Aachs%26aulast%3DThaimattam%26aufirst%3DR.%26aulast%3DBanerjee%26aufirst%3DR.%26aulast%3DMiglani%26aufirst%3DR.%26aulast%3DIqbal%26aufirst%3DJ.%26atitle%3DProtein%2520kinase%2520inhibitors%253A%2520structural%2520insights%2520into%2520selectivity%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D2751%26epage%3D2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0ljr-LAjhDoCyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lhevvuKofdKvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluge, A. F.</span><span> </span><span class="NLM_article-title">Targeted covalent drugs of the kinase family</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2Fj.cbpa.2010.06.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20609616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=475-480&author=J.+Singhauthor=R.+C.+Petterauthor=A.+F.+Kluge&title=Targeted+covalent+drugs+of+the+kinase+family"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent drugs of the kinase family</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Kluge, Arthur F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-480</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the past decade tremendous progress has been made toward a new class of therapeutics termed 'targeted covalent drugs', in which structure-based approaches are employed to create small mols. that inactivate their protein target through targeted covalent attachment to a specific cysteine.  In the kinase field, this approach is demonstrating promise in overcoming the potency, selectivity, and efficacy challenges currently faced by reversible kinase inhibitors, with several advancing into late stage clin. testing.  This design paradigm has been successfully applied to making drug candidates for epidermal growth factor receptor (EGFR), Her2, and Bruton's tyrosine kinase (Btk).  Here we review recent pre-clin. and clin. advances with targeted covalent kinase inhibitors, and the potential for broader application of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQb40Eok-vbVg90H21EOLACvtfcHk0lhevvuKofdKvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D&md5=ee3b8b9e0c6ec317f975a426cf08428f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.168%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DTargeted%2520covalent%2520drugs%2520of%2520the%2520kinase%2520family%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D475%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Mao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uckun, F. M.</span><span> </span><span class="NLM_article-title">Crystal structure of Bruton’s tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">41435</span><span class="NLM_x">–</span> <span class="NLM_lpage">41443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=41435-41443&author=C.+Maoauthor=M.+Zhouauthor=F.+M.+Uckun&title=Crystal+structure+of+Bruton%E2%80%99s+tyrosine+kinase+domain+suggests+a+novel+pathway+for+activation+and+provides+insights+into+the+molecular+basis+of+X-linked+agammaglobulinemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DUckun%26aufirst%3DF.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520domain%2520suggests%2520a%2520novel%2520pathway%2520for%2520activation%2520and%2520provides%2520insights%2520into%2520the%2520molecular%2520basis%2520of%2520X-linked%2520agammaglobulinemia%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D41435%26epage%3D41443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Marcotte, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arduini, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hession, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miatkowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildes, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertsching, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanowski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvian, L. F.</span><span> </span><span class="NLM_article-title">Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&author=D.+J.+Marcotteauthor=Y.+T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+human+Bruton%E2%80%99s+tyrosine+kinase+in+active+and+inactive+conformations+suggest+a+mechanism+of+activation+for+TEC+family+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0liARHSv6UkLHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520human%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520active%2520and%2520inactive%2520conformations%2520suggest%2520a%2520mechanism%2520of%2520activation%2520for%2520TEC%2520family%2520kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span> </span><span class="NLM_article-title">Insights into the conformational flexibility of Bruton’s tyrosine kinase from multiple ligand complex structures</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1002%2Fpro.575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=21280133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=428-436&author=A.+Kuglstatterauthor=A.+Wongauthor=S.+Tsingauthor=S.+W.+Leeauthor=Y.+Louauthor=A.+G.+Villasenorauthor=J.+M.+Bradshawauthor=D.+Shawauthor=J.+W.+Barnettauthor=M.+F.+Browner&title=Insights+into+the+conformational+flexibility+of+Bruton%E2%80%99s+tyrosine+kinase+from+multiple+ligand+complex+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures</span></div><div class="casAuthors">Kuglstatter, Andreas; Wong, April; Tsing, Stan; Lee, Simon W.; Lou, Yan; Villasenor, Armando G.; Bradshaw, J. Michael; Shaw, David; Barnett, Jim W.; Browner, Michelle F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases.  We have detd. the X-ray crystal structures of BTK kinase domain in complex with six inhibitors from distinct chem. classes.  Five different BTK protein conformations are stabilized by the bound inhibitors, providing insights into the structural flexibility of the Gly-rich loop, helix C, the DFG sequence, and activation loop.  The conformational changes occur independent of activation loop phosphorylation and do not correlate with the structurally unchanged WEI motif in the Src homol. 2-kinase domain linker.  Two novel activation loop conformations and an atypical DFG conformation are obsd. representing unique inactive states of BTK.  Two regions within the activation loop are shown to structurally transform between 310- and α-helixes, one of which collapses into the adenosine-5'-triphosphate binding pocket.  The first crystal structure of a Tec kinase family member in the pharmacol. important DFG-out conformation and bound to a type II kinase inhibitor is described.  The different protein conformations obsd. provide insights into the structural flexibility of BTK, the mol. basis of its regulation, and the structure-based design of specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbjgkMYHniALVg90H21EOLACvtfcHk0liARHSv6UkLHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFWnuro%253D&md5=4e46f4d05ac3d7b90f1a3e89c0275516</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fpro.575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.575%26sid%3Dliteratum%253Aachs%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DTsing%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26atitle%3DInsights%2520into%2520the%2520conformational%2520flexibility%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520from%2520multiple%2520ligand%2520complex%2520structures%26jtitle%3DProtein%2520Sci.%26date%3D2011%26volume%3D20%26spage%3D428%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Di Paolo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barck, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carano, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForge, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrando, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staker, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lgDEtmEqiVv5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span> </span><span class="NLM_article-title">Structural biology contributions to tyrosine kinase drug discovery</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2Fj.ceb.2009.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=19208462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVCksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=280-287&author=S.+W.+Cowan-Jacobauthor=H.+Mobitzauthor=D.+Fabbro&title=Structural+biology+contributions+to+tyrosine+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structural biology contributions to tyrosine kinase drug discovery</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Moebitz, Henrik; Fabbro, Doriano</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-287</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Successful kinase inhibitor drug discovery relies heavily on the structural knowledge of the interaction of inhibitors with the target.  Structural biol. of kinases and in particular of tyrosine kinases has given detailed insights into the intrinsic flexibility of the catalytic domain and has provided a rational basis for obtaining selective inhibitors.  Important progress was made recently, both in academia and in the pharmaceutical industry, with respect to solving structures of inactive, multidomain or protein-protein complexes of kinases, which helps our understanding of the dynamics of regulation of kinase activity.  This leads to a better understanding of how mutations lead to activation of kinases and resistance, in addn. to providing opportunities for novel modes of targeting kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo09-Hgo00-bLVg90H21EOLACvtfcHk0liAgiTVSrT2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVCksr8%253D&md5=125e7217308850813cde9dce356bf1a4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMobitz%26aufirst%3DH.%26aulast%3DFabbro%26aufirst%3DD.%26atitle%3DStructural%2520biology%2520contributions%2520to%2520tyrosine%2520kinase%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D280%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0liAgiTVSrT2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M. J.</span><span> </span><span class="NLM_article-title">Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2345</span><span class="NLM_x">–</span> <span class="NLM_lpage">2353</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9012906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2345-2353&author=D.+M.+Goldsteinauthor=A.+Kuglstatterauthor=Y.+Louauthor=M.+J.+Soth&title=Selective+p38alpha+inhibitors+clinically+evaluated+for+the+treatment+of+chronic+inflammatory+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm9012906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9012906%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DSoth%26aufirst%3DM.%2BJ.%26atitle%3DSelective%2520p38alpha%2520inhibitors%2520clinically%2520evaluated%2520for%2520the%2520treatment%2520of%2520chronic%2520inflammatory%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2345%26epage%3D2353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudbeck, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hupke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uckun, F. M.</span><span> </span><span class="NLM_article-title">Rational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-<i>N</i>-(2,5-dibromophenyl)propenamide]</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">9587</span><span class="NLM_x">–</span> <span class="NLM_lpage">9599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=9587-9599&author=S.+Mahajanauthor=S.+Ghoshauthor=E.+A.+Sudbeckauthor=Y.+Zhengauthor=S.+Downsauthor=M.+Hupkeauthor=F.+M.+Uckun&title=Rational+design+and+synthesis+of+a+novel+anti-leukemic+agent+targeting+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%2C+LFM-A13+%5Balpha-cyano-beta-hydroxy-beta-methyl-N-%282%2C5-dibromophenyl%29propenamide%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DSudbeck%26aufirst%3DE.%2BA.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DDowns%26aufirst%3DS.%26aulast%3DHupke%26aufirst%3DM.%26aulast%3DUckun%26aufirst%3DF.%2BM.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%2520a%2520novel%2520anti-leukemic%2520agent%2520targeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%252C%2520LFM-A13%2520%255Balpha-cyano-beta-hydroxy-beta-methyl-N-%25282%252C5-dibromophenyl%2529propenamide%255D%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D9587%26epage%3D9599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0liuIoaTrU6uvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S. C.</span><span> </span><span class="NLM_article-title">Crystal structures of c-Src reveal features of its autoinhibitory mechanism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1016%2FS1097-2765%2800%2980356-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=10360179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADyaK1MXjslCqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=629-638&author=W.+Xuauthor=A.+Doshiauthor=M.+Leiauthor=M.+J.+Eckauthor=S.+C.+Harrison&title=Crystal+structures+of+c-Src+reveal+features+of+its+autoinhibitory+mechanism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of c-Src reveal features of its autoinhibitory mechanism</span></div><div class="casAuthors">Xu, Wenqing; Doshi, Amish; Lei, Ming; Eck, Michael J.; Harrison, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-638</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Src family kinases are maintained in an assembled, inactive conformation by intramol. interactions of their SH2 and SH3 domains.  Full catalytic activity requires release of these restraints as well as phosphorylation of Tyr-416 in the activation loop.  In previous structures of inactive Src kinases, Tyr-416 and flanking residues are disordered.  We report here four addnl. c-Src structures in which this segment adopts an ordered but inhibitory conformation.  The ordered activation loop forms an α helix that stabilizes the inactive conformation of the kinase domain, blocks the peptide substrate-binding site, and prevents Tyr-416 phosphorylation.  Disassembly of the regulatory domains, induced by SH2 or SH3 ligands, or by dephosphorylation of Tyr-527, could lead to exposure and phosphorylation of Tyr-416.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCsIh6d9RHa7Vg90H21EOLACvtfcHk0li7FopTJeKaLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslCqu7o%253D&md5=926f6a6a4097ce667168b5b81d9a1092</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980356-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980356-1%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%26aulast%3DDoshi%26aufirst%3DA.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DHarrison%26aufirst%3DS.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520c-Src%2520reveal%2520features%2520of%2520its%2520autoinhibitory%2520mechanism%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D629%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicheri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pico, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=639-648&author=T.+Schindlerauthor=F.+Sicheriauthor=A.+Picoauthor=A.+Gazitauthor=A.+Levitzkiauthor=J.+Kuriyan&title=Crystal+structure+of+Hck+in+complex+with+a+Src+family-selective+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DPico%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520Hck%2520in%2520complex%2520with%2520a%2520Src%2520family-selective%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D639%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kutach, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belunis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deval, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novak, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span> </span><span class="NLM_article-title">Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1111%2Fj.1747-0285.2010.00993.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20545945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2010&pages=154-163&author=A.+K.+Kutachauthor=A.+G.+Villasenorauthor=D.+Lamauthor=C.+Belunisauthor=C.+Jansonauthor=S.+Lokauthor=L.+N.+Hongauthor=C.+M.+Liuauthor=J.+Devalauthor=T.+J.+Novakauthor=J.+W.+Barnettauthor=W.+Chuauthor=D.+Shawauthor=A.+Kuglstatter&title=Crystal+structures+of+IL-2-inducible+T+cell+kinase+complexed+with+inhibitors%3A+insights+into+rational+drug+design+and+activity+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation</span></div><div class="casAuthors">Kutach, Alan K.; Villasenor, Armando G.; Lam, Diana; Belunis, Charles; Janson, Cheryl; Lok, Stephen; Hong, Li-Na; Liu, Chao-Min; Deval, Jerome; Novak, Thomas J.; Barnett, Jim W.; Chu, Wei; Shaw, David; Kuglstatter, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">IL-2-inducible T cell kinase plays an essential role in T cell receptor signaling and is considered a drug target for the treatment of Th2-mediated inflammatory diseases.  By applying high-throughput protein engineering and crystn., we have detd. the x-ray crystal structures of IL-2-inducible T cell kinase in complex with its selective inhibitor BMS-509744 and the broad-spectrum kinase inhibitors sunitinib and RO5191614.  Sunitinib uniquely stabilizes IL-2-inducible T cell kinase in the helix C-in conformation by inducing side chain conformational changes in the ATP-binding site.  This preference of sunitinib to bind to an active kinase conformation is reflective of its broad-spectrum kinase activity.  BMS-509744 uniquely stabilizes the activation loop in a substrate-blocking inactive conformation, indicating that structural changes described for Src family kinases are also involved in the regulation of IL-2-inducible T cell kinase activity.  The obsd. BMS-509744 binding mode allows rationalization of structure-activity relationships reported for this inhibitor class and facilitates further structure-based drug design.  Sequence-based anal. of this binding mode provides guidance for the rational design of inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXxFkkRUV7B7Vg90H21EOLACvtfcHk0li7FopTJeKaLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleqs7Y%253D&md5=24b9225c52eff5cca4e295dad1c554c3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2010.00993.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2010.00993.x%26sid%3Dliteratum%253Aachs%26aulast%3DKutach%26aufirst%3DA.%2BK.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DLam%26aufirst%3DD.%26aulast%3DBelunis%26aufirst%3DC.%26aulast%3DJanson%26aufirst%3DC.%26aulast%3DLok%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DL.%2BN.%26aulast%3DLiu%26aufirst%3DC.%2BM.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DNovak%26aufirst%3DT.%2BJ.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DKuglstatter%26aufirst%3DA.%26atitle%3DCrystal%2520structures%2520of%2520IL-2-inducible%2520T%2520cell%2520kinase%2520complexed%2520with%2520inhibitors%253A%2520insights%2520into%2520rational%2520drug%2520design%2520and%2520activity%2520regulation%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D76%26spage%3D154%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Chen, W.; Loury, D. J.; Mody, T. D.; Verner, E.; Smyth, M. S.; Luo, W.</span><span> </span><span class="NLM_article-title">Preparation of Pyrazolo-pyrimidine Compounds as Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application WO 2011/046964,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=W.+Chen&author=D.+J.+Loury&author=T.+D.+Mody&author=E.+Verner&author=M.+S.+Smyth&author=W.+Luo&title=Preparation+of+Pyrazolo-pyrimidine+Compounds+as+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26atitle%3DPreparation%2520of%2520Pyrazolo-pyrimidine%2520Compounds%2520as%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Honigberg, L.; Verner, E.; Buggy, J.; Loury, D.; Chen, W.</span><span> </span><span class="NLM_article-title">Preparation of Substituted Pyrazolopyrimidinamines as Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application WO 2010/009342,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=L.+Honigberg&author=E.+Verner&author=J.+Buggy&author=D.+Loury&author=W.+Chen&title=Preparation+of+Substituted+Pyrazolopyrimidinamines+as+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%26atitle%3DPreparation%2520of%2520Substituted%2520Pyrazolopyrimidinamines%2520as%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Honigberg, L.; Verner, E.; Buggy, J. J.; Loury, D.; Chen, W.</span><span> </span><span class="NLM_article-title">Preparation of Substituted Pyrazolopyrimidinamines As Therapeutic Inhibitors of Bruton’s Tyrosine Kinase and Other Kinases</span>. Patent Application WO 2008/121742,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=L.+Honigberg&author=E.+Verner&author=J.+J.+Buggy&author=D.+Loury&author=W.+Chen&title=Preparation+of+Substituted+Pyrazolopyrimidinamines+As+Therapeutic+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase+and+Other+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%26atitle%3DPreparation%2520of%2520Substituted%2520Pyrazolopyrimidinamines%2520As%2520Therapeutic%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520and%2520Other%2520Kinases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Honigberg, L.; Verner, E.; Pan, Z.</span><span> </span><span class="NLM_article-title">Preparation of Substituted Pyrazolopyrimidinamines as Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application US 2008/0108636,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=L.+Honigberg&author=E.+Verner&author=Z.+Pan&title=Preparation+of+Substituted+Pyrazolopyrimidinamines+as+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%26atitle%3DPreparation%2520of%2520Substituted%2520Pyrazolopyrimidinamines%2520as%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Honigberg, L.; Verner, E.; Pan, Z.</span><span> </span><span class="NLM_article-title">Preparation of 1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives as Bruton’s Tyrosine Kinase Inhibitors</span>. Patent Application US 2008/0076921,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=L.+Honigberg&author=E.+Verner&author=Z.+Pan&title=Preparation+of+1H-Pyrazolo%5B3%2C4-d%5Dpyrimidine+Derivatives+as+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%26atitle%3DPreparation%2520of%25201H-Pyrazolo%255B3%252C4-d%255Dpyrimidine%2520Derivatives%2520as%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Pan, Z.; Li, S. J.; Schereens, H.; Honigberg, L.; Verner, E.</span><span> </span><span class="NLM_article-title">Inhibitor-Derived Reporter Molecules for Detection of Bruton’s Tyrosine Kinase and Their Uses</span>. Patent Application WO 2008/054827,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=Z.+Pan&author=S.+J.+Li&author=H.+Schereens&author=L.+Honigberg&author=E.+Verner&title=Inhibitor-Derived+Reporter+Molecules+for+Detection+of+Bruton%E2%80%99s+Tyrosine+Kinase+and+Their+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DInhibitor-Derived%2520Reporter%2520Molecules%2520for%2520Detection%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520and%2520Their%2520Uses%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span>ClinicalTrials.gov. Safety and Efficacy of PCI-32765 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (MCL) (PCYC-1104-CA). <a href="http://clinicaltrials.gov/ct2/show/NCT01236391" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01236391</a> (accessed Aug 25, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Safety+and+Efficacy+of+PCI-32765+in+Subjects+with+Relapsed%2FRefractory+Mantle+Cell+Lymphoma+%28MCL%29+%28PCYC-1104-CA%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01236391+%28accessed+Aug+25%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Byrd, J. C.; Blum, K. A.; Burger, J. A.; Coutre, S. E.; Sharman, J. R.; Furman, R. R.; Flinn, I. W.; Grant, B. W.; Richards, D. A.; Zhao, W.; Heerema, N. A.; Johnson, A. J.; Izumi, R.; Hamdy, A.; O’Brien, S. M.</span><span> </span><span class="NLM_article-title">Activity and Tolerability of the Bruton’s Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Interim Results of a Phase Ib/II Study</span>. Presented at the 2011 ASCO Annual Meeting, Chicago, IL,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Poster 6508.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+C.+Byrd&author=K.+A.+Blum&author=J.+A.+Burger&author=S.+E.+Coutre&author=J.+R.+Sharman&author=R.+R.+Furman&author=I.+W.+Flinn&author=B.+W.+Grant&author=D.+A.+Richards&author=W.+Zhao&author=N.+A.+Heerema&author=A.+J.+Johnson&author=R.+Izumi&author=A.+Hamdy&author=S.+M.+O%E2%80%99Brien&title=Activity+and+Tolerability+of+the+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+Inhibitor+PCI-32765+in+Patients+with+Chronic+Lymphocytic+Leukemia%2FSmall+Lymphocytic+Lymphoma+%28CLL%2FSLL%29%3A+Interim+Results+of+a+Phase+Ib%2FII+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DActivity%2520and%2520Tolerability%2520of%2520the%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520Inhibitor%2520PCI-32765%2520in%2520Patients%2520with%2520Chronic%2520Lymphocytic%2520Leukemia%252FSmall%2520Lymphocytic%2520Lymphoma%2520%2528CLL%252FSLL%2529%253A%2520Interim%2520Results%2520of%2520a%2520Phase%2520Ib%252FII%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Advani, R.; Porte Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.</span><span> </span><span class="NLM_article-title">The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study</span>. Presented at the 11th International Conference on Malignant Lymphoma, ICML, Palazzo dei Congressi, Lugano, Switzerland,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+Advani&author=J.+Porte+Sharman&author=S.+Smith&author=T.+Boyd&author=B.+Grant&author=K.+Kolibaba&author=R.+Furman&author=J.+Buggy&author=D.+Loury&author=E.+Hedrick&author=R.+Izumi&author=A.+Hamdy&author=N.+Fowler&title=The+Btk+Inhibitor+PCI-32765+Is+Highly+Active+and+Well+Tolerated+in+Patients+with+Relapsed%2FRefractory+B+Cell+Malignancies%3A+Final+Results+from+a+Phase+I+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%26atitle%3DThe%2520Btk%2520Inhibitor%2520PCI-32765%2520Is%2520Highly%2520Active%2520and%2520Well%2520Tolerated%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B%2520Cell%2520Malignancies%253A%2520Final%2520Results%2520from%2520a%2520Phase%2520I%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">O’Brien, S.; Burger, J. A.; Coutre, S. E.; Porte Sharman, J.; Furman, R. R.; Flinn, I. W.; Grant, B.; Richards, D.; Heerema, N.; Johnson, A. J.; Izumi, R.; Hamdy, A.; Blum, K. A.; Byrd, J. C.</span><span> </span><span class="NLM_article-title">The Btk Inhibitor PCI-32765 Is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study</span>. Presented at the 11th International Conference on Malignant Lymphoma, ICML, Palazzo dei Congressi, Lugano, Switzerland,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+O%E2%80%99Brien&author=J.+A.+Burger&author=S.+E.+Coutre&author=J.+Porte+Sharman&author=R.+R.+Furman&author=I.+W.+Flinn&author=B.+Grant&author=D.+Richards&author=N.+Heerema&author=A.+J.+Johnson&author=R.+Izumi&author=A.+Hamdy&author=K.+A.+Blum&author=J.+C.+Byrd&title=The+Btk+Inhibitor+PCI-32765+Is+Highly+Active+and+Tolerable+in+Patients+with+Poor-Risk+CLL%3A+Interim+Results+from+a+Phase+Ib%2FII+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DThe%2520Btk%2520Inhibitor%2520PCI-32765%2520Is%2520Highly%2520Active%2520and%2520Tolerable%2520in%2520Patients%2520with%2520Poor-Risk%2520CLL%253A%2520Interim%2520Results%2520from%2520a%2520Phase%2520Ib%252FII%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Pollyea, D. A.; Smith, S.; Fowler, N.; Boyd, T.; Smith, A. M.; Sirisawad, M.; Honigberg, L. A.; Hamdy, A.; Advani, R.</span><span> </span><span class="NLM_article-title">A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay</span>. Presented at the 51st ASH Annual Meeting and Exposition, New Orleans, LA,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Poster 3713.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=D.+A.+Pollyea&author=S.+Smith&author=N.+Fowler&author=T.+Boyd&author=A.+M.+Smith&author=M.+Sirisawad&author=L.+A.+Honigberg&author=A.+Hamdy&author=R.+Advani&title=A+Phase+I+Dose+Escalation+Study+of+the+Btk+Inhibitor+PCI-32765+in+Relapsed+and+Refractory+B+Cell+Non-Hodgkin+Lymphoma+and+Use+of+a+Novel+Fluorescent+Probe+Pharmacodynamic+Assay"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26atitle%3DA%2520Phase%2520I%2520Dose%2520Escalation%2520Study%2520of%2520the%2520Btk%2520Inhibitor%2520PCI-32765%2520in%2520Relapsed%2520and%2520Refractory%2520B%2520Cell%2520Non-Hodgkin%2520Lymphoma%2520and%2520Use%2520of%2520a%2520Novel%2520Fluorescent%2520Probe%2520Pharmacodynamic%2520Assay%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fowler, N.; Sharman, J. P.; Smith, S. S.; Boyd, T.; Grant, B.; Kolibaba, K. S.; Furman, R. R.; Buggy, J.; Loury, D.; Hamdy, A.; Advani, R.</span><span> </span><span class="NLM_article-title">The BTK Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity in Patients with Relapsed/Refractory B-Cell Malignancies: Results from a Phase I Study</span>. Presented at the 52nd ASH Annual Meeting and Exposition, Orlando, FL,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+Fowler&author=J.+P.+Sharman&author=S.+S.+Smith&author=T.+Boyd&author=B.+Grant&author=K.+S.+Kolibaba&author=R.+R.+Furman&author=J.+Buggy&author=D.+Loury&author=A.+Hamdy&author=R.+Advani&title=The+BTK+Inhibitor%2C+PCI-32765%2C+Induces+Durable+Responses+with+Minimal+Toxicity+in+Patients+with+Relapsed%2FRefractory+B-Cell+Malignancies%3A+Results+from+a+Phase+I+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DFowler%26aufirst%3DN.%26atitle%3DThe%2520BTK%2520Inhibitor%252C%2520PCI-32765%252C%2520Induces%2520Durable%2520Responses%2520with%2520Minimal%2520Toxicity%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B-Cell%2520Malignancies%253A%2520Results%2520from%2520a%2520Phase%2520I%2520Study%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">de Rooij, M. F. M.; Kuil, A.; Geest, C. R.; Eldering, E.; Chang, B. Y.; Buggy, J. J.; Pals, S. T.; Spaargaren, M.</span><span> </span><span class="NLM_article-title">The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia</span>.  <span class="citation_source-journal">Blood</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1182/blood-2011-11-390989</span> . Published Online: Jan 25,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1182%2Fblood-2011-11-390989" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+F.+M.+de+Rooij&author=A.+Kuil&author=C.+R.+Geest&author=E.+Eldering&author=B.+Y.+Chang&author=J.+J.+Buggy&author=S.+T.+Pals&author=M.+Spaargaren&title=The+clinically+active+BTK+inhibitor+PCI-32765+targets+B-cell+receptor-+and+chemokine-controlled+adhesion+and+migration+in+chronic+lymphocytic+leukemia&doi=10.1182%2Fblood-2011-11-390989"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-11-390989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-11-390989%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRooij%26aufirst%3DM.%2BF.%2BM.%26atitle%3DThe%2520clinically%2520active%2520BTK%2520inhibitor%2520PCI-32765%2520targets%2520B-cell%2520receptor-%2520and%2520chemokine-controlled%2520adhesion%2520and%2520migration%2520in%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26doi%3D10.1182%2Fblood-2011-11-390989%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span>ClinicalTrials.gov. Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <a href="http://clinicaltrials.gov/ct2/show/NCT01325701?term=PCI-32765&amp;rank=7" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01325701?term=PCI-32765&rank=7</a> (accessed Aug 25, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Safety+and+Efficacy+Study+of+Bruton%27s+Tyrosine+Kinase+Inhibitor+in+Subjects+with+Relapsed+or+Refractory+Diffuse+Large+B-Cell+Lymphoma.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01325701%3Fterm%3DPCI-32765%26rank%3D7+%28accessed+Aug+25%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span>ClinicalTrials.gov. Safety and Tolerability Study of PCI-32765 Combined with Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL). <a href="http://clinicaltrials.gov/ct2/show/NCT01292135" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01292135</a> (accessed Aug 25, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Safety+and+Tolerability+Study+of+PCI-32765+Combined+with+Fludarabine%2FCyclophosphamide%2FRituximab+%28FCR%29+and+Bendamustine%2FRituximab+%28BR%29+in+Chronic+Lymphocytic+Leukemia+%28CLL%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01292135+%28accessed+Aug+25%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakabayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamaki, K.</span><span> </span><span class="NLM_article-title">Predicting key example compounds in competitors’ patent applications using structural information alone</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci7002686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisV2qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=135-142&author=K.+Hattoriauthor=H.+Wakabayashiauthor=K.+Tamaki&title=Predicting+key+example+compounds+in+competitors%E2%80%99+patent+applications+using+structural+information+alone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Key Example Compounds in Competitors' Patent Applications Using Structural Information Alone</span></div><div class="casAuthors">Hattori, Kazunari; Wakabayashi, Hiroaki; Tamaki, Kenta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-142</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In drug discovery programs, predicting key example compds. in competitors' patent applications is important work for scientists working in the same or in related research areas.  In general, medicinal chemists are responsible for this work, and they attempt to guess the identity of key compds. based on information provided in patent applications, such as biol. data, scale of reaction, and/or optimization of the salt form for a particular compd.  However, this is sometimes made difficult by the lack of such information.  This paper describes a method for predicting key compds. in competitors' patent applications by using only structural information of example compds.  Based on the assumption that medicinal chemists usually carry out extensive structure-activity relationship (SAR) studies around key compds., the method identifies compds. located at the centers of densely populated regions in the patent examples' chem. space, as represented by Extended Connectivity Fingerprints (ECFPs).  For the validation of the method, a total of 30 patents contg. structures of launched drugs were selected to test whether or not the method is able to predict key compds. (the launched drugs).  In 17 out of the 30 patents (57%), the method was able to successfully predict the key compds.  The result indicates that our method could provide an alternative approach to predicting key compds. in cases where the conventional medicinal chemist's approach does not work well.  This method could also be used as a complement to the traditional medicinal chemist's approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_Rwj3qzEf7Vg90H21EOLACvtfcHk0lgaZWTm9zB8fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisV2qtA%253D%253D&md5=ae6a5758a22b2bf13072d2fcc8071aed</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fci7002686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci7002686%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DWakabayashi%26aufirst%3DH.%26aulast%3DTamaki%26aufirst%3DK.%26atitle%3DPredicting%2520key%2520example%2520compounds%2520in%2520competitors%25E2%2580%2599%2520patent%2520applications%2520using%2520structural%2520information%2520alone%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26spage%3D135%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiemann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francesco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jejurkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D. J.</span><span> </span><span class="NLM_article-title">PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in mouse models of arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">286</span><div class="note"><p class="first last"> (Abstract)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=286&issue=Suppl.+10&author=B.+Y.+Changauthor=P.+Thiemannauthor=M.+Francescoauthor=M.+M.+Huangauthor=M.+Sirisawadauthor=N.+Purroauthor=P.+Jejurkarauthor=C.+Maniauthor=D.+Tonevauthor=W.+Chenauthor=J.+J.+Buggyauthor=D.+J.+Loury&title=PCI-45292%2C+a+novel+Btk+inhibitor+with+optimized+pharmaceutical+properties%2C+demonstrates+potent+activities+in+mouse+models+of+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DThiemann%26aufirst%3DP.%26aulast%3DFrancesco%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DM.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DPurro%26aufirst%3DN.%26aulast%3DJejurkar%26aufirst%3DP.%26aulast%3DMani%26aufirst%3DC.%26aulast%3DTonev%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DLoury%26aufirst%3DD.%2BJ.%26atitle%3DPCI-45292%252C%2520a%2520novel%2520Btk%2520inhibitor%2520with%2520optimized%2520pharmaceutical%2520properties%252C%2520demonstrates%2520potent%2520activities%2520in%2520mouse%2520models%2520of%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26issue%3DSuppl.%252010%26spage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span>Pharmacyclics. Update on Preclinical Finding and Development Timeline for PCI-45292. <a href="http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=553831" class="extLink">http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=553831</a> (accessed Aug 25, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pharmacyclics.+Update+on+Preclinical+Finding+and+Development+Timeline+for+PCI-45292.+http%3A%2F%2Fir.pharmacyclics.com%2Freleasedetail.cfm%3FReleaseID%3D553831+%28accessed+Aug+25%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Kluge, A. F.; Petter, R. C.; Tester, R. W.; Qiao, L.; Niu, D.; Westlin, W. F.; Singh, J.; Mazdiyasni, H.</span><span> </span><span class="NLM_article-title">Heteroaryl Compounds and Uses Thereof</span>. Patent Application WO 2009/158571,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+F.+Kluge&author=R.+C.+Petter&author=R.+W.+Tester&author=L.+Qiao&author=D.+Niu&author=W.+F.+Westlin&author=J.+Singh&author=H.+Mazdiyasni&title=Heteroaryl+Compounds+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DHeteroaryl%2520Compounds%2520and%2520Uses%2520Thereof%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Singh, J.; Ghosh, S.; Kluge, A. F.; Petter, R. C.; Tester, R. W.</span><span> </span><span class="NLM_article-title">Heteroaryl Compounds and Uses Thereof</span>. Patent Application US 2010/0016296,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Singh&author=S.+Ghosh&author=A.+F.+Kluge&author=R.+C.+Petter&author=R.+W.+Tester&title=Heteroaryl+Compounds+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DHeteroaryl%2520Compounds%2520and%2520Uses%2520Thereof%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Singh, J.; Petter, R. C.; Tester, R. W.; Kluge, A. F.; Mazdiyasni, H.; Westlin, W. F.; Niu, D.; Qiao, L.</span><span> </span><span class="NLM_article-title">Heteroaryl Compounds and Uses Thereof</span>. Patent Application US 2010/0249092,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Singh&author=R.+C.+Petter&author=R.+W.+Tester&author=A.+F.+Kluge&author=H.+Mazdiyasni&author=W.+F.+Westlin&author=D.+Niu&author=L.+Qiao&title=Heteroaryl+Compounds+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DHeteroaryl%2520Compounds%2520and%2520Uses%2520Thereof%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Singh, J.; Petter, R. C.; Niu, D.</span><span> </span><span class="NLM_article-title">Algorithm for Designing Irreversible Inhibitors</span>. Patent Application WO 2010/028236,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Singh&author=R.+C.+Petter&author=D.+Niu&title=Algorithm+for+Designing+Irreversible+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DAlgorithm%2520for%2520Designing%2520Irreversible%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Evans, E.; Sheets, M.; Bernard, H.; Martin, T. S.; Nacht, M.; Zhu, Z.; Tester, R.; Mazdiyasni, H.; Chaturvedi, P.; Petter, R.; Westlin, W.; Singh, J.</span><span> </span><span class="NLM_article-title">Prolonged Inhibition of BCR Signaling and Suppression of B Cell Lymphoma through Irreversible Inhibition of Bruton’s Tyrosine Kinase</span>. Presented at the 50th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>Poster 2608.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Evans&author=M.+Sheets&author=H.+Bernard&author=T.+S.+Martin&author=M.+Nacht&author=Z.+Zhu&author=R.+Tester&author=H.+Mazdiyasni&author=P.+Chaturvedi&author=R.+Petter&author=W.+Westlin&author=J.+Singh&title=Prolonged+Inhibition+of+BCR+Signaling+and+Suppression+of+B+Cell+Lymphoma+through+Irreversible+Inhibition+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%26atitle%3DProlonged%2520Inhibition%2520of%2520BCR%2520Signaling%2520and%2520Suppression%2520of%2520B%2520Cell%2520Lymphoma%2520through%2520Irreversible%2520Inhibition%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Karp, R.; Evans, E.; Aslanian, S.; Chaturvedi, P.; Mazdiyasni, H.; Nacht, M.; Petter, R.; Sheets, M.; Singh, J.; Tester, R.; Westlin, W.</span><span> </span><span class="NLM_article-title">Inhibition of BTK with AVL-292 Translates to Protective Activity in Rodent Models of Rheumatoid Arthritis</span>. Presented at the 16th International IRA Conference Meeting, Chantilly, VA,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span>Poster A113.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+Karp&author=E.+Evans&author=S.+Aslanian&author=P.+Chaturvedi&author=H.+Mazdiyasni&author=M.+Nacht&author=R.+Petter&author=M.+Sheets&author=J.+Singh&author=R.+Tester&author=W.+Westlin&title=Inhibition+of+BTK+with+AVL-292+Translates+to+Protective+Activity+in+Rodent+Models+of+Rheumatoid+Arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520BTK%2520with%2520AVL-292%2520Translates%2520to%2520Protective%2520Activity%2520in%2520Rodent%2520Models%2520of%2520Rheumatoid%2520Arthritis%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Evans, E.; Tester, R; Mazdiyasni, H.; Ponader, S.; Tesar, B.; Chaturavedi, P.; Nacht, M.; Stiede, S.; Witowski, S.; Lounsbury, H.; Silver, B.; Burger, J.; Brown, J. R.; Mahadevan, D.; Sharman, J.; Harb, W.; Petter, R.; Singh, J.; Westlin, W.</span><span> </span><span class="NLM_article-title">Clinical Development of AVL-292: A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies</span>. Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, CA,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Poster 3485.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=E.+Evans&author=R+Tester&author=H.+Mazdiyasni&author=S.+Ponader&author=B.+Tesar&author=P.+Chaturavedi&author=M.+Nacht&author=S.+Stiede&author=S.+Witowski&author=H.+Lounsbury&author=B.+Silver&author=J.+Burger&author=J.+R.+Brown&author=D.+Mahadevan&author=J.+Sharman&author=W.+Harb&author=R.+Petter&author=J.+Singh&author=W.+Westlin&title=Clinical+Development+of+AVL-292%3A+A+Potent%2C+Selective+Covalent+Btk+Inhibitor+for+the+Treatment+of+B+Cell+Malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%26atitle%3DClinical%2520Development%2520of%2520AVL-292%253A%2520A%2520Potent%252C%2520Selective%2520Covalent%2520Btk%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520B%2520Cell%2520Malignancies%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Konteatis, Z.; Moffett, K.; Lee, Y.; Chao, W.</span><span> </span><span class="NLM_article-title">Pyrrolotriazine compounds</span>. Patent Application WO 2010/126960,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Z.+Konteatis&author=K.+Moffett&author=Y.+Lee&author=W.+Chao&title=Pyrrolotriazine+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKonteatis%26aufirst%3DZ.%26atitle%3DPyrrolotriazine%2520compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-<i>a</i>]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6258</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6258-6263&author=K.+H.+Kimauthor=A.+Madernaauthor=M.+E.+Schnuteauthor=M.+Hegenauthor=S.+Mohanauthor=J.+Miyashiroauthor=L.+Linauthor=E.+Liauthor=S.+Keeganauthor=J.+Lussierauthor=C.+Wrocklageauthor=C.+L.+Nickerson-Nutterauthor=A.+J.+Wittwerauthor=H.+Soutterauthor=N.+Caspersauthor=S.+Hanauthor=R.+Kurumbailauthor=K.+Dunussi-Joannopoulosauthor=J.+Douhanauthor=A.+Wissner&title=Imidazo%5B1%2C5-a%5Dquinoxalines+as+irreversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DSoutter%26aufirst%3DH.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DImidazo%255B1%252C5-a%255Dquinoxalines%2520as%2520irreversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6258%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Currie, K. S.; Desimone, R. W.; Pippin, D. A.; Darrow, J. W.; Mitchell, S. A.</span><span> </span><span class="NLM_article-title">Preparation of Imidazo[1,2-<i>a</i>]pyrazin-8-ylamines as Kinase Modulators, Particularly Btk Inhibitors, for Treating Btk-Related Diseases and Conditions</span>. Patent Application WO 2005/047290,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+S.+Currie&author=R.+W.+Desimone&author=D.+A.+Pippin&author=J.+W.+Darrow&author=S.+A.+Mitchell&title=Preparation+of+Imidazo%5B1%2C2-a%5Dpyrazin-8-ylamines+as+Kinase+Modulators%2C+Particularly+Btk+Inhibitors%2C+for+Treating+Btk-Related+Diseases+and+Conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPreparation%2520of%2520Imidazo%255B1%252C2-a%255Dpyrazin-8-ylamines%2520as%2520Kinase%2520Modulators%252C%2520Particularly%2520Btk%2520Inhibitors%252C%2520for%2520Treating%2520Btk-Related%2520Diseases%2520and%2520Conditions%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Currie, K. S.; Desimone, R. W.; Mitchell, S. A.; Pippin, D. A.; Darrow, J. W.; Qian, X.; Velleca, M.; Qian, D.</span><span> </span><span class="NLM_article-title">Preparation of Imidazo[1,2-<i>a</i>]pyrazin-8-ylamines for Inhibition of Bruton’s Tyrosine Kinase</span>. Patent Application WO 2005/014599,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+S.+Currie&author=R.+W.+Desimone&author=S.+A.+Mitchell&author=D.+A.+Pippin&author=J.+W.+Darrow&author=X.+Qian&author=M.+Velleca&author=D.+Qian&title=Preparation+of+Imidazo%5B1%2C2-a%5Dpyrazin-8-ylamines+for+Inhibition+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPreparation%2520of%2520Imidazo%255B1%252C2-a%255Dpyrazin-8-ylamines%2520for%2520Inhibition%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Currie, K. S.; Desimone, R. W.; Mitchell, S.; Pippin, D. A.</span><span> </span><span class="NLM_article-title">Preparation of Imidazo[1,2-<i>a</i>]pyrazin-8-ylamines as Bruton’s Tyrosine Kinase (Btk) Inhibitors for the Treatment of Cancer</span>. Patent Application WO 2005/005429,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+S.+Currie&author=R.+W.+Desimone&author=S.+Mitchell&author=D.+A.+Pippin&title=Preparation+of+Imidazo%5B1%2C2-a%5Dpyrazin-8-ylamines+as+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+Inhibitors+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPreparation%2520of%2520Imidazo%255B1%252C2-a%255Dpyrazin-8-ylamines%2520as%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Targeting B-cells in inflammatory disease</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=175-190&author=K.+S.+Currie&title=Targeting+B-cells+in+inflammatory+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DTargeting%2520B-cells%2520in%2520inflammatory%2520disease%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D175%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of a Novel Series of Highly Selective Inhibitors of Bruton’s Tyrosine Kinase</span>. Presented at the EFMC 21st International Symposium on Medicinal Chemistry, Brussels, Belgium,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=K.+S.+Currie&title=Discovery+and+Optimization+of+a+Novel+Series+of+Highly+Selective+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Novel%2520Series%2520of%2520Highly%2520Selective%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+effect+of+a+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+in+rat+collagen-induced+arthritis+and+mechanism-based+pharmacokinetic%2Fpharmacodynamic+modeling%3A+relationships+between+inhibition+of+BTK+phosphorylation+and+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0lgi8c-nf4BNfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520effect%2520of%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520in%2520rat%2520collagen-induced%2520arthritis%2520and%2520mechanism-based%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%253A%2520relationships%2520between%2520inhibition%2520of%2520BTK%2520phosphorylation%2520and%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D154%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coraggio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgardner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopaul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuebler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase (BTK) inhibitor</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">21742900</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=21742900&author=L.+Liuauthor=J.+Halladayauthor=Y.+Shinauthor=S.+Wongauthor=M.+Coraggioauthor=H.+Laauthor=M.+Baumgardnerauthor=H.+Leauthor=S.+Gopaulauthor=J.+Boggsauthor=P.+Kueblerauthor=J.+Davisauthor=C.+Liaoauthor=J.+Lubachauthor=A.+Deeseauthor=G.+Sowellauthor=K.+Currieauthor=W.+Youngauthor=C.+Khojastehauthor=C.+Hopauthor=H.+Wong&title=Significant+species+difference+in+amide+hydrolysis+of+GDC-0834%2C+a+novel+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DKuebler%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DLubach%26aufirst%3DJ.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DG.%26aulast%3DCurrie%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DW.%26aulast%3DKhojasteh%26aufirst%3DC.%26aulast%3DHop%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DSignificant%2520species%2520difference%2520in%2520amide%2520hydrolysis%2520of%2520GDC-0834%252C%2520a%2520novel%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26spage%3D21742900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dewdney, N. J.; Kondru, R. K.; Lou, Y.; Soth, M.; Gabriel, T.</span><span> </span><span class="NLM_article-title">BTK Protein Kinase Inhibitors</span>. Patent Application US 2009/0105209,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+J.+Dewdney&author=R.+K.+Kondru&author=Y.+Lou&author=M.+Soth&author=T.+Gabriel&title=BTK+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DBTK%2520Protein%2520Kinase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit60b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dewdney, N. J.; Lou, Y.; Soth, M.</span><span> </span><span class="NLM_article-title">Novel Imidazo[1,2-A]pyridine and Imidazo[1,2-B]pyridazine Derivatives</span>. Patent Application WO 2009/077334,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+J.+Dewdney&author=Y.+Lou&author=M.+Soth&title=Novel+Imidazo%5B1%2C2-A%5Dpyridine+and+Imidazo%5B1%2C2-B%5Dpyridazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DNovel%2520Imidazo%255B1%252C2-A%255Dpyridine%2520and%2520Imidazo%255B1%252C2-B%255Dpyridazine%2520Derivatives%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit60c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dewdney, N. J.; Kennedy-Smith, J.; Kondru, R. K.; Loe, B. E.; Lou, Y.; McIntosh, J.; Owens, T. D.; Soth, M.; Sweeney, Z. K.; Taygerly, J. P.G.</span><span> </span><span class="NLM_article-title">Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application US 2009/0306041,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+J.+Dewdney&author=J.+Kennedy-Smith&author=R.+K.+Kondru&author=B.+E.+Loe&author=Y.+Lou&author=J.+McIntosh&author=T.+D.+Owens&author=M.+Soth&author=Z.+K.+Sweeney&author=J+P.+G+Taygerly&title=Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DInhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit60d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Dewdney, N. J.; Lou, Y.; Sjogren, E. B.; Soth, M.</span><span> </span><span class="NLM_article-title">Novel Phenyl-imidazopyridines and Pyridazines</span>. Patent Application WO 2010/006947,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+J.+Dewdney&author=Y.+Lou&author=E.+B.+Sjogren&author=M.+Soth&title=Novel+Phenyl-imidazopyridines+and+Pyridazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DNovel%2520Phenyl-imidazopyridines%2520and%2520Pyridazines%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit60e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dewdney, N. J.; Lou, Y.; Sjogren, E. B.; Soth, M.; Sweeney, Z. K.</span><span> </span><span class="NLM_article-title">Novel Phenylpyrazinones as Kinase Inhibitors</span>. Patent Application WO 2010/000633,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+J.+Dewdney&author=Y.+Lou&author=E.+B.+Sjogren&author=M.+Soth&author=Z.+K.+Sweeney&title=Novel+Phenylpyrazinones+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DNovel%2520Phenylpyrazinones%2520as%2520Kinase%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit60f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Dewdney, N. J.; Hawley, R. C.; Kondru, R. K.; Lai, Y.; Lou, Y.</span><span> </span><span class="NLM_article-title">Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application WO 2010/122038,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=N.+J.+Dewdney&author=R.+C.+Hawley&author=R.+K.+Kondru&author=Y.+Lai&author=Y.+Lou&title=Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewdney%26aufirst%3DN.%2BJ.%26atitle%3DInhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit60g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Berthel, S.; Firooznia, F.; Fishlock, D.; Hong, J.; Lou, Y.; Lucas, M.; Owens, T. D.; Sarma, K.; Sweeney, Z. K.; Taygerly, J. P. G.</span><span> </span><span class="NLM_article-title">Inhibitors of Bruton’s Tyrosine Kinase</span>. Patent Application US 2010/0222325,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Berthel&author=F.+Firooznia&author=D.+Fishlock&author=J.+Hong&author=Y.+Lou&author=M.+Lucas&author=T.+D.+Owens&author=K.+Sarma&author=Z.+K.+Sweeney&author=J.+P.+G.+Taygerly&title=Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBerthel%26aufirst%3DS.%26atitle%3DInhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Xu, D.; Kim, Y.; Postelnek, J.; Vu, M. D.; Hu, D.-Q.; Hsu, J.; Liao, C.; Zhang, J.; Pashine, A.; Srinivasan, D.; Woods, J.; Owens, T.; Lou, Y.; Hill, R.; Narula, S.; DeMartino, J.; Fine, J. S.</span><span> </span><span class="NLM_article-title">RN486 [6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2<i>H</i>-isoquinolin-1-one], a selective Bruton’s tyrosine kinase (Btk) inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span>.  <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A280%3ADC%252BC38zhtFymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90&author=D.+Xu&author=Y.+Kim&author=J.+Postelnek&author=M.+D.+Vu&author=D.-Q.+Hu&author=J.+Hsu&author=C.+Liao&author=J.+Zhang&author=A.+Pashine&author=D.+Srinivasan&author=J.+Woods&author=T.+Owens&author=Y.+Lou&author=R.+Hill&author=S.+Narula&author=J.+DeMartino&author=J.+S.+Fine&title=RN486+%5B6-cyclopropyl-8-fluoro-2-%282-hydroxymethyl-3-%7B1-methyl-5-%5B5-%284-methyl-piperazin-1-yl%29-pyridin-2-ylamino%5D-6-oxo-1%2C6-dihydro-pyridin-3-yl%7D-phenyl%29-2H-isoquinolin-1-one%5D%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents</span></div><div class="casAuthors">Xu Daigen; Kim Yong; Postelnek Jennifer; Vu Minh Diem; Hu Dong-Qing; Liao Cheng; Bradshaw Mike; Hsu Jonathan; Zhang Jun; Pashine Achal; Srinivasan Dinesh; Woods John; Levin Anita; O'Mahony Alison; Owens Timothy D; Lou Yan; Hill Ronald J; Narula Satwant; Demartino Julie; Fine Jay S</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic mutation and pharmacological inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor cross-linking-induced degranulation in mast cells (IC(50) = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α production in monocytes (IC(50) = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC(50) = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-molecule disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqSnPYc5dDCNj_Vg2vObihfW6udTcc2eZM_Vsz0Y4Plrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zhtFymtQ%253D%253D&md5=a04c33939073dc33beda20c4b5e833d3</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26atitle%3DRN486%2520%255B6-cyclopropyl-8-fluoro-2-%25282-hydroxymethyl-3-%257B1-methyl-5-%255B5-%25284-methyl-piperazin-1-yl%2529-pyridin-2-ylamino%255D-6-oxo-1%252C6-dihydro-pyridin-3-yl%257D-phenyl%2529-2H-isoquinolin-1-one%255D%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Lindauer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span> </span><span class="NLM_article-title">Dasatinib</span> <span class="citation_source-journal">Recent Results Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm300035p&amp;key=10.1007%2F978-3-642-01222-8_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm300035p&amp;key=20072833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm300035p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=83-102&author=M.+Lindauerauthor=A.+Hochhaus&title=Dasatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib</span></div><div class="casAuthors">Lindauer, Markus; Hochhaus, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">83-102</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">0080-0015</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Dasatinib, (former BMS 354825), is an orally available small-mol. multikinase inhibitor.  It potently inhibits BCR-ABL and SRC-family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-α and β, and ephrin receptor kinase.  Dasatinib is about 300 times more potent than imatinib in cells expressing unmutated BCR-ABL in vitro.  The drug has demonstrated activity against clin. relevant mutations, including those assocd. with poor prognosis during ongoing imatinib therapy.  Dasatinib is approved for the treatment of patients with BCR-ABL-pos. chronic myeloid leukemia (CML), resistant or intolerant to imatinib in chronic, accelerated, and blast phase.  It also is approved for the treatment of Philadelphia Chromosome pos. (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to imatinib.  A single daily dose of 100 mg in chronic phase CML results in high hematol. and mol. remission rates and prolongation of survival.  In accelerated and blastic phase as well as in ALL, 70 mg twice daily is recommended.  Complete hematol. and cytogenetic remissions (CR) frequently occur even in this patient group with poor prognosis.  Remissions however are very short.  Side effects of dasatinib are frequent but mostly moderate and manageable and include cytopenias and pleural effusions.  The role of dasatinib in other diseases, including solid tumors, has to be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbjaDV5Fc3frVg90H21EOLACvtfcHk0ljMMgbsZYbu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsLnK&md5=062b34461639470b554c895b74a295f7</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-01222-8_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-01222-8_7%26sid%3Dliteratum%253Aachs%26aulast%3DLindauer%26aufirst%3DM.%26aulast%3DHochhaus%26aufirst%3DA.%26atitle%3DDasatinib%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2010%26volume%3D184%26spage%3D83%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burckstummer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutze, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">13283</span><span class="NLM_x">–</span> <span class="NLM_lpage">13288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13283-13288&author=O.+Hantschelauthor=U.+Rixauthor=U.+Schmidtauthor=T.+Burckstummerauthor=M.+Kneidingerauthor=G.+Schutzeauthor=J.+Colingeauthor=K.+L.+Bennettauthor=W.+Ellmeierauthor=P.+Valentauthor=G.+Superti-Furga&title=The+Btk+tyrosine+kinase+is+a+major+target+of+the+Bcr-Abl+inhibitor+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBurckstummer%26aufirst%3DT.%26aulast%3DKneidinger%26aufirst%3DM.%26aulast%3DSchutze%26aufirst%3DG.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520Btk%2520tyrosine%2520kinase%2520is%2520a%2520major%2520target%2520of%2520the%2520Bcr-Abl%2520inhibitor%2520dasatinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D13283%26epage%3D13288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Sillaber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herndlhofer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschachler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jager, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span> </span><span class="NLM_article-title">Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily</span> <span class="citation_source-journal">Eur. J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">–</span> <span class="NLM_lpage">1109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=1098-1109&author=C.+Sillaberauthor=H.+Herrmannauthor=K.+Bennettauthor=U.+Rixauthor=C.+Baumgartnerauthor=A.+Bohmauthor=S.+Herndlhoferauthor=E.+Tschachlerauthor=G.+Superti-Furgaauthor=U.+Jagerauthor=P.+Valent&title=Immunosuppression+and+atypical+infections+in+CML+patients+treated+with+dasatinib+at+140+mg+daily"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSillaber%26aufirst%3DC.%26aulast%3DHerrmann%26aufirst%3DH.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DBohm%26aufirst%3DA.%26aulast%3DHerndlhofer%26aufirst%3DS.%26aulast%3DTschachler%26aufirst%3DE.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26aulast%3DJager%26aufirst%3DU.%26aulast%3DValent%26aufirst%3DP.%26atitle%3DImmunosuppression%2520and%2520atypical%2520infections%2520in%2520CML%2520patients%2520treated%2520with%2520dasatinib%2520at%2520140%2520mg%2520daily%26jtitle%3DEur.%2520J.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D39%26spage%3D1098%26epage%3D1109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Kneidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleixner, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vales, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupinek, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weghofer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schebesta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrtala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span> </span><span class="NLM_article-title">The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">3097</span><span class="NLM_x">–</span> <span class="NLM_lpage">3107</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=3097-3107&author=M.+Kneidingerauthor=U.+Schmidtauthor=U.+Rixauthor=K.+V.+Gleixnerauthor=A.+Valesauthor=C.+Baumgartnerauthor=C.+Lupinekauthor=M.+Weghoferauthor=K.+L.+Bennettauthor=H.+Herrmannauthor=A.+Schebestaauthor=W.+R.+Thomasauthor=S.+Vrtalaauthor=R.+Valentaauthor=F.+Y.+Leeauthor=W.+Ellmeierauthor=G.+Superti-Furgaauthor=P.+Valent&title=The+effects+of+dasatinib+on+IgE+receptor-dependent+activation+and+histamine+release+in+human+basophils"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKneidinger%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DGleixner%26aufirst%3DK.%2BV.%26aulast%3DVales%26aufirst%3DA.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DLupinek%26aufirst%3DC.%26aulast%3DWeghofer%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DHerrmann%26aufirst%3DH.%26aulast%3DSchebesta%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DW.%2BR.%26aulast%3DVrtala%26aufirst%3DS.%26aulast%3DValenta%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26aulast%3DValent%26aufirst%3DP.%26atitle%3DThe%2520effects%2520of%2520dasatinib%2520on%2520IgE%2520receptor-dependent%2520activation%2520and%2520histamine%2520release%2520in%2520human%2520basophils%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D3097%26epage%3D3107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Liu, Q.; Batt, D. G.; DeLucca, G. V.; Shi, Q.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Carbazole Carboxamide Compounds Useful as Kinase Inhibitors</span>. Patent Application US 2010/0160303,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Q.+Liu&author=D.+G.+Batt&author=G.+V.+DeLucca&author=Q.+Shi&author=A.+J.+Tebben&title=Carbazole+Carboxamide+Compounds+Useful+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DCarbazole%2520Carboxamide%2520Compounds%2520Useful%2520as%2520Kinase%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Liu, C.; Leftheris, K.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Fused Heterocyclic Compounds Useful for the Treatment of Proliferative, Allergic, Autoimmune or Inflammatory Diseases</span>. Patent Application WO 2008/116064,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Liu&author=K.+Leftheris&author=A.+J.+Tebben&title=Fused+Heterocyclic+Compounds+Useful+for+the+Treatment+of+Proliferative%2C+Allergic%2C+Autoimmune+or+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DFused%2520Heterocyclic%2520Compounds%2520Useful%2520for%2520the%2520Treatment%2520of%2520Proliferative%252C%2520Allergic%252C%2520Autoimmune%2520or%2520Inflammatory%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Liu, C.; Leftheris, K.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Fused Heterocyclic Compounds Useful as Kinase Modulators</span>. Patent Application WO 2010/011837,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+Liu&author=K.+Leftheris&author=A.+J.+Tebben&title=Fused+Heterocyclic+Compounds+Useful+as+Kinase+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DFused%2520Heterocyclic%2520Compounds%2520Useful%2520as%2520Kinase%2520Modulators%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Duan, J.; Jiang, B.; Lu, Z.</span><span> </span><span class="NLM_article-title">Azaindazoles as BTK Kinase Modulators and Use Thereof</span>. Patent Application WO 2011/019780,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Duan&author=B.+Jiang&author=Z.+Lu&title=Azaindazoles+as+BTK+Kinase+Modulators+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26atitle%3DAzaindazoles%2520as%2520BTK%2520Kinase%2520Modulators%2520and%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bui, M.; Conlon, P.; Erlanson, D. A.; Fan, J.; Guan, B.; Hopkins, B. T.; Ishchenko, A.; Jenkins, T. J.; Kumaravel, G.; Marcotte, D.; Powell, N.; Scott, D.; Taveras, A.; Wang, D.; Zhong, M.</span><span> </span><span class="NLM_article-title">Heteroaryl BTK Inhibitors</span>. Patent Application WO 2011/029043,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Bui&author=P.+Conlon&author=D.+A.+Erlanson&author=J.+Fan&author=B.+Guan&author=B.+T.+Hopkins&author=A.+Ishchenko&author=T.+J.+Jenkins&author=G.+Kumaravel&author=D.+Marcotte&author=N.+Powell&author=D.+Scott&author=A.+Taveras&author=D.+Wang&author=M.+Zhong&title=Heteroaryl+BTK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBui%26aufirst%3DM.%26atitle%3DHeteroaryl%2520BTK%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit70b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Erlanson, D. A.; Marcotte, D.; Kumaravel, G.; Fan, J.; Wang, D.; Cuervo, J. H.; Silvian, L.; Powell, N.; Bui, M.; Hopkins, B. T.; Taveras, A.; Guan, B.; Conlon, P.; Zhong, M.; Jenkins, T. J.; Scott, D.; Lugovskoy, A. A.</span><span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitors</span>. Patent Application WO 2011/029046,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+A.+Erlanson&author=D.+Marcotte&author=G.+Kumaravel&author=J.+Fan&author=D.+Wang&author=J.+H.+Cuervo&author=L.+Silvian&author=N.+Powell&author=M.+Bui&author=B.+T.+Hopkins&author=A.+Taveras&author=B.+Guan&author=P.+Conlon&author=M.+Zhong&author=T.+J.+Jenkins&author=D.+Scott&author=A.+A.+Lugovskoy&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300035p&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm300035p%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-10%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300035p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6679879a4e7f2367","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
